UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)
 
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2011

OR

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ____________ to ___________

Commission File Number 1-12031



UNIVERSAL DISPLAY CORPORATION
(Exact name of registrant as specified in its charter)

Pennsylvania
 
23-2372688
(State or other jurisdiction of
 
(I.R.S. Employer Identification No.)
incorporation or organization)
   
     
375 Phillips Boulevard
   
Ewing, New Jersey
 
08618
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code: (609) 671-0980

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  X    No     

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes  X    No     

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer  
Accelerated filer       X       
Non-accelerated filer  ___ (Do not check if a smaller reporting company)
Smaller reporting company ___
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes        No  X 
 
 
As of November 2, 2011, the registrant had outstanding 46,026,058 shares of common stock.
 


 
 

 

TABLE OF CONTENTS
   
PART I – FINANCIAL INFORMATION
 
   
 
   
PART II – OTHER INFORMATION
 
   


 
2

 


PART I – FINANCIAL INFORMATION

ITEM 1.
FINANCIAL STATEMENTS

UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS
(UNAUDITED)

   
September 30,
   
December 31,
 
   
2011
   
2010
 
ASSETS
 
CURRENT ASSETS:
           
Cash and cash equivalents
  $ 67,124,442     $ 20,368,852  
Short-term investments
    270,829,172       52,794,545  
Accounts receivable
    11,761,280       7,247,873  
Inventory
    2,230,620       2,209  
Other current assets
    1,715,179       1,986,030  
                 
Total current assets
    353,660,693       82,399,509  
PROPERTY AND EQUIPMENT, net of accumulated depreciation of
               
$18,376,487 and $17,335,662
    10,827,191       9,711,093  
ACQUIRED TECHNOLOGY, net of accumulated amortization of
               
$16,984,912 and $16,950,718
    405,450        
OTHER ASSETS
    312,384       216,529  
                 
TOTAL ASSETS
  $ 365,205,718     $ 92,327,131  
                 
LIABILITIES AND SHAREHOLDERS’ EQUITY
 
CURRENT LIABILITIES:
               
Accounts payable
  $ 5,780,710     $ 2,155,489  
Accrued expenses
    6,519,459       6,906,289  
Deferred revenue
    5,911,922       5,323,154  
Stock warrant liability
          10,659,755  
Other current liabilities
    24,546        
                 
Total current liabilities
    18,236,637       25,044,687  
DEFERRED REVENUE
    3,281,843       2,775,024  
RETIREMENT PLAN BENEFIT LIABILITY
    7,773,056       7,077,901  
                 
Total liabilities
    29,291,536       34,897,612  
                 
COMMITMENTS AND CONTINGENCIES (Note 11)
               
                 
SHAREHOLDERS’ EQUITY:
               
Preferred Stock, par value $0.01 per share, 5,000,000 shares authorized, 200,000 shares of Series A Nonconvertible Preferred Stock issued and outstanding (liquidation value of $7.50 per share or $1,500,000)
    2,000       2,000  
Common Stock, par value $0.01 per share, 100,000,000 shares authorized, 46,061,998 and 38,936,571 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively
    460,620       389,366  
Additional paid-in capital
    560,635,634       280,102,227  
Accumulated deficit
    (219,604,845 )     (217,026,115 )
Accumulated other comprehensive loss
    (5,579,227 )     (6,037,959 )
                 
Total shareholders’ equity
    335,914,182       57,429,519  
                 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY
  $ 365,205,718     $ 92,327,131  
                 



The accompanying notes are an integral part of these consolidated statements.


UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)

   
Three Months Ended September 30,
 
   
2011
   
2010
 
REVENUE:
           
Commercial revenue
  $ 9,881,533     $ 2,836,587  
Developmental revenue
    11,895,607       4,219,274  
                 
Total revenue
    21,777,140       7,055,861  
                 
OPERATING EXPENSES:
               
Cost of chemicals sold
    2,405,493       329,629  
Research and development
    6,079,433       5,760,105  
Selling, general and administrative
    4,957,085       3,452,815  
Patent costs
    1,938,143       1,177,383  
Royalty and license expense
    461,917       218,474  
                 
Total operating expenses
    15,842,071       10,938,406  
                 
Operating income (loss)
    5,935,069       (3,882,545 )
INTEREST INCOME
    363,700       64,373  
INTEREST EXPENSE
    (13,263 )     (5,957 )
GAIN (LOSS) ON STOCK WARRANT LIABILITY
    239,562       (3,362,441 )
                 
INCOME (LOSS) BEFORE INCOME TAX EXPENSE
    6,525,068       (7,186,570 )
                 
INCOME TAX EXPENSE
    (535,642 )      
                 
NET INCOME (LOSS)
  $ 5,989,426     $ (7,186,570 )
                 
NET INCOME (LOSS) PER COMMON SHARE:
               
        BASIC
  $ 0.13     $ (0.19 )
        DILUTED
  $ 0.12     $ (0.19 )
                 
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING
    NET INCOME (LOSS) PER COMMON SHARE:
               
         BASIC
    45,314,893       37,741,107  
         DILUTED
    46,799,557       37,741,107  
                 



The accompanying notes are an integral part of these consolidated statements.



UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES


   
Nine Months Ended September 30,
 
   
2011
   
2010
 
REVENUE:
           
Commercial revenue
  $ 19,904,312     $ 6,618,626  
Developmental revenue
    22,725,783       13,130,714  
                 
Total revenue
    42,630,095       19,749,340  
                 
OPERATING EXPENSES:
               
Cost of chemicals sold
    2,650,695       646,666  
Research and development
    18,186,043       16,089,409  
Selling, general and administrative
    13,324,863       9,719,643  
Patent costs
    5,466,245       2,802,549  
Royalty and license expense
    881,956       507,094  
                 
Total operating expenses
    40,509,802       29,765,361  
                 
Operating income (loss)
    2,120,293       (10,016,021 )
INTEREST INCOME
    644,050       201,153  
INTEREST EXPENSE
    (31,331 )     (18,664 )
LOSS ON STOCK WARRANT LIABILITY
    (4,190,283 )     (5,231,626 )
                 
LOSS BEFORE INCOME TAX (EXPENSE) BENEFIT
    (1,457,271 )     (15,065,158 )
                 
INCOME TAX (EXPENSE) BENEFIT
    (1,121,459 )     464,162  
                 
NET LOSS
  $ (2,578,730 )   $ (14,600,996 )
                 
BASIC AND DILUTED NET LOSS PER COMMON SHARE
  $ (0.06 )   $ (0.39 )
                 
WEIGHTED AVERAGE SHARES USED IN COMPUTING BASIC AND DILUTED NET LOSS PER COMMON SHARE
    43,101,933       37,380,190  
                 



The accompanying notes are an integral part of these consolidated statements.



UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES


   
Nine Months Ended September 30,
 
   
2011
   
2010
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
  $ (2,578,730 )   $ (14,600,996 )
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
               
Amortization of deferred revenue
    (2,234,413 )     (3,653,330 )
Depreciation
    1,092,305       1,329,279  
Amortization of intangibles
    34,194       1,234,272  
Amortization of premium and discount on investments, net
    (483,288 )     (121,891 )
Stock-based employee compensation
    3,270,286       1,902,701  
Stock-based non-employee compensation
    2,899       43,308  
Non-cash expense under a materials agreement
    9,181       896,184  
Stock-based compensation to Board of Directors and Scientific Advisory Board
    1,252,275       660,983  
Loss on stock warrant liability
    4,190,283       5,231,626  
Retirement plan benefit expense
    1,145,154       684,164  
(Increase) decrease in assets:
               
Accounts receivable
    (4,513,407 )     (1,352,085 )
Inventory
    (2,228,411 )     (1,568 )
Other current assets
    270,851       (211,372 )
Other assets
    (95,855 )     (38,835 )
Increase in liabilities:
               
Accounts payable and accrued expenses
    5,306,827       2,335,190  
Other current liabilities
    24,546       -  
Deferred revenue
    3,330,000       688,623  
                 
Net cash provided by (used in) operating activities
    7,794,697       (4,973,747 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:
               
Purchase of property and equipment
    (2,208,403 )     (218,609 )
Purchase of intangibles
    (439,644 )     -  
Purchase of short-term investments
    (290,269,260 )     (71,972,672 )
Proceeds from sale of short-term investments
    72,726,654       56,454,984  
                 
Net cash used in investing activities
    (220,190,653 )     (15,736,297 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:
               
Proceeds from the issuance of common stock
    249,867,265       191,618  
Proceeds from the exercise of common stock options and warrants
    13,282,797       7,167,562  
Payment of withholding taxes related to stock-based employee compensation
    (3,998,516 )     (1,147,522 )
                 
Net cash provided by financing activities
    259,151,546       6,211,658  
                 
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
    46,755,590       (14,498,386 )
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD
    20,368,852       22,701,126  
                 
CASH AND CASH EQUIVALENTS, END OF PERIOD
  $ 67,124,442     $ 8,202,740  
                 
The following non-cash activities occurred:
               
                 
Unrealized gain (loss) on available-for-sale securities
  $ 8,733     $ (8,072 )
Common stock issued to Board of Directors and Scientific Advisory Board that was earned in a previous period
    299,943       314,181  
Common stock issued to employees that was accrued for in a previous period, net of shares withheld for taxes
    1,113,483       929,552  
Common stock issued for royalties that was earned in a previous period
          81,273  
Fair value of stock warrant liability reclassified to shareholders’ equity upon exercise
    14,850,038        



The accompanying notes are an integral part of these consolidated statements.


UNIVERSAL DISPLAY CORPORATION AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

1.
BACKGROUND

Universal Display Corporation (the Company) is engaged in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials for use in flat panel display, solid-state lighting and other product applications. The Company’s primary business strategy is to develop proprietary OLED technologies and materials, and to license these technologies and sell these materials to OLED product manufacturers. Through internal research and development efforts and relationships with entities such as Princeton University (Princeton), the University of Southern California (USC), the University of Michigan (Michigan), Motorola Solutions, Inc. (f/k/a Motorola, Inc.) (Motorola) and PPG Industries, Inc. (PPG Industries), the Company has established a significant portfolio of proprietary OLED technologies and materials (Notes 5 and 7).

2.
BASIS OF PRESENTATION

Interim Financial Information

In the opinion of management, the accompanying unaudited consolidated financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the Company’s financial position as of September 30, 2011 and results of operations for the three and nine months ended September 30, 2011 and 2010, and cash flows for the nine months ended September 30, 2011 and 2010. While management believes that the disclosures presented are adequate to make the information not misleading, these unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto in the Company’s latest year-end financial statements, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.  The results of Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or for the full year.

Management’s Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value of Financial Instruments

The carrying value of cash equivalents, accounts receivable, other current assets and accounts payable approximates fair value in the accompanying financial statements due to the short-term nature of those instruments. See Notes 3 and 4 for a discussion of cash equivalents, short-term investments and stock warrant liability.

Cost of Chemicals Sold

Cost of chemicals sold represents costs associated with the sale of chemicals that have been classified as commercial.  Certain reclassifications were made to the statement of operations between cost of chemicals sold and research and development expenses for the three and nine months ended September 30, 2010 to reflect this current presentation.
Recent Accounting Pronouncements

In September 2009, the Financial Accounting Standards Board (FASB) issued guidance which affects the revenue recognition accounting policies for transactions that involve multiple deliverables. The new guidance requires companies to allocate revenue in arrangements involving multiple deliverables based on the estimated selling price of each deliverable, even though those deliverables are not sold separately either by the company itself or other vendors. This new guidance eliminates the requirement that all undelivered elements have objective and reliable evidence of fair value before a company can recognize the portion of the overall arrangement fee that is attributable to items that already have been delivered. In the absence of vendor-specific objective evidence and third-party evidence for one or more elements in a multiple-element arrangement, companies will estimate the selling prices of those elements. The overall arrangement fee will be allocated to each element whether delivered or undelivered, based on their relative selling prices, regardless of whether those estimated
 
selling prices are evidenced by vendor-specific objective evidence, third-party evidence of fair value or are based on the company’s judgment. The new guidance was effective prospectively for revenue arrangements entered into or materially modified in fiscal years beginning on or after June 15, 2010. The Company adopted this new guidance on a prospective basis beginning January 1, 2011. The adoption of this new guidance did not have an impact on the Company’s results of operations or financial position.

In January 2010, the FASB issued amended standards that require additional fair value disclosures. These amended standards require disclosures about inputs and valuation techniques used to measure fair value as well as disclosures about significant transfers, beginning in the first quarter of 2010.  Additionally, these amended standards require presentation of disaggregated activity within the reconciliation for fair value measurements using significant unobservable inputs (Level 3), beginning in the first quarter of 2011. The adoption of the additional disclosure requirements of this new guidance in the first quarter of 2011 did not have an impact on the Company’s results of operations, financial position, or disclosures.

In April 2010, the FASB issued guidance allowing the milestone method as an acceptable revenue recognition methodology when an arrangement includes substantive milestones. The guidance provides a definition of a substantive milestone and should be applied regardless of whether the arrangement includes single or multiple deliverables or units of accounting. The scope of this consensus is limited to the transactions involving milestones relating to research and development deliverables. The guidance includes enhanced disclosure requirements about each arrangement, individual milestones and related contingent consideration, information about substantive milestones and factors considered in the determination. The consensus is effective prospectively to milestones achieved in annual reporting periods, and interim periods within those years, beginning after June 15, 2010. The Company adopted this new guidance on a prospective basis beginning January 1, 2011. The adoption of this new guidance did not have an impact on the Company’s results of operations or financial position.

In May 2011, the FASB issued amended standards that revised the application of the valuation premise of highest and best use of an asset, the application of premiums and discounts for fair value determination, as well as the required disclosures for transfers between Level 1 and Level 2 fair value measures and the highest and best use of nonfinancial assets. The update provides additional disclosures regarding Level 3 fair value measurements and clarifies certain other existing disclosure requirements. The new guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2011. The Company is currently evaluating the requirements of this new guidance and has not yet determined the impact on the Company’s results of operations or financial position.

In June 2011, the FASB issued amended standards for the reporting of other comprehensive income.  The amendments require that all non-owner changes in stockholders’ equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements.  In either case, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income.  Regardless of which option is chosen, the entity is required to present on the face of the financial statements any adjustments for items that are reclassified from other comprehensive income to net income in the statements where the components of net income and the components of other comprehensive income are presented. The new guidance is effective retrospectively for fiscal years, and interim periods within those years, beginning after December 15, 2011.  The Company does not expect this new guidance to have a material impact on its results of operations or financial position, but it will change the Company’s presentation of comprehensive income (loss).

3.
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents. The Company’s remaining marketable securities are classified as available-for-sale. These securities are carried at fair market value, with unrealized gains and losses reported in shareholders’ equity. Gains or losses on securities sold are based on the specific identification method.

Short-term investments at September 30, 2011 consisted of the following:

   
Amortized
   
Unrealized
   
Aggregate Fair
 
Investment Classification
 
Cost
   
Gains
   
(Losses)
   
Market Value
 
September 30, 2011 –
                       
Certificates of deposit
  $ 5,713,230     $ 130     $ (5,130 )   $ 5,708,230  
Corporate bonds
    258,859,623       73,289       (44,850 )     258,888,062  
U.S. government bonds
    6,233,885       846       ( 1,851 )     6,232,880  
    $ 270,806,738     $ 74,265     $ (51,831 )   $ 270,829,172  

 
Short-term investments at December 31, 2010 consisted of the following:

   
Amortized
   
Unrealized
   
Aggregate Fair
 
Investment Classification
 
Cost
   
Gains
   
(Losses)
   
Market Value
 
December 31, 2010 –
                       
Certificates of deposit
  $ 7,167,818     $ 62     $ (7,919 )   $ 7,159,961  
Corporate bonds
    30,423,518       19,964       (642 )     30,442,840  
U.S. government bonds
    15,189,511       3,040       (807 )     15,191,744  
    $ 52,780,847     $ 23,066     $ (9,368 )   $ 52,794,545  

All short-term investments held at September 30, 2011 will mature within one year.

4.
FAIR VALUE MEASUREMENTS

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2011:

         
Fair Value Measurements, Using
 
   
Total carrying
value as of
September 30, 2011
   
Quoted prices
 in active markets
(Level 1)
   
Significant other observable inputs
(Level 2)
   
Significant unobservable inputs
(Level 3)
 
Cash equivalents
  $ 44,730,776     $ 44,730,776     $     $  
Short-term investments
    270,829,172       270,829,172              

The following table provides the assets and liabilities carried at fair value measured on a recurring basis as of December 31, 2010:

         
Fair Value Measurements, Using
 
   
Total carrying
 value as of December 31, 2010
   
Quoted prices in active markets 
(Level 1)
   
Significant other observable inputs
(Level 2)
   
Significant unobservable inputs
(Level 3)
 
Cash equivalents
  $ 8,234,698     $ 8,234,698     $     $  
Short-term investments
    52,794,545       52,794,545              
Stock warrant liability
    10,659,755                   10,659,755  

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on management’s own assumptions used to measure assets and liabilities at fair value. A financial asset or liability’s classification is determined based on the lowest level input that is significant to the fair value measurement.

The following table is a reconciliation of the changes in fair value of the Company’s stock warrant liability for the three months ended September 30, 2011 and 2010 which had been classified in Level 3 in the fair value hierarchy:

   
2011
   
2010
 
Fair value of stock warrant liability, beginning of period
  $ 4,588,178     $ 5,589,350  
(Gain) loss for period
    (239,562 )     3,362,441  
Warrants exercised
    (4,348,616 )      
Fair value of stock warrant liability, end of period
  $     $ 8,951,791  

The following table is a reconciliation of the changes in fair value of the Company’s stock warrant liability for the nine months ended September 30, 2011 and 2010 which has been classified in Level 3 in the fair value hierarchy:

   
2011
   
2010
 
Fair value of stock warrant liability, beginning of period
  $ 10,659,755     $ 3,720,165  
Loss for period
    4,190,283       5,231,626  
Warrants exercised
    (14,850,038 )      
Fair value of stock warrant liability, end of period
  $     $ 8,951,791  

 
The fair value of the stock warrant liability was determined using the Black-Scholes option pricing model with the following inputs at September 30, 2010:

   
2010
 
Contractual life (years)
    0.9  
Expected volatility
    54.6 %
Risk-free interest rate
    0.2 %
Annual dividend yield
     

5.
RESEARCH AND LICENSE AGREEMENTS WITH PRINCETON, USC AND MICHIGAN

The Company funded OLED technology research at Princeton and, on a subcontractor basis, at USC, for 10 years under a Research Agreement executed with Princeton in August 1997 (the 1997 Research Agreement).  The Principal Investigator conducting work under the 1997 Research Agreement transferred to Michigan in January 2006.  Following this transfer, the 1997 Research Agreement was allowed to expire on July 31, 2007.

As a result of the transfer, the Company entered into a new Sponsored Research Agreement with USC to sponsor OLED technology research at USC and, on a subcontractor basis, Michigan.  This new Research Agreement (as amended, the 2006 Research Agreement) was effective as of May 1, 2006, and had an original term of three years.  The 2006 Research Agreement superseded the 1997 Research Agreement with respect to all work being performed at USC and Michigan.  Payments under the 2006 Research Agreement were made to USC on a quarterly basis as actual expenses were incurred.  The Company incurred $2,155,570 in research and development expense for work performed under the 2006 Research Agreement during the original term, which ended on April 30, 2009.

Effective May 1, 2009, the Company amended the 2006 Research Agreement to extend the term of the agreement for an additional four years. Under the amendment, the Company is obligated to pay USC up to $7,456,294 for work actually performed during the extended term, which runs through April 30, 2013.  From May 1, 2009 through September 30, 2011, the Company incurred $2,055,916 in research and development expense for work performed under the amended 2006 Research Agreement.

On October 9, 1997, the Company, Princeton and USC entered into an Amended License Agreement (as amended, the 1997 Amended License Agreement) under which Princeton and USC granted the Company worldwide, exclusive license rights, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of work performed by Princeton and USC under the 1997 Research Agreement.  Under this agreement, the Company is required to pay Princeton royalties for licensed products sold by the Company or its sublicensees.  For licensed products sold by the Company, the Company is required to pay Princeton 3% of the net sales price of these products.  For licensed products sold by the Company’s sublicensees, the Company is required to pay Princeton 3% of the revenues received by the Company from these sublicensees.  These royalty rates are subject to renegotiation for products not reasonably conceivable as arising out of the 1997 Research Agreement if Princeton reasonably determines that the royalty rates payable with respect to these products are not fair and competitive.

The Company is obligated under the 1997 Amended License Agreement to pay to Princeton minimum annual royalties.  The minimum royalty payment is $100,000 per year.  The Company accrued royalty expense in connection with this agreement of $364,108 and $136,613 for the three months ended September 30, 2011 and 2010, respectively, and $779,147 and $318,245 for the nine months ended September 30, 2011 and 2010, respectively.

The Company also is required under the 1997 Amended License Agreement to use commercially reasonable efforts to bring the licensed OLED technology to market.  However, this requirement is deemed satisfied if the Company invests a minimum of $800,000 per year in research, development, commercialization or patenting efforts respecting the patent rights licensed to the Company.

In connection with entering into the 2006 Research Agreement, the Company amended the 1997 Amended License Agreement to include Michigan as a party to that agreement effective as of January 1, 2006.  Under this amendment, Princeton, USC and Michigan have granted the Company a worldwide exclusive license, with rights to sublicense, to make, have made, use, lease and/or sell products and to practice processes based on patent applications and issued patents arising out of work performed under the 2006 Research Agreement.  The financial terms of the 1997 Amended License Agreement were not impacted by this amendment.

 
6.
ACQUIRED TECHNOLOGY

In 2000, the Company entered into a license agreement with Motorola whereby Motorola granted the Company perpetual license rights to what are now 74 issued U.S. patents relating to Motorola’s OLED technologies, together with foreign counterparts in various countries. These patents will start expiring in the U.S. in 2012.

The Company was required under the license agreement with Motorola to pay Motorola annual royalties on gross revenues received on account of the Company’s sales of OLED products or components, or from its OLED technology licensees, whether or not these revenues related specifically to inventions claimed in the patent rights licensed from Motorola.

On March 9, 2011, the Company purchased these patents from Motorola, including all existing and future claims and causes of action for any infringement of the patents, pursuant to a Patent Purchase Agreement.  The Patent Purchase Agreement effectively terminated the Company’s license agreement with Motorola, including any obligation to make royalty payments to Motorola.

The technology acquired from Motorola had an assigned value of $439,644, which is being amortized over a period of 7.5 years.  The Company accrued royalty expense in connection with the Motorola license agreement of $79,361 and $181,349 for the three and nine months ended September 30, 2010, respectively.  There was no corresponding royalty expense for the three or nine months ended September 30, 2011.

7.
EQUITY AND CASH COMPENSATION UNDER THE PPG INDUSTRIES AGREEMENTS

On October 1, 2000, the Company entered into a five-year Development and License Agreement (the Development Agreement) and a seven-year Supply Agreement (the Supply Agreement) with PPG Industries.  Under the Development Agreement, a team of PPG Industries scientists and engineers assisted the Company in developing its proprietary OLED materials and supplied the Company with these materials for evaluation purposes.  Under the Supply Agreement, PPG Industries supplied the Company with its proprietary OLED materials that were intended for resale to customers for commercial purposes.

On July 29, 2005, the Company entered into an OLED Materials Supply and Service Agreement with PPG Industries (the OLED Materials Agreement). The OLED Materials Agreement superseded and replaced in their entireties the Development Agreement and Supply Agreement effective as of January 1, 2006, and extended the term of the Company’s relationship with PPG Industries through December 31, 2009. The term of the OLED Materials Agreement was subsequently extended through December 31, 2012. Under the OLED Materials Agreement, PPG Industries continued to assist the Company in developing its proprietary OLED materials and supplying the Company with those materials for evaluation purposes and for resale to its customers.

On September 22, 2011, the Company entered into an Amended and Restated OLED Materials Supply and Service Agreement with PPG Industries (the New OLED Materials Agreement).  The New OLED Materials Agreement replaced the original OLED Materials Agreement with PPG Industries effective as of October 1, 2011.  The term of the New OLED Materials Agreement runs through December 31, 2014.  The new agreement contains provisions that are substantially similar to those of the original OLED Materials Agreement.

Under the OLED Materials Agreement and New OLED Materials Agreement, the Company compensates PPG Industries on a cost-plus basis for the services provided during each calendar quarter.  The Company is required to pay for some of these services in all cash. Up to 50% of the remaining services are payable, at the Company’s sole discretion, in cash or shares of the Company’s common stock, with the balance payable in all cash.  The actual number of shares of common stock issuable to PPG Industries is determined based on the average closing price for the Company’s common stock during a specified number of days prior to the end of the relevant calendar quarter.  If, however, this average closing price is less than a specified dollar amount, the Company is required to compensate PPG Industries in all cash.

The Company is also required under the OLED Materials Agreement and New OLED Materials Agreement to reimburse PPG Industries for raw materials used for research and development. The Company records the purchases of these raw materials as a current asset until such materials are used for research and development efforts.

The Company issued 181 and 41,978 shares of the Company’s common stock to PPG Industries as consideration for services provided by PPG Industries under the OLED Materials Agreement during the nine months ended September 30, 2011 and 2010, respectively. For these shares, the Company recorded expense of $9,181 and $500,757 for the nine months ended September 30, 2011 and 2010, respectively.  For the portion of these shares associated with the three months ended September 30, 2011 and 2010, the Company recorded expense of $0 and $338,961, respectively.

The Company recorded expense of $593,081 and $775,059 for the three months ended September 30, 2011 and 2010, respectively, and $2,981,608 and $1,606,621 for the nine months ended September 30, 2011 and 2010, respectively, in relation to the cash portion of the reimbursement of expenses and work performed by PPG Industries, excluding amounts paid for commercial chemicals.

8.
SHAREHOLDERS’ EQUITY

   
Series A
                           
Accumulated
       
   
Nonconvertible
               
Additional
         
Other
   
Total
 
   
Preferred Stock
   
Common Stock
   
Paid-In
   
Accumulated
   
Comprehensive
   
Shareholders’
 
   
Shares
   
Amount
   
Shares
   
Amount
   
Capital
   
Deficit
   
Income (Loss)
   
Equity
 
BALANCE, JANUARY 1, 2011
    200,000     $ 2,000       38,936,571     $ 389,366     $ 280,102,227     $ (217,026,115 )   $ (6,037,959 )   $ 57,429,519  
Net loss
                                  (2,578,730 )           (2,578,730 )
Other comprehensive (loss) income:
                                                               
Unrealized gain
 on available-for-sale securities
                                        8,733       8,733  
Amortization of prior service cost and actuarial loss for retirement plan
                                        449,999       449,999  
Comprehensive loss
                                                            (2,119,998 )
Exercise of common stock options and warrants, net of tendered shares
                1,222,192       12,222       28,120,613                   28,132,835  
Stock-based employee compensation, net of shares withheld for taxes (A)
                103,124       1,031       1,039,232                   1,040,263  
Stock-based non-employee compensation
                72       1       2,898                   2,899  
Issuance of common stock to Board of Directors and Scientific Advisory Board (B)
                41,536       415       1,551,803                   1,552,218  
Issuance of common stock in connection with materials agreements
                181       2       9,179                   9,181  
Issuance of common stock under an Employee Stock Purchase Plan
                8,322       83       238,368                   238,451  
Issuance of common stock through a public offering, net of expenses of  $14,871,186 (C)
                5,750,000       57,500       249,571,314                   249,628,814  
                                                                 
BALANCE,
SEPTEMBER 30, 2011
    200,000     $ 2,000       46,061,998     $ 460,620     $ 560,635,634     $ (219,604,845 )   $ (5,579,227 )   $ 335,914,182  

(A)
Includes $1,768,493 (50,848 shares) that was accrued for in a previous period and charged to expense when earned, but issued in 2011, less shares withheld for taxes in the amount of $655,010 (18,792 shares).
(B)
Includes $299,943 (8,624 shares) that was earned in a previous period and charged to expense when earned, but issued in 2011.
(C)
In March 2011, the Company sold 5,750,000 shares of its Common Stock at $46.00 per share in a registered underwritten public offering. The offering resulted in proceeds to the Company of $249,628,814, which was net of $14,871,186 in underwriting discounts and commissions and other costs associated with completion of the offering.

9.
STOCK-BASED COMPENSATION

The Company recognizes in its results of operations the grant-date fair value of stock options and other equity-based compensation issued to employees and directors. The grant-date fair value of stock options is determined using the Black-Scholes option pricing model. The fair value of share-based awards is recognized as compensation expense on a straight-line basis over the requisite service period, net of estimated forfeitures.  The Company relies primarily upon historical experience to estimate expected forfeitures and recognizes compensation expense on a straight-line basis from the date of the grant.  The Company issues new shares upon the respective exercise, grant or vesting of share-based awards, as applicable.
 
Equity Compensation Plan
 
In 2003, the Company amended and restated its Stock Option Plan (now called the Equity Compensation Plan). Through September 30, 2011, the Company’s shareholders have approved increases in the number of shares reserved for issuance under the Equity Compensation Plan to 8,000,000, and have extended the term of the plan through 2015.

The Equity Compensation Plan provides for the granting of incentive and nonqualified stock options, shares of common stock, stock appreciation rights and performance units to employees, directors and consultants of the Company.  Stock options are exercisable over periods determined by the Compensation Committee, but for no longer than 10 years from the grant date. Options to purchase shares of the Company’s common stock are authorized to be granted at prices not less than the fair market value of the common stock on the date of the grant, as determined by the Compensation Committee of the Board of Directors.

During the nine months ended September 30, 2011, the Company did not grant any stock options to employees. The Company did not record any compensation expense for the three months ended September 30, 2011 and 2010, respectively, and the Company recorded compensation expense of $0 and $30,497 for the nine months ended September 30, 2011 and 2010, respectively, in relation to the vesting of all previously granted employee stock options.

During the nine months ended September 30, 2010, the Company granted to a non-employee stock options to purchase 10,000 shares of the Company’s common stock, which options have since been exercised. These stock options vested immediately and had exercise prices ranging from $8.56 to $9.44.  The fair value of the options granted was $38,366, which was charged to research and development expense for the nine months ended September 30, 2010. No such grants were made for the nine months ended September 30, 2011.

During the nine months ended September 30, 2011, the Company granted a total of 92,822 shares of restricted stock awards and restricted stock units to employees.  The shares associated with these restricted stock awards and restricted stock units had a fair value of $3,228,349 on the date of grant, and will vest over one to six years from the date of grant, provided that the grantee is still an employee of the Company on the applicable vesting date.

For the nine months ended September 30, 2011 and 2010, the Company recorded compensation expense related to the vesting of restricted stock awards and restricted stock units previously granted to employees.  These expenses were charged to general and administrative expense in amounts of $752,550 and $577,609, and to research and development expense in amounts of $296,309 and $112,474, for the three months ended September 30, 2011 and 2010, respectively, and to general and administrative expense in amounts of $2,224,581 and $1,444,707, and to research and development expense in amounts of $871,704 and $344,863, for the nine months ended September 30, 2011 and 2010, respectively.

During the nine months ended September 30, 2011, the Company also granted to employees 2,210 shares of common stock, which shares were issued and fully vested as of the date of grant.  For the fair value of fully-vested shares that were issued to employees, the Company recorded charges to research and development expense of $40,931 and zero for the three months ended September 30, 2011 and 2010, respectively, and $95,728 and $21,734 for the nine months ended September 30, 2011 and 2010, respectively.

In connection with all common stock issued to employees for the nine months ended September 30, 2011, 101,057 shares of common stock with a fair value of $3,998,516 were withheld in satisfaction of tax withholding obligations.

During the nine months ended September 30, 2011, the Company granted 24,000 cash-settled stock appreciation rights (SARs) to certain executive officers. The SARs represent the right to receive, for each SAR, a cash payment equal to the amount, if any, by which the fair market value of a share of the common stock of the Company on the vesting date exceeds the base price of the SAR award.  The base price of each SAR award was $34.78 per share.  The SARs vest on the first anniversary of the date of grant, provided that the grantee is still an employee of the Company on the applicable vesting date. In relation to the vesting of the cash-settled SARs, the Company recorded $61,374 to general and administrative expense and $149,052 to research and development expense for the three months ended September 30, 2011, and $85,770 to general and administrative expense and $208,300 to research and development expense for the nine months ended September 30, 2011.  No such grants were made in 2010.

For the nine months ended September 30, 2011, the Company issued a total 15,000 shares of common stock to members of its Board of Directors as partial compensation for services performed.  For the fair value of shares issued to members of its Board of Directors, the Company recorded charges to general and administrative expense of $197,000 and $67,631 for the three months ended September 30, 2011 and 2010, respectively, and $591,000 and $202,892 for the nine months ended September 30, 2011 and 2010, respectively.

For the nine months ended September 30, 2011, the Company granted a total of 6,900 shares of restricted stock to certain members of its Scientific Advisory Board.  These shares of restricted stock will vest and be issued in equal increments annually over three years from the date of grant, provided that the grantee is still engaged as a consultant of the Company on the applicable vesting date.  In relation to the vesting of all restricted stock awards granted to the Scientific Advisory Board, the Company recorded $337,158 and $208,687 to research and development expense for the three months ended September 30, 2011 and 2010, respectively, and $661,275 and $458,091 to research and development expense for the nine months ended September 30, 2011 and 2010, respectively.

Employee Stock Purchase Plan

On April 7, 2009, the Board of Directors of the Company adopted an Employee Stock Purchase Plan (ESPP).  The ESPP was approved by the Company’s shareholders and became effective on June 25, 2009.  The Company has reserved 1,000,000 shares of common stock for issuance under the ESPP.  Unless sooner terminated by the Board of Directors, the ESPP will expire when all reserved shares have been issued.

Eligible employees may elect to contribute to the ESPP through payroll deductions during consecutive three-month purchase periods, the first of which began on July 1, 2009.  Each employee who elects to participate will be deemed to have been granted an option to purchase shares of the Company’s common stock on the first day of the purchase period.  Unless the employee opts out during the purchase period, the option will automatically be exercised on the last day of the period, which is the purchase date, based on the employee’s accumulated contributions to the ESPP.  The purchase price will equal 85% of the lesser of the price per share of common stock on the first day of the period or the last day of the period.

Employees may allocate up to 10% of their base compensation to purchase shares of common stock under the ESPP; however, each employee may purchase no more than 12,500 shares on a given purchase date, and no employee may purchase more than $25,000 of common stock under the ESPP during a given calendar year.

For the nine months ended September 30, 2011, the Company issued 8,322 shares of its common stock under the ESPP, resulting in proceeds of $238,451.  In relation to the ESPP, the Company recorded $8,457 and $6,783 to general and administrative expense, and $21,142 and $14,132 to research and development expense, for the three months ended September 30, 2011 and 2010, respectively, and $22,102 and $20,887 to general and administrative expense, and $56,172 and $40,011 to research and development expense, for the nine months ended September 30, 2011 and 2010, respectively.  The expense recorded equals the amount of the discount and the value of the look-back feature for the shares that were issued under the ESPP.

10.
SUPPLEMENTAL EXECUTIVE RETIREMENT PLAN

On March 18, 2010, the Compensation Committee and the Board of Directors of the Company approved and adopted the Universal Display Corporation Supplemental Executive Retirement Plan (the SERP), effective as of April 1, 2010.  The purpose of the SERP, which is unfunded, is to provide certain of the Company’s executive officers with supplemental pension benefits following a cessation of their employment. As of September 30, 2011, there were six participants in the SERP. The SERP benefit is based on a percentage of the participant’s annual base salary and the number of years of service.

The Company records amounts relating to the SERP based on calculations that incorporate various actuarial and other assumptions, including discount rates, rate of compensation increases, retirement dates and life expectancies. The net periodic costs are recognized as employees render the services necessary to earn the SERP benefits.
 
The components of net periodic pension cost were as follows for the three months ended September 30,

   
2011
   
2010
 
Service cost
  $ 135,460     $ 110,613  
Interest cost
    96,259       85,347  
Amortization of prior service cost
    146,121       146,122  
Amortization of actuarial loss
    3,878       -  
Total net periodic benefit cost
  $ 381,718     $ 342,082  

The components of net periodic pension cost were as follows for the nine months ended September 30,
 
   
2011
   
2010
 
Service cost
  $ 406,378     $ 221,226  
Interest cost
    288,777       170,694  
Amortization of prior service cost
    438,365       292,244  
Amortization of actuarial loss
    11,634       -  
Total net periodic benefit cost
  $ 1,145,154     $ 684,164  

11.
COMMITMENTS AND CONTINGENCIES

Commitments

Under the 2006 Research Agreement with USC, the Company is obligated to make certain payments to USC based on work performed by USC under that agreement, and by Michigan under its subcontractor agreement with USC.  See Note 5 for further explanation.

Under the terms of the 1997 Amended License Agreement, the Company is required to make minimum royalty payments to Princeton.  See Note 5 for further explanation.

Opposition to European Patent No. 0946958

On December 8, 2006, Cambridge Display Technology (CDT), which was acquired in 2007 by Sumitomo Chemical Company (Sumitomo), filed a Notice of Opposition to European Patent No. 0946958 (EP ‘958 patent). The EP ‘958 patent, which was issued on March 8, 2006, is a European counterpart patent to U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073. These patents relate to the Company’s FOLED™ flexible OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The European Patent Office (the EPO) conducted an Oral Hearing in this matter on October 6, 2009. No representative from CDT attended the Oral Hearing. At the conclusion of the Oral Hearing, the EPO panel announced its decision to reject the opposition and to maintain the patent as granted. The minutes of the Oral Hearing were dispatched on October 27, 2009, and a written decision was issued on November 26, 2009.

CDT filed an appeal to the EPO panel decision on January 25, 2010. CDT timely filed its grounds for the appeal with the EPO on or about April 1, 2010. The EPO set August 12, 2010 as the due date for filing the Company’s reply to this appeal. The Company’s reply was timely filed.

At this time, based on its current knowledge, Company management believes that the EPO panel decision will be upheld on appeal. However, Company management cannot make any assurances of this result.

Opposition to European Patent No. 1449238

On March 8, 2007, Sumation Company Limited (Sumation), a joint venture between Sumitomo and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (EP ‘238 patent). The EP ‘238 patent, which was issued on November 2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. These patents and this patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

Two other parties filed additional oppositions to the EP ‘238 patent just prior to the August 2, 2007 expiration date for such filings. On July 24, 2007, Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim, Germany, filed a third Notice of Opposition to the EP ‘238 patent. The EPO combined all three oppositions into a single opposition proceeding.

The EPO conducted an Oral Hearing in this matter on November 3, 2011.  At the conclusion of the Oral Hearing, the EPO panel announced its decision to maintain the patent with claims directed to OLEDs comprising phosphorescent
 
organometallic iridium compounds.  The Company expects that the official minutes from the Oral Hearing will be published in the near future, and a written decision will follow.  The EPO panel decision is open to appeal.
 
At this time, based on its current knowledge, Company management believes that the EPO panel decision, if appealed, would be upheld on appeal.  However, Company management cannot make any assurances of this result.

Invalidation Trial in Japan for Japan Patent No. 3992929

On April 19, 2010, the Company received a copy of a Notice of Invalidation Trial from the Japanese Patent Office (the JPO) for the Company’s Japan Patent No. 3992929 (the JP ‘929 patent), which was issued on August 3, 2007. The request for the Invalidation Trial was filed by Semiconductor Energy Laboratory Co., Ltd. (SEL), of Kanagawa, Japan. The JP ‘929 patent is a Japanese counterpart patent, in part, to the above-noted EP ‘238 patent and to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. Under the Company’s license agreement with Princeton, the Company is required to pay all legal costs and fees associated with this proceeding.

An Oral Hearing in this matter was held on November 16, 2010.  On February 28, 2011, the Company learned that the JPO had issued a decision recognizing the Company’s invention and upholding the validity of most of the claims, but finding the broadest claims in the patent invalid. Company management believes that the JPO’s decision invalidating these claims was erroneous, and the Company filed an appeal to the Japanese IP High Court.

Both parties are in the process of filing appeal briefs in this matter with the Japanese IP High Court.  A technical explanation hearing has been tentatively scheduled for February 1, 2012.  At the hearing, both parties will be required to file technical materials supporting their respective positions.

At this time, based on its current knowledge, Company management believes that the JPO decision invalidating certain claims in the Company’s JP ‘929 patent should be overturned on appeal as to all or a significant portion of the claims. However, Company management cannot make any assurances of this result.

Opposition to European Patent No. 1394870

On about April 20, 2010, five European companies filed Notices of Opposition to European Patent No. 1394870 (the EP ‘870 patent). The EP ‘870 patent, which was issued on July 22, 2009, is a European counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542; 7,563,519; and 7,901,795; and to pending U.S. patent application 13/035051, filed on February 25, 2011. These patents and this patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding. The five companies are Merck Patent GmbH; BASF Schweitz AG of Basel, Switzerland; Osram GmbH of Munich, Germany; Siemens Aktiengesellschaft of Munich, Germany; and Koninklijke Philips Electronics N.V., of Eindhoven, The Netherlands.

The EPO combined the oppositions into a single opposition proceeding.  The matter has been briefed and the Company is waiting for the EPO to provide notice of the date of the Oral Hearing. The Company is also waiting to see whether any of the other parties in the opposition file additional documents, to which the Company might respond.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, Company management cannot make any assurances of this result.

Invalidation Trials in Japan for Japan Patent Nos. 4357781 and 4358168

On May 24, 2010, the Company received copies of two additional Notices of Invalidation Trials against Japan Patent Nos. 4357781 (the JP ‘781 patent) and 4358168 (the JP ‘168 patent), which were both issued on August 14, 2009. The requests for these two additional Invalidation Trials were also filed by SEL. The JP ‘781 and ‘168 patents are also Japanese counterpart patents, in part, to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. Under the Company’s license agreement with Princeton, the Company is also required to pay all legal costs and fees associated with these two proceedings.

An Oral Hearing in this matter was held on February 1, 2011.  On March 31, 2011, the Company learned that the JPO had issued decisions finding all claims in the JP ‘781 and JP ‘168 patents invalid.  Company management believes that the JPO’s
 
decisions invalidating these claims were erroneous, and the Company filed appeals for both cases to the Japanese IP High Court.

Both parties are in the process of filing appeal briefs in this matter with the Japanese IP High Court.  The Japanese IP High Court has scheduled a first hearing for this matter on November 22, 2011.

At this time, based on its current knowledge, Company management believes that the JPO decisions invalidating all the claims in the Company’s JP ‘781 and JP ‘168 patents should be overturned on appeal as to all or a significant portion of the claims.  However, Company management cannot make any assurances of this result.

Interference No. 105,771 involving Claims 48-52 of US Patent No. 6,902,830

Patent Interference No. 105,771 was declared by the United States Patent and Trademark Office (the USPTO) on November 17, 2010 between The University of Southern California and The Trustees of Princeton University (the Universities), Junior Party, and Fujifilm Holding Corporation (Fuji), Senior Party. The dispute is between the Universities’ U.S. Patent No 6,902,830 (the ’830 patent), claims 48-52, and Fuji’s Patent Application No. 11/802,492, claims 1-5 (the Fuji application). The ‘830 patent relates to the Company’s UniversalPHOLED phosphorescent OLED technology. It is exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The USPTO declares an interference when two or more parties claim the same patentable invention. The objective of an interference is to contest which party, if any, has both a right to participate in the proceeding and a right to the claimed invention and, if more than one party does, then to contest which party has the earliest priority date for the claimed invention.

Subsequent to the filing of motions and responsive motions in this matter, the interference was concluded by the Company’s purchase of the Fuji application.  As a result of this purchase, the Fuji application was assigned to the Company effective September 13, 2011.  The Company then requested that adverse judgment be entered against the Fuji application, which was entered by the USPTO on October 4, 2011.  Thus, the Company’s claims 48-52 of the ‘830 patent, and the ‘830 patent as a whole, remain intact as granted.

Invalidation Trial in Korea for Patent No. KR-0998059

On March 10, 2011, the Company received informal notice from its Korean patent counsel of a Request for an Invalidation Trial from the Korean Intellectual Property Office (KIPO) for the Company’s Korean Patent No. 10-0998059 (the KR ‘059 patent), which was issued on November 26, 2010. The Request was filed by a certain individual petitioner, but the Company still does not know which company, if any, was ultimately responsible for filing this Request.  The KR ‘059 patent is a Korean counterpart patent to the OVJP, Organic Vapor Jet Printing, family of U.S. patents originating from US 7,431,968.

On April 21, 2011, the Company’s Korean patent counsel received a copy of the Appeal Brief for the Request from KIPO.  The Company filed a response to the Request on June 20, 2011.  The petitioner filed a rebuttal brief on August 8, 2011, and the Company filed a response to the rebuttal brief on October 12, 2011.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, Company management cannot make any assurances of this result.

Invalidation Trials in Korea for Patent Nos. KR-558632 and KR-963857

On May 11 and May 31, 2011, respectively, the Company learned that further Requests for Invalidation Trials were filed in Korea, on May 3 and May 26, 2011, respectively, for the Company’s Korean Patent Nos. KR-558632 (the KR ‘632 patent), which issued on March 2, 2006, and KR-963857 (the KR ‘857 patent), which issued on June 8, 2010. The Requests were filed by Duk San Hi-metal, Ltd. (Duk San) of Korea. The KR ‘632 and KR ‘857 patents are both Korean counterpart patents, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542 and 7,563,519; and to pending U.S. patent application 12/489,045, filed on June 22, 2009; to the EP ‘870 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘024 patent, which is subject to the below-noted Japanese Invalidation Trial. These patents and the pending U.S. patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The Company timely filed its formal responses to the Requests by the due dates of August 27, 2011 and September 8, 2011, respectively.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, Company management cannot make any assurances of this result.

Invalidation Trials in Korea for Patent Nos. KR-744199 and KR-913568

On May 10 and May 31, 2011, respectively, the Company learned that further Requests for Invalidation Trials were filed in Korea, on May 3 and May 26, 2011, respectively, for the Company’s Korean Patent Nos. KR-744199 (the KR ‘199 patent), which issued on July 24, 2007, and KR-913568 (the KR ‘568 patent), which issued on August 17, 2009. The Requests were also filed by Duk San. The KR ‘199 and KR ‘568 patents are both Korean counterpart patents, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011; to the EP ‘238 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘929 patent, which is subject to one of the above-noted Japanese Invalidation Trials. These patents and this patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The Company timely filed its formal responses to the Requests by the due dates of September 1, 2011 and August 23, 2011, respectively.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, Company management cannot make any assurances of this result.

Invalidation Trial in Japan for Japan Patent No. 4511024

On June 16, 2011, the Company learned that a further Request for an Invalidation Trial was filed in Japan for the Company’s Japanese Patent No. JP-4511024 (the JP ‘024 patent), which issued on May 14, 2010. The Request was filed by SEL, the same opponent as in the above-noted Japanese Invalidation Trial for the JP ‘929 patent. The JP ‘024 patent is a counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542; 7,563,519; and 7,901,795; and to pending U.S. patent application 13/035051, filed on February 25, 2011; to the EP ‘870 patent, which is subject to one of the above-noted European Oppositions; and to the KR ‘632 and KR ‘857 patents, which are subject to one of the above noted Korean Invalidation Trials. These patents and the pending U.S. patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The Company timely filed a Written Reply to the Request for Invalidation Trial by the due date of November 2, 2011.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, Company management cannot make any assurances of this result.

Opposition to European Patent No. 1252803

On July 12 and 13, 2011, Oppositions were filed to the Company’s European Patent No. 1252803 (the EP ‘803 patent). These Oppositions were filed by Sumitomo, Merck Patent GmbH and BASF SE, of Ludwigshaven, Germany. The EP ‘803 patent, which was issued on October 13, 2010, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. These patents and this patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

The EPO combined the oppositions into a single opposition proceeding and set December 18, 2011 as the due date for the Company to file its response, subject to extension.

At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, Company management cannot make any assurances of this result.

Invalidation Trials in Korea for Patent Nos. KR-840,637 and KR-937,470

On August 8, 2011, the Company received information indicating that further Requests for Invalidation Trials were filed against the Company’s Korean Patent Nos. KR-840,637 (the KR ‘637 patent) and KR-937,470 (the KR ‘470 patent), which issued on June 17, 2008 and January 11, 2010, respectively. The Requests were also filed by Duk San. The KR ‘637 and KR ‘470 patents are both Korean counterpart patents, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011; to the EP ‘803 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘781 and JP ‘168 patents, which are subject to the above-noted Japanese Invalidation Trials. These patents and this patent application relate to the Company’s UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to the Company by Princeton, and under the license agreement the Company is required to pay all legal costs and fees associated with this proceeding.

Formal, substantially non-substantive responses were originally due in Korea on September 7 and 8, 2011, respectively, but these due dates have now been extended until December 7 and 8, 2011, respectively.  
 
At this time, based on its current knowledge, Company management believes there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, Company management cannot make any assurances of this result.

12.
CONCENTRATION OF RISK

Contract research revenue, which is included in developmental revenue in the accompanying statement of operations, of $1,300,658 and $1,288,745 for the three months ended September 30, 2011 and 2010, respectively, and $4,591,702 and $3,662,284 for the nine months ended September 30, 2011 and 2010, respectively, has been derived from contracts with United States government agencies. Revenues derived from contracts with government agencies represented 6% and 18% of consolidated revenue for the three months ended September 30, 2011 and 2010, respectively, and 11% and 19% of consolidated revenue for the nine months ended September 30, 2011 and 2010, respectively.

Revenues for the nine months ended September 30, 2011 and 2010, and accounts receivable as of September 30, 2011 from our largest non-government customers, were as follows:

     
% of Total Revenue
   
Accounts Receivable
 
Customer
   
2011
   
2010
   
September 30, 2011
 
  A       43 %     31 %   $ 4,341,679  
  B       12 %     20 %     1,771,700  
  C       24 %     3 %     2,786,808  

Revenues for the three months ended September 30, 2011 and 2010, from the same non-government customers, were as follows:

     
% of Total Revenue
 
Customer
   
2011
   
2010
 
  A       41 %     40 %
  B       9 %     20 %
  C       36 %     3 %

The Company’s relationships with customers B and C are under agreements that are presently scheduled to expire in less than twelve months.

Revenues from outside of North America represented 93% and 81% of the consolidated revenue for the three months ended September 30, 2011 and 2010, respectively. Revenues by geographic area are as follows:
 
Country
 
2011
   
2010
 
United States
  $ 1,424,608     $ 1,366,246  
                 
South Korea
    11,225,215       4,440,324  
Japan
    9,032,499       754,540  
Taiwan
    67,600       466,027  
Other
    27,218       28,724  
All foreign locations
    20,352,532       5,689,615  
                 
Total revenue
  $ 21,777,140     $ 7,055,861  
 
Revenues from outside of North America represented 89% and 80% of the consolidated revenue for the nine months ended September 30, 2011 and 2010, respectively. Revenues by geographic area are as follows:

Country
 
2011
   
2010
 
United States
  $ 4,871,667     $ 3,936,434  
                 
South Korea
    24,300,274       10,462,769  
Japan
    12,743,123       4,263,877  
Taiwan
    605,310       1,040,124  
Other
    109,721       46,136  
All foreign locations
    37,758,428       15,812,906  
                 
Total revenue
  $ 42,630,095     $ 19,749,340  

The Company attributes revenue to different geographic areas on the basis of the location of the customer.

Long-lived tangible assets at international locations are not significant for each of the periods presented.

All chemical materials were purchased from one supplier. See Note 7.

13.
INCOME TAXES

The Company filed for and was granted a five-year exemption from withholding tax on royalty payments received from Samsung Mobile Display Co., Ltd. (Samsung SMD) under its patent license agreement as part of a tax incentive program in Korea. The exemption was granted in May 2005 and remained in effect until May 2010. Since then, Samsung SMD has been required to withhold tax upon payment of royalties to the Company.  In 2011 and 2010, the withholding tax rate for royalty payments made by Samsung SMD was 16.5%. For the three and nine months ended September 30, 2011, foreign income taxes of $535,642 and $1,121,459, respectively, were withheld in connection with royalty payments. No such taxes were withheld during the nine months ended September 30, 2010.

During the nine months ended September 30, 2010, the Company sold approximately $3.8 million of its state-related income tax net operating losses and $194,088 of its research and development tax credits under the New Jersey Technology Tax Certificate Transfer Program.  The Company received proceeds of $464,162 from these sales and recorded these proceeds as an income tax benefit.  No corresponding sales of state-related income tax net operating losses or research and development tax credits occurred during the nine months ended September 30, 2011.

14.
NET INCOME (LOSS) PER COMMON SHARE

Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of shares of common stock outstanding for the period.  Diluted net income (loss) per common share reflects the potential dilution from the exercise or conversion of securities into common stock, the effect of unvested restricted stock awards and restricted stock units, and the impact of shares to be issued under the ESPP.

The following table is a reconciliation of net income (loss) and the shares used in calculating basic and diluted net income (loss) per common share for the three months ended September 30, 2011 and 2010:

   
2011
   
2010
 
Numerator:
           
Net income (loss) – Basic
  $ 5,989,426     $ (7,186,570 )
Effect of warrants
    (239,562 )      
     Net income(loss) – Diluted
  $ 5,749,864     $ (7,186,570 )
Denominator:
               
Weighted average common shares outstanding – Basic
    45,314,893       37,741,107  
Effect of dilutive shares:
               
Common stock equivalents arising from stock options, warrants and ESPP
    1,059,293        
Restricted stock awards and units
    425,371        
                 
Weighted average common shares outstanding – Diluted
    46,799,557       37,741,107  
Net income (loss) per common share:
               
Basic
  $ 0.13     $ (0.19 )
Diluted
  $ 0.12     $ (0.19 )
 
For the three months ended September 30, 2010, the effects of the exercise of the combined outstanding stock options and warrants and unvested restricted stock awards and restricted stock units of 3,777,027, and the impact of shares to be issued under the ESPP, which was minor, were excluded from the calculation of diluted EPS as the impact would have been antidilutive.

The following table is a reconciliation of net loss and the shares used in calculating basic and diluted net loss per common share for the nine months ended September 30, 2011 and 2010:

   
2011
   
2010
 
Numerator:
           
     Net loss
  $ (2,578,730 )   $ (14,600,996 )
Denominator:
               
Weighted average common shares outstanding – Basic
    43,101,933       37,380,190  
Effect of dilutive shares
           
Weighted average common shares outstanding – Diluted
    43,101,933       37,380,190  
Net loss per share:
               
Basic and diluted
  $ (0.06 )   $ (0.39 )

For the nine months ended September 30, 2011 and 2010, the effects of the exercise of the combined outstanding stock options and warrants and unvested restricted stock awards and restricted stock units of 1,769,470 and 3,777,027, respectively, and the impact of shares to be issued under the ESPP, which was minor, were excluded from the calculation of diluted EPS as the impact would have been antidilutive.

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and related notes above.

CAUTIONARY STATEMENT
CONCERNING FORWARD-LOOKING STATEMENTS

This discussion and analysis contains some “forward-looking statements.” Forward-looking statements concern our possible or assumed future results of operations, including descriptions of our business strategies and customer relationships. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may” or similar expressions. These statements are based on assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances.

As you read and consider this discussion and analysis, you should not place undue reliance on any forward-looking statements. You should understand that these statements involve substantial risk and uncertainty and are not guarantees of
 
future performance or results. They depend on many factors that are discussed further in the section entitled (Risk Factors) in our Annual Report on Form 10-K for the year ended December 31, 2010, as supplemented by any disclosures in Item 1A of Part II of our Quarterly Report for the quarter ended March 31, 2011, and by any disclosures in Item 1A of Part II below. Changes or developments in any of these areas could affect our financial results or results of operations, and could cause actual results to differ materially from those contemplated in the forward-looking statements.

All forward-looking statements speak only as of the date of this report or the documents incorporated by reference, as the case may be. We do not undertake any duty to update any of these forward-looking statements to reflect events or circumstances after the date of this report or to reflect the occurrence of unanticipated events.

OVERVIEW

We are a leader in the research, development and commercialization of organic light emitting diode, or OLED, technologies for use in flat panel display and solid-state lighting applications. Since 1994, we have been exclusively engaged, and expect to continue to be exclusively engaged, in funding and performing research and development activities relating to OLED technologies and materials, and in commercializing these technologies and materials. Our revenues are generated through contract research, sales of development and commercial chemicals, technology development and evaluation agreements and license fees and royalties. Over time, we anticipate that revenues from licensing our intellectual property and selling our proprietary materials will become the dominant elements of our revenue stream.

We have made significant progress over the past few years developing and commercializing our PHOLED™ and other OLED technologies and materials.  Nevertheless, we have incurred significant losses since our inception, resulting in an accumulated deficit of $219,604,845 as of September 30, 2011.

We anticipate fluctuations in our annual and quarterly results of operations due to uncertainty regarding, among other factors:

·
the timing of our receipt of license fees and royalties, as well as fees for future technology development and evaluation activities;
   
·
the timing and volume of sales of our OLED materials for both commercial usage and evaluation purposes;
   
·
the timing and magnitude of expenditures we may incur in connection with our ongoing research and development activities; and
   
·
the timing and financial consequences of our formation of new business relationships and alliances.

RESULTS OF OPERATIONS

Three Months Ended September 30, 2011 Compared to Three Months Ended September 30, 2010

We had operating income of $5,935,069 for the three months ended September 30, 2011, compared to an operating loss of $3,882,545 for the three months ended September 30, 2010. The change to an operating profit from an operating loss was due to the following:

·
an increase in revenue of $14,721,279; offset by

·
an increase in operating expenses of $4,903,665.

We had net income of $5,989,426 (or $0.13 per basic share and $0.12 per diluted share) for the three months ended September 30, 2011, compared to a net loss of $7,186,570 (or $0.19 per basic and diluted share) for the three months ended September 30, 2010.

The change to net income from a net loss was due mainly to the increase in operating income of $9,817,614, as well as a gain on stock warrant liability of $239,562 for the three months ended September 30, 2011, compared to a loss on stock warrant liability of $3,362,441 for the same period in 2010.

Our revenues were $21,777,140 for the three months ended September 30, 2011, compared to $7,055,861 for the three months ended September 30, 2010.

Commercial revenue increased to $9,881,533 for the three months ended September 30, 2011, compared to $2,836,587 for the three months ended September 30, 2010.  Commercial revenue relates to the incorporation of our OLED technologies and materials into our customers’ commercial products, and includes commercial chemical revenue, royalty and license revenues, and commercialization assistance revenue.  The increase in commercial revenue was primarily due to the following:

·
an increase of $3,464,613 in commercial chemical revenue, of which $2,870,748 represents an increase in sales of our host materials, as discussed in further detail below; and

·
an increase of $3,560,628 in royalty and license revenue, which mainly represents license fees received under our license agreement with Samsung Mobile Display Co., Ltd. (Samsung SMD) executed in August 2011.

On April 19, 2005, we entered into an OLED Patent License Agreement and an OLED Supplemental License Agreement with Samsung SDI Co., Ltd. (Samsung SDI).  Under the license agreement, we granted Samsung SDI Co. license rights under various patents that we owned or controlled for Samsung SDI to make and sell specified OLED display products. In consideration of this license grant, Samsung SDI Co. agreed to pay us up front license fees and running royalties on its sales of these display products.  The 2005 agreements had terms that ran through June 30, 2010.

Effective as of September 5, 2008, the 2005 agreements were assigned by Samsung SDI to Samsung SMD, a subsidiary of Samsung SDI, in connection with Samsung SDI’s transfer of all its OLED assets and liabilities to Samsung SMD.  In July 2010, we entered into an amendment extending the terms of the 2005 agreements for three months.  We subsequently entered into further amendments extending the terms of the 2005 agreements for additional three-month periods through September 30, 2011.

On August 22, 2011, we entered into a new OLED Patent License Agreement and a new Supplemental OLED Material Purchase Agreement with Samsung SMD.  These agreements replaced the 2005 agreements in their entirety, effectively terminating the 2005 agreements.  The 2011 agreements have terms that run through December 31, 2017.

Under the 2011 license agreement, we granted Samsung SMD license rights under various patents that we owned or controlled for Samsung SMD to manufacture and sell specified OLED display products.  In consideration of the license grant, Samsung SMD agreed to pay us a fixed license fee, payable in installments over the agreement term.  These installments increase on an annual basis over the term of the license agreement.  The installment amounts were determined through negotiation based on a number of factors, including, without limitation, estimates of Samsung SMD’s OLED business growth as a percentage of published OLED market forecasts, the use of red and green phosphorescent materials in Samsung SMD’s OLED display products, and appropriate royalty rates relating to Samsung SMD’s practice under the licensed patents.  For the three months and nine months ended September 30, 2011, we received and recognized as revenue $3,246,315 in license fees from Samsung SMD under the 2011 license agreement.

Pursuant to the 2011 supplemental agreement, Samsung SMD agreed to purchase from us a minimum dollar amount of phosphorescent materials for use in the manufacture of licensed products.  This minimum purchase commitment is subject to us being able to supply Samsung SMD with sufficient material to meet its requirements over the agreement term.  The minimum purchase amounts increase on an annual basis over the term of the supplemental agreement.  The minimum purchase amounts were determined through negotiation based on a number of factors, including, without limitation, estimates of Samsung SMD’s OLED business growth as a percentage of published OLED market forecasts and Samsung SMD’s projected minimum usage of red and green phosphorescent emitter materials over the term of the agreement.

Commercial chemical revenue for the three months ended September 30, 2011 included revenue received from sales of both phosphorescent emitter and host materials.  Host material sales were approximately 31% of our total commercial chemical revenue for this period, compared to no commercial chemical revenue from host material sales for the corresponding period in 2010.  We believe that host material sales can enhance our phosphorescent emitter material sales business.  However, the host material business is more competitive than the phosphorescent emitter material sales business, and our long-term prospects for host material sales are uncertain.

We cannot accurately predict how long our phosphorescent emitter material sales or host material sales to particular customers will continue, as our customers frequently update and alter their product offerings in response to market demands. Continued sales of our OLED materials to these customers will depend on several factors, including pricing, availability, continued technical improvement and competitive product offerings.

Developmental revenue increased to $11,895,607 for the three months ended September 30, 2011, compared to $4,219,274 for the three months ended September 30, 2010.  Developmental revenue relates to OLED technology and material development and evaluation activities for which we are paid, and includes contract research revenue, development chemical
 
revenue and technology development revenue.  The increase in developmental revenue was due primarily to an increase of $7,512,138 in development chemical revenue, of which $4,275,236 represents an increase in sales of our host materials, mainly due to increased purchases of development chemicals by customers that are preparing for commercial production.

Cost of chemicals sold increased to $2,405,493 for the three months ended September 30, 2011, compared to $329,629 for the three months ended September 30, 2010. Cost of chemicals sold includes the cost of producing materials that have been classified as commercial and shipping costs for such materials, but excludes the cost of producing certain commercial materials which costs have already been included in research and development expense. Cost of chemicals sold does not include costs associated with producing materials that have not yet been classified as commercial, which costs are included in research and development expenses. Depending on the timing and stage of materials being classified as commercial, we expect the cost of chemicals for these materials to fluctuate from quarter to quarter.  As a result of these timing issues, and due to increased sales of commercial chemicals, cost of chemicals sold increased for the three months ended September 30, 2011 compared to the same period in 2010. During the quarter, costs associated with $4,146,800 of development chemical sales related to materials classified as commercial were included in cost of sales.
 
We incurred research and development expenses of $6,079,433 for the three months ended September 30, 2011, compared to $5,760,105 for the three months ended September 30, 2010. Although total expenses remained relatively consistent over the corresponding periods, the following significant changes occurred:

·
employee costs increased by $599,918, due mainly to new employees, increased salaries and stock compensation for certain executive officers;

·
development costs with PPG Industries decreased by $520,939; and

·
amortization costs decreased by $372,082, due to certain acquired technology being fully amortized as of December 31, 2010.

Selling, general and administrative expenses were $4,957,085 for the three months ended September 30, 2011, compared to $3,452,815 for the three months ended September 30, 2010. The overall increase in these costs was driven in part by increased commercial activities and non-cash expenses related to stock compensation and in part by costs incurred to establish new subsidiaries in Hong Kong, Korea and Japan. Specifically, we incurred increased costs in the following areas:

·
increased employee costs of $324,496, due mainly to increased salaries and stock compensation for certain  executive officers;

·
increased general legal fees of $305,629, due in large part to expanded licensing negotiations;

·
increased international consulting fees of $267,008 related to increased revenues; and

·
costs of $138,813 resulting from the incorporation and commencement of operations for certain of our foreign subsidiaries.

Patent costs increased to $1,938,143 for the three months ended September 30, 2011, compared to $1,177,383 for the three months ended September 30, 2010. The increase was mainly due to increased costs associated with our defense of certain ongoing and new patent challenges to our issued patents, as well as the timing of prosecution and maintenance costs associated with a number of patents and patent applications.

Interest income increased to $363,700 for the three months ended September 30, 2011, compared to $64,373 for the three months ended September 30, 2010.  The increase was mainly attributable to interest earned on higher average cash and investment balances as a result of proceeds received from the completion of our public offering in March 2011.

In August 2011, all remaining outstanding stock warrants to purchase shares of our common stock were exercised, and we received $2,948,463 in proceeds for issuing 214,746 common shares based on the exercise of these warrants. The warrants, which contained a “down-round” provision, were previously recorded as a liability. The change in fair value of the warrants during the period prior to the exercise date resulted in a $239,562 non-cash gain on our statement of operations for the three months ended September 30, 2011, compared to a $3,362,441 non-cash loss for the three months ended September 30, 2010.

For the three months ended September 30, 2011, we incurred an income tax expense of $535,642. No corresponding expense was incurred for the three months ended September 30, 2010. We filed for and were granted a five-year exemption from withholding tax on royalties and license fees received from Samsung SMD under our 2005 license agreement as part of a tax
 
incentive program in Korea. The exemption was granted in May 2005 and remained in effect until May 2010. Since then, Samsung SMD has been required to withhold tax upon payment of royalties to us.  This is also the case under the 2011 license agreement that we entered into with Samsung SMD in August 2011.
In 2011 and 2010, the withholding tax rate for royalties and license fees paid by Samsung SMD was 16.5%. For the three months ended September 30, 2011, foreign income taxes of $535,642 were withheld in connection with these payments. We anticipate the amount of withholding taxes to increase as license fees received from Samsung SMD increase in the future.

Nine Months Ended September 30, 2011 Compared to Nine Months Ended September 30, 2010

We had operating income of $2,120,293 for the nine months ended September 30, 2011, compared to an operating loss of $10,016,021 for the nine months ended September 30, 2010. The change from an operating loss to an operating profit was due to the following:

·
an increase in revenue of $22,880,755; offset by

·
an increase in operating expenses of $10,744,441.

We had a net loss of $2,578,730 (or $0.06 per basic and diluted share) for the nine months ended September 30, 2011, compared to a net loss of $14,600,996 (or $0.39 per basic and diluted share) for the nine months ended September 30, 2010. The decrease in net loss was mainly due to the following:
 
·
the increase in operating income of $12,136,314;

·
a decrease in loss on stock warrant liability of $1,041,343;

·
an increase in interest income of $442,897; offset primarily by

·
an increase in income tax expense of $1,585,621.

Our revenues were $42,630,095 for the nine months ended September 30, 2011, compared to $19,749,340 for the nine months ended September 30, 2010.

Commercial revenue increased to $19,904,312 for the nine months ended September 30, 2011, compared to $6,618,626 for the nine months ended September 30, 2010.  Commercial revenue relates to the incorporation of our OLED technologies and materials into our customers’ commercial products, and includes commercial chemical revenue, royalty and license revenues, and commercialization assistance revenue.  The increase in commercial revenue was primarily due to the following:

·
an increase of $6,161,658 in commercial chemical revenue, of which $2,870,748 represents an increase in sales of our host materials, and discussed in further detail below; and

·
an increase of $7,064,914 in royalty and license revenue, which in substantial part represents royalty and license fee payments received under our patent license agreements with Samsung SMD, including our new agreement executed in August 2011, as discussed earlier.

Commercial chemical revenue for the nine months ended September 30, 2011 included revenue received from sales of both phosphorescent emitter and host materials.  Host material sales were approximately 41% of our total commercial chemical revenue for this period, compared to no commercial chemical revenue from host material sales for the corresponding period in 2010.  We believe that host material sales can enhance our phosphorescent emitter material sales business.  However, the host material business is more competitive than the phosphorescent emitter material sales business, and our long-term prospects for host material sales are uncertain.

We cannot accurately predict how long our phosphorescent emitter material sales or host material sales to particular customers will continue, as our customers frequently update and alter their product offerings in response to market demands. Continued sales of our OLED materials to these customers will depend on several factors, including pricing, availability, continued technical improvement and competitive product offerings.

Developmental revenue increased to $22,725,783 for the nine months ended September 30, 2011, compared to $13,130,714 for the nine months ended September 30, 2010.  Developmental revenue relates to OLED technology and material
 
development and evaluation activities for which we are paid, and includes contract research revenue, development chemical revenue and technology development revenue.  The increase in developmental revenue was due to:

·
an increase of $10,539,025 in development chemical revenue, of which $5,693,331 represents an increase in sales of our host materials, mainly due to increased purchases of development chemicals by customers that are preparing for commercial production; and

·
an increase in contract revenue of $929,417; offset in part by

·
a decrease of $1,873,374 in technology development revenue, due to the recognition as revenue during the nine months ended September 30, 2010 of non-refundable payments totaling $2,100,000 that were received from a customer through the fourth quarter of 2006.
 
The $2,100,000 received from a customer referenced above was for technical assistance previously provided under an agreement to conduct OLED development, evaluation and sampling activities.  These payments were made between the years 2001 and 2006, and the agreement itself expired at the end of 2006.  We had previously classified these payments as deferred revenue because they were creditable against the license fee under a commercial license agreement in the event we entered into one with the customer.  In May 2010, based on information received from the customer regarding its future OLED plans, we determined that the likelihood of us entering into a commercial license agreement was remote.  As a result of this determination, we recorded the $2,100,000 payment as technology development revenue in the second quarter of 2010. No similar revenue was recognized during the nine months ended September 30, 2011.

Cost of chemicals sold increased to $2,650,695 for the nine months ended September 30, 2011, compared to $646,666 for the nine months ended September 30, 2010. Cost of chemicals sold includes the cost of producing materials that have been classified as commercial and shipping costs for such materials, but excludes the cost of producing certain commercial materials which costs have already been included in research and development expense. Cost of chemicals sold does not include costs associated with producing materials that have not yet been classified as commercial, which costs are included in research and development expenses. Depending on the timing and stage of materials being classified as commercial, we expect the costs of chemicals for these materials to fluctuate from quarter to quarter. As a result of these timing issues, and due to increased sales of commercial chemicals, cost of chemicals sold increased for the nine months ended September 30, 2011 compared to the same period in 2010. During the period, costs associated with $9,138,435 of development chemical sales related to materials classified as commercial were included in cost of sales.

We incurred research and development expenses of $18,186,043 for the nine months ended September 30, 2011, compared to $16,089,409 for the nine months ended September 30, 2010. The increase was mainly due to:

·
increased employee costs of $1,476,281, due primarily to new employees, increased salaries, costs associated with retirement benefits and stock compensation for certain executive officers;

·
increased costs of $790,477, due to overall expanded research and development efforts to support the growth of our business;

·
costs of $492,399 resulting from commencement of research and development activities at certain of our foreign subsidiaries;

·
increased costs of $487,984 incurred under our agreement with PPG Industries; offset in part by

·
decreased amortization costs of $1,200,078 due to part of our acquired technology being fully amortized as of December 31, 2010.

Selling, general and administrative expenses were $13,324,863 for the nine months ended September 30, 2011, compared to $9,719,643 for the nine months ended September 30, 2010. The overall increase in these costs was driven in part by increased commercial activities and non-cash expenses related to stock compensation, and in part by costs incurred to establish new subsidiaries in Hong Kong, Korea and Japan. Specifically, we incurred increased costs in the following areas:

·
increased employee costs of $1,320,785, due primarily to increased salaries,   costs associated with retirement benefits and stock compensation for certain executive officers;

·
costs of $400,648 resulting from the incorporation and commencement of operations of certain of our foreign subsidiaries;

·
increased costs of $388,108 related to stock compensation for members of our Board of Directors;

·
increased general legal fees of $351,405, due in large part to expanded licensing negotiations; and

·
increased international consulting fees related to increased revenues of $322,318.

Patent costs increased to $5,466,245 for the nine months ended September 30, 2011, compared to $2,802,549 for the nine months ended September 30, 2010. The increase was mainly due to increased costs associated with our defense of certain ongoing and new patent challenges to our issued patents, as well as the timing of prosecution and maintenance costs associated with a number of patents and patent applications.
 
Interest income increased to $644,050 for the nine months ended September 30, 2011, compared to $201,153 for the nine months ended September 30, 2010. The increase was mainly attributable to interest earned on higher average cash and investment balances as a result of proceeds received from the completion of our public offering in March 2011.

In 2011, all remaining outstanding stock warrants to purchase shares of our common stock were exercised, and we received $7,397,710 in proceeds for issuing 586,972 common shares based on the exercise of these warrants. The warrants, which contained a “down-round” provision, were previously recorded as a liability. The change in fair value of these warrants during the period prior to the exercise date resulted in a $4,190,283 non-cash loss on our statement of operations for the nine months ended September 30, 2011, compared to a $5,231,626 non-cash loss for the nine months ended September 30, 2010.

For the nine months ended September 30, 2011, we incurred an income tax expense of $1,121,459, compared to an income tax benefit of $464,162 for the nine months ended September 30, 2010. We had previously filed for and were granted a five-year exemption from withholding tax on royalties and license fees received from Samsung SMD under our 2005 license agreement as part of a tax incentive program in Korea. The exemption was granted in May 2005 and remained in effect until May 2010. Since then, Samsung SMD has been required to withhold tax upon payment of royalties to us.  This is also the case under the 2011 license agreement that we entered into with Samsung SMD in August 2011.

In 2011 and 2010, the withholding tax rate for royalties and license fees paid by Samsung SMD was 16.5%. For the nine months ended September 30, 2011, foreign income taxes of $1,121,459 were withheld in connection with these payments. We anticipate the amount of withholding taxes to increase as associated payments received from Samsung SMD increase in the future.

During the nine months ended September 30, 2010, we sold approximately $3.8 million of our state-related income tax net operating losses (NOLs) and $194,088 of our research and development tax credits under the New Jersey Technology Tax Certificate Transfer Program.  We received proceeds of $464,162 from our sale of these NOLs and research and development tax credits, and we recorded these proceeds as an income tax benefit.  No corresponding sales have occurred during the nine months ended September 30, 2011.

Liquidity and Capital Resources

As of September 30, 2011, we had cash and cash equivalents of $67,124,442 and short-term investments of $270,829,172, for a total of $337,953,614. This compares to cash and cash equivalents of $20,368,852 and short-term investments of $52,794,545, for a total of $73,163,397, as of December 31, 2010. The increase in cash and cash equivalents and short-term investments of $264,790,217 was primarily due to the completion in March 2011 of our public offering of 5,750,000 shares of our common stock at a price of $46.00 per share. The offering resulted in net proceeds to us of $249,628,814.

Cash provided from operating activities was $7,794,694 for the nine months ended September 30, 2011, compared to cash used of $4,973,747 for the same period in 2010. The increase in cash provided by operating activities was primarily due to the following:

·
a decrease in net loss of $12,093,843, which amount excludes the impact of non-cash items;

·
the impact of the timing of payment of accounts payable and accrued expenses of $2,971,637; and

·
an increase of $2,641,377 in deferred revenue and licensing fees received; offset partially by

·
the impact of the timing of receipt of accounts receivable of $3,161,322; and

·
the impact of the timing of inventory purchases of $2,226,843.

Cash used in investing activities was $220,190,650 for the nine months ended September 30, 2011, compared to $15,736,297 for the same period in 2010. The increase in cash used in investing activities was mainly due to increased purchases of short-term investments as a result of the completion of our public offering described below.

Cash provided by financing activities was $259,151,546 for the nine months ended September 30, 2011, compared to $6,211,658 for the same period in 2010. The increase in cash provided by financing activities was due primarily to the completion of our March 2011 public offering. The offering resulted in proceeds to us of $249,628,814, which was net of $14,871,186 in underwriting discounts and commissions and other costs associated with completion of the offering. In addition, for the nine months ended September 30, 2010, we received proceeds of $13,282,797 from the exercise of options and warrants to purchase shares of our common stock, compared to proceeds of $7,167,562 from the exercise of options and warrants to purchase shares of our common stock for the same period in 2010.

Working capital was $335,424,056 as of September 30, 2011, compared to $57,354,822, which included a stock warrant liability of $10,659,755, as of December 31, 2010. The stock warrants associated with this liability were all exercised by August 2011, resulting in no cash outlay by us. Working capital, excluding the stock warrant liability, was $335,424,056 as of September 30, 2011 and $68,014,577 at December 31, 2010.  Again, the increase in working capital was primarily due to proceeds from the common stock offering we completed in March 2011.

We anticipate, based on our internal forecasts and assumptions relating to our operations (including, among others, assumptions regarding our working capital requirements, the progress of our research and development efforts, the availability of sources of funding for our research and development work, and the timing and costs associated with the preparation, filing, prosecution, maintenance, defense and enforcement of our patents and patent applications), that we have sufficient cash, cash equivalents and short-term investments to meet our obligations for at least the next 12 months.

We believe that potential additional financing sources for us include long-term and short-term borrowings, public and private sales of our equity and debt securities and the receipt of cash upon the exercise of outstanding stock options. It should be noted, however, that additional funding may be required in the future for research, development and commercialization of our OLED technologies and materials, to obtain, maintain and enforce patents respecting these technologies and materials, and for working capital and other purposes, the timing and amount of which are difficult to ascertain. There can be no assurance that additional funds will be available to us when needed, on commercially reasonable terms or at all , particularly in the current economic environment.

Critical Accounting Policies

Revenue Recognition and Deferred Revenue

We receive non-refundable cash payments under certain development and technology evaluation agreements with our customers. These payments are generally recognized as revenue over the term of the agreement.  On occasion, however, these payments are creditable against license fees and/or royalties payable by the customer if a license agreement is subsequently executed with the customer.  These payments are classified as deferred revenues, and are recorded as liabilities in the consolidated balance sheet until such time as revenue can be recognized.  Revenue is deferred until a license agreement is executed or negotiations have ceased and there is no appreciable likelihood of executing a license agreement with the customer. If a license agreement is executed, these payments are recorded as revenue over the estimated useful life of the licensed technology and the revenue is classified based on the terms of the license.  Otherwise, these payments are recorded as revenue at the time negotiations with the customer show that there is no appreciable likelihood of executing a license agreement.  If we used different estimates for the useful life of the licensed technology, reported revenue during the relevant period would differ. As of September 30, 2011, $9,193,765 was recorded as deferred revenue, of which $3,366,667 may be recognized under license agreements that have not yet been executed or deemed effective. For the three and nine months ended September 30, 2010, $0 and $2,100,000, respectively, of revenue was recognized relating to cash payments received that were creditable against license fees and/or royalties for which we determined there was no appreciable likelihood of executing a license agreement with the customer. For the three and nine months ended September 30, 2011, no such revenue was recognized.

Contract research revenue represents reimbursements by the U.S. government for all or a portion of the research and development expenses we incur related to our government contracts. Revenue is recognized proportionally as research and
 
development expenses are incurred or as defined milestones are achieved. In order to ascertain the revenue associated with these contracts for a period, we estimate the proportion of related research and development expenses incurred and whether defined milestones have been achieved. Different estimates would result in different revenues for the period.

Valuation of Stock-Based Compensation

We recognize in the statement of operations the grant-date fair value of equity-based compensation issued to employees and directors (see Note 9 of the Notes to Consolidated Financial Statements). We also record an expense for equity-based compensation grants to non-employees, in exchange for goods or services, based on the fair value, which is remeasured over the vesting period of such awards.

We use the Black-Scholes option-pricing model to estimate the fair value of options and warrants we have granted for purposes of recording charges to the statement of operations. In order to calculate the fair value of the options and warrants, assumptions are made for certain components of the model, including expected volatility, expected dividend yield rate and expected option life. Expected volatilities utilized in the model are based mainly on the historical volatility of our stock price over a period commensurate with the expected life of the share option. The risk-free interest rate is derived from the U.S. Treasury yield curve in effect at the time of grant. In the case of stock options granted to employees, we estimate the expected term of options granted based on our historical experience with our employees’ exercise of stock options. In the case of stock options granted to non-employees, the contractual life is used. Although we use our best estimates when setting these assumptions, changes to the assumptions could cause significant adjustments to the valuation of future grants or the remeasurement of non-employee awards.

Accounting for Warrants

On January 1, 2009, we adopted certain revised provisions of Accounting Standards Codification (ASC) 815, Derivatives and Hedging. These provisions apply to freestanding financial instruments or embedded features that have the characteristics of a derivative and to freestanding financial instruments that are potentially settled in an entity’s own common stock.  As a result, certain of our warrants were considered to be derivatives since they contained “down-round” provisions and needed to be remeasured at fair value at the end of each period as they were recorded as liabilities. At September 30, 2011, there was no liability relating to such warrants, as a result of all the warrants having been exercised by such date.

The fair value of the stock warrant liability when the warrants were outstanding was determined by the Black-Scholes option pricing model using assumptions for certain components of the model, including expected volatility and expected annual dividend yield. Expected volatilities utilized in the model were based mainly on the historical volatility of our stock price over a period commensurate with the remaining contractual life of the warrant. The risk-free interest rate was derived from the U.S. Treasury yield curve. The expected term of the warrants was based on the remaining contractual life. Although we used our best estimates when setting these assumptions, changes in assumptions could have caused significant adjustments to our valuation of the stock warrant liability. The change in fair value of the stock warrant liability when the warrants were outstanding was recorded as a gain or loss on the statement of operations.

Retirement Plan

We have recorded a significant retirement plan benefit liability that is developed from actuarial valuations. The determination of our retirement plan benefit liability requires key assumptions regarding discount rates, as well as rates of compensation increases, retirement dates and life expectancies used to determine the present value of future benefit payments. We determine these assumptions in consultation with, and after input from, our actuaries and considering our experience and expectations for the future.  Actual results for a given period will often differ from assumed amounts because of economic and other factors.

The discount rate reflects the estimated rate at which the benefit liabilities could be settled at the end of the year. The discount rate is determined by selecting a single rate that produces a result equivalent to discounting expected benefit payments from the plan using the Citigroup Above-Median Pension Discount Curve (Curve). Based upon this analysis using the Curve, we used a discount rate to measure our retirement plan benefit liability of 5.44% at September 30, 2011. A change of 25 basis points in the discount rate would increase or decrease the expense on an annual basis by approximately $21,000.

Contractual Obligations

Refer to our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of our contractual obligations.

Off-Balance Sheet Arrangements

Refer to our Annual Report on Form 10-K for the year ended December 31, 2010 for a discussion of off-balance sheet arrangements.  As of September 30, 2011, we had no off-balance sheet arrangements.

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We do not utilize financial instruments for trading purposes and hold no derivative financial instruments, other financial instruments or derivative commodity instruments that could expose us to significant market risk other than our short-term investments disclosed in Note 4 to the consolidated financial statements included herein. We invest in investment grade financial instruments to reduce our exposure.  Our primary market risk exposure with regard to financial instruments is to changes in interest rates, which would impact interest income earned on investments.

ITEM 4.
CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2011. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures, as of the end of the period covered by this report, are effective to provide reasonable assurance that the information required to be disclosed by us in reports filed or submitted under the Securities Exchange Act of 1934, as amended, is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to our management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding disclosure. However, a controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the three months ended September 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS

Opposition to European Patent No. 0946958

On December 8, 2006, Cambridge Display Technology (CDT), which was acquired in 2007 by Sumitomo Chemical Company (Sumitomo), filed a Notice of Opposition to European Patent No. 0946958 (EP ‘958 patent). The EP ‘958 patent, which was issued on March 8, 2006, is a European counterpart patent to U.S. patents 5,844,363, 6,602,540, 6,888,306 and 7,247,073. These patents relate to our FOLED™ flexible OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

The European Patent Office (the EPO) conducted an Oral Hearing in this matter on October 6, 2009. No representative from CDT attended the Oral Hearing. At the conclusion of the Oral Hearing, the EPO panel announced its decision to reject the opposition and to maintain the patent as granted. The minutes of the Oral Hearing were dispatched on October 27, 2009, and a written decision was issued on November 26, 2009.

CDT filed an appeal to the EPO panel decision on January 25, 2010. CDT timely filed its grounds for the appeal with the EPO on or about April 1, 2010. The EPO set August 12, 2010 as the due date for filing our reply to this appeal. Our reply was timely filed.

At this time, based on our current knowledge, we believe that the EPO panel decision will be upheld on appeal.  However, we cannot make any assurances of this result.

Opposition to European Patent No. 1449238

On March 8, 2007, Sumation Company Limited (Sumation), a joint venture between Sumitomo and CDT, filed a first Notice of Opposition to European Patent No. 1449238 (EP ‘238 patent). The EP ‘238 patent, which was issued on November 2, 2006, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. These patents and this patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

Two other parties filed additional oppositions to the EP ‘238 patent just prior to the August 2, 2007 expiration date for such filings. On July 24, 2007, Merck Patent GmbH, of Darmstadt, Germany, filed a second Notice of Opposition to the EP ‘238 patent, and on July 27, 2007, BASF Aktiengesellschaft, of Mannheim, Germany, filed a third Notice of Opposition to the EP ‘238 patent. The EPO combined all three oppositions into a single opposition proceeding.

The EPO conducted an Oral Hearing in this matter on November 3, 2011.  At the conclusion of the Oral Hearing, the EPO panel announced its decision to maintain the patent with claims directed to OLEDs comprising phosphorescent organometallic iridium compounds.  We expect that the official minutes from the Oral Hearing will be published in the near future, and a written decision will follow.  The EPO panel decision is open to appeal.

At this time, based on our current knowledge, we believe that the EPO panel decision, if appealed, would be upheld on appeal.  However, we cannot make any assurances of this result.

Invalidation Trial in Japan for Japan Patent No. 3992929

On April 19, 2010, we received a copy of a Notice of Invalidation Trial from the Japanese Patent Office (the JPO) for our Japan Patent No. 3992929 (the JP ‘929 patent), which was issued on August 3, 2007. The request for the Invalidation Trial was filed by Semiconductor Energy Laboratory Co., Ltd. (SEL), of Kanagawa, Japan. The JP ‘929 patent is a Japanese counterpart patent, in part, to the above-noted EP ‘238 patent and to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. Under our license agreement with Princeton, we are required to pay all legal costs and fees associated with this proceeding.

An Oral Hearing in this matter was held on November 16, 2010.  On February 28, 2011, we learned that the JPO had issued a decision recognizing our invention and upholding the validity of most of the claims, but finding the broadest claims in the patent invalid. We believe that the JPO’s decision invalidating these claims was erroneous, and we filed an appeal to the Japanese IP High Court.

Both parties are in the process of filing appeal briefs in this matter with the Japanese IP High Court.  A technical explanation hearing has been tentatively scheduled for February 1, 2012.  At the hearing, both parties will be required to file technical materials supporting their respective positions.

At this time, based on our current knowledge, we believe that the JPO decision invalidating certain claims in our JP ‘929 patent should be overturned on appeal as to all or a significant portion of the claims.  However, we cannot make any assurances of this result.

Opposition to European Patent No. 1394870

On about April 20, 2010, five European companies filed Notices of Opposition to European Patent No. 1394870 (the EP ‘870 patent). The EP ‘870 patent, which was issued on July 22, 2009, is a European counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542; 7,563,519; and 7,901,795; and to pending U.S. patent application 13/035051, filed on February 25, 2011. These patents and this patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding. The five companies are Merck Patent GmbH; BASF Schweitz AG of Basel, Switzerland; Osram GmbH of Munich, Germany; Siemens Aktiengesellschaft of Munich, Germany; and Koninklijke Philips Electronics N.V., of Eindhoven, The Netherlands.

The EPO combined the oppositions into a single opposition proceeding.  The matter has been briefed and we are waiting for the EPO to provide notice of the date of the Oral Hearing. We are also waiting to see whether any of the other parties in the opposition file additional documents, to which we might respond.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, we cannot make any assurances of this result.

Invalidation Trials in Japan for Japan Patent Nos. 4357781 and 4358168

On May 24, 2010, we received copies of two additional Notices of Invalidation Trials against Japan Patent Nos. 4357781 (the JP ‘781 patent) and 4358168 (the JP ‘168 patent), which were both issued on August 14, 2009. The requests for these two additional Invalidation Trials were also filed by SEL. The JP ‘781 and ‘168 patents are also Japanese counterpart patents, in part, to the above-noted family of U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. Under our license agreement with Princeton, we are also required to pay all legal costs and fees associated with these two proceedings.

An Oral Hearing in this matter was held on February 1, 2011.  On March 31, 2011, we learned that the JPO had issued decisions finding all claims in the JP ‘781 and JP ‘168 patents invalid.  We believe that the JPO’s decisions invalidating these claims were erroneous, and we filed appeals for both cases to the Japanese IP High Court.
 
Both parties are in the process of filing appeal briefs in this matter with the Japanese IP High Court.  The Japanese IP High Court has scheduled a first hearing for this matter on November 22, 2011.

At this time, based on our current knowledge, we believe that the JPO decisions invalidating all the claims in our JP ‘781 and JP ‘168 patents should be overturned on appeal as to all or a significant portion of the claims.  However, we cannot make any assurances of this result.

Interference No. 105,771 involving Claims 48-52 of US Patent No. 6,902,830

Patent Interference No. 105,771 was declared by the United States Patent and Trademark Office (the USPTO) on November 17, 2010 between The University of Southern California and The Trustees of Princeton University (the Universities), Junior Party, and Fujifilm Holding Corporation (Fuji), Senior Party. The dispute is between the Universities’ U.S. Patent No 6,902,830 (the ’830 patent), claims 48-52, and Fuji’s Patent Application No. 11/802,492, claims 1-5 (the Fuji application). The ‘830 patent relates to our UniversalPHOLED phosphorescent OLED technology. It is exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

The USPTO declares an interference when two or more parties claim the same patentable invention. The objective of an interference is to contest which party, if any, has both a right to participate in the proceeding and a right to the claimed invention and, if more than one party does, then to contest which party has the earliest priority date for the claimed invention.

Subsequent to the filing of motions and responsive motions in this matter, the interference was concluded by our purchase of the Fuji application.  As a result of this purchase, the Fuji application was assigned to us effective September 13, 2011.  We then requested that adverse judgment be entered against the Fuji application, which was entered by the USPTO on October 4, 2011.  Thus, our claims 48-52 of the ‘830 patent, and the ‘830 patent as a whole, remain intact as granted.

Invalidation Trial in Korea for Patent No. KR-0998059

On March 10, 2011, we received informal notice from our Korean patent counsel of a Request for an Invalidation Trial from the Korean Intellectual Property Office (KIPO) for our Korean Patent No. 10-0998059 (the KR ‘059 patent), which was issued on November 26, 2010. The Request was filed by a certain individual petitioner, but we still do not know which company, if any, was ultimately responsible for filing this Request.  The KR ‘059 patent is a Korean counterpart patent to the OVJP, Organic Vapor Jet Printing, family of U.S. patents originating from US 7,431,968.

On April 21, 2011, our Korean patent counsel received a copy of the Appeal Brief for the Request from KIPO.  We filed a response to the Request on June 20, 2011.  The petitioner filed a rebuttal brief on August 8, 2011, and we filed a response to the rebuttal brief on October 12, 2011.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, we cannot make any assurances of this result.

Invalidation Trials in Korea for Patent Nos. KR-558632 and KR-963857

On May 11 and May 31, 2011, respectively, we learned that further Requests for Invalidation Trials were filed in Korea, on May 3 and May 26, 2011, respectively, for our Korean Patent Nos. KR-558632 (the KR ‘632 patent), which issued on March 2, 2006, and KR-963857 (the KR ‘857 patent), which issued on June 8, 2010. The Requests were filed by Duk San Hi-metal, Ltd. (Duk San) of Korea. The KR ‘632 and KR ‘857 patents are both Korean counterpart patents, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542 and 7,563,519; and to pending U.S. patent application 12/489,045, filed on June 22, 2009; to the EP ‘870 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘024 patent, which is subject to the below-noted Japanese Invalidation Trial. These patents and the pending U.S. patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

We timely filed our formal responses to the Requests by the due dates of August 27, 2011 and September 8, 2011, respectively.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, we cannot make any assurances of this result.
 
Invalidation Trials in Korea for Patent Nos. KR-744199 and KR-913568

On May 10 and May 31, 2011, respectively, we learned that further Requests for Invalidation Trials were filed in Korea, on May 3 and May 26, 2011, respectively, for our Korean Patent Nos. KR-744199 (the KR ‘199 patent), which issued on July 24, 2007, and KR-913568 (the KR ‘568 patent), which issued on August 17, 2009. The Requests were also filed by Duk San. The KR ‘199 and KR ‘568 patents are both Korean counterpart patents, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011; to the EP ‘238 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘929 patent, which is subject to one of the above-noted Japanese Invalidation Trials. These patents and this patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

We timely filed our formal responses to the Requests by the due dates of September 1, 2011 and August 23, 2011, respectively.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, we cannot make any assurances of this result.

Invalidation Trial in Japan for Japan Patent No. 4511024

On June 16, 2011, we learned that a further Request for an Invalidation Trial was filed in Japan for our Japanese Patent No. JP-4511024 (the JP ‘024 patent), which issued on May 14, 2010. The Request was filed by SEL, the same opponent as in the above-noted Japanese Invalidation Trial for the JP ‘929 patent. The JP ‘024 patent is a counterpart patent, in part, to U.S. patents 6,303,238; 6,579,632; 6,872,477; 7,279,235; 7,279,237; 7,488,542; 7,563,519; and 7,901,795; and to pending U.S. patent application 13/035051, filed on February 25, 2011; to the EP ‘870 patent, which is subject to one of the above-noted European Oppositions; and to the KR ‘632 and KR ‘857 patents, which are subject to one of the above noted Korean Invalidation Trials. These patents and the pending U.S. patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

We timely filed a Written Reply to the Request for Invalidation Trial by the due date of November 2, 2011.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, we cannot make any assurances of this result.

Opposition to European Patent No. 1252803

On July 12 and 13, 2011, Oppositions were filed to our European Patent No. 1252803 (the EP ‘803 patent). These Oppositions were filed by Sumitomo, Merck Patent GmbH and BASF SE, of Ludwigshaven, Germany. The EP ‘803 patent,
 
which was issued on October 13, 2010, is a European counterpart patent, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011. These patents and this patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

The EPO combined the oppositions into a single opposition proceeding and set December 18, 2011 as the due date for us to file our response, subject to extension.

At this time, based on our current knowledge, we believe there is a substantial likelihood that the patent being challenged will be declared valid, and that all or a significant portion of its claims will be upheld.  However, we cannot make any assurances of this result.

Invalidation Trials in Korea for Patent Nos. KR-840,637 and KR-937,470

On August 8, 2011, we received information indicating that further Requests for Invalidation Trials were filed against our Korean Patent Nos. KR-840,637 (the KR ‘637 patent) and KR-937,470 (the KR ‘470 patent), which issued on June 17, 2008 and January 11, 2010, respectively. The Requests were also filed by Duk San. The KR ‘637 and KR ‘470 patents are both Korean counterpart patents, in part, to U.S. patents 6,830,828; 6,902,830; 7,001,536; 7,291,406; 7,537,844; and 7,883,787; and to pending U.S. patent application 13/009001, filed on January 19, 2011; to the EP ‘803 patent, which is subject to one of the above-noted European Oppositions; and to the JP ‘781 and JP ‘168 patents, which are subject to the above-noted Japanese Invalidation Trials. These patents and this patent application relate to our UniversalPHOLED phosphorescent OLED technology. They are exclusively licensed to us by Princeton, and under the license agreement we are required to pay all legal costs and fees associated with this proceeding.

Formal, substantially non-substantive responses were originally due in Korea on September 7 and 8, 2011, respectively, but these due dates have now been extended until December 7 and 8, 2011, respectively.  
 
At this time, based on our current knowledge, we believe there is a substantial likelihood that the patents being challenged will be declared valid, and that all or a significant portion of their claims will be upheld.  However, we cannot make any assurances of this result.

ITEM 1A.
RISK FACTORS

There have been no material changes to the risk factors previously discussed in Part I, Item 1A “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2010, as supplemented by our Quarterly Report on Form 10-Q for the quarter ended March 31, 2011.

ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

Issuance of Unregistered Shares Upon the Exercise of Outstanding Warrants

During the quarter ended September 30, 2011, we issued an aggregate of 214,746 unregistered shares of our common stock upon the exercise of outstanding warrants. The warrants had a weighted average exercise price of $13.73 per share. All of the shares were issued in reliance on the exemption from registration contained in Section 4(2) of the Securities Act of 1933, as amended.

Withholding of Shares to Satisfy Tax Liabilities

During the quarter ended September 30, 2011, we acquired 187 shares of common stock through transactions related to the vesting of restricted share awards previously granted to certain employees. Upon vesting, the employees turned in shares of common stock in amounts sufficient to pay their minimum statutory tax withholding at rates required by the relevant tax authorities.

The following table provides information relating to the shares we received during the quarter ended September 30, 2011.

ISSUER PURCHASES OF EQUITY SECURITIES
Period
 
Total Number of Shares Purchased
   
Weighted Average Price Paid per Share
   
Total Number of Shares Purchased as Part of Publicly Announced Program
   
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Program
 
July 1 – July 31
    187     $ 29.80       n/a       --  
August 1 – August 31
                n/a       --  
September 1 – September 30
                n/a       --  
Total
    187     $ 29.80       n/a       --  

ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.
REMOVED AND RESERVED

ITEM 5.
OTHER INFORMATION

None.

ITEM 6.
EX HIBITS
 
The following is a list of the exhibits included as part of this report.  Where so indicated by footnote, exhibits that were previously included are incorporated by reference.  For exhibits incorporated by reference, the location of the exhibit in the previous filing is indicated parenthetically, together with a reference to the filing indicated by footnote.
 
Exhibit
   
Number
 
Description
     
10.1 +#
 
OLED Patent License Agreement between the registrant and Samsung Mobile Display Co., Ltd., dated as of August 22, 2011
     
10.2 +#
 
Supplemental OLED Material Purchase Agreement between the registrant and Samsung Mobile Display Co., Ltd., dated as of August 22, 2011
     
10.3* #
 
Limited-Term OLED Technology License Agreement between the registrant and Panasonic Idemitsu OLED Lighting Co., Ltd., dated as of August 23, 2011
     
10.4* #
 
Amended and Restated OLED Materials Supply and Service Agreement between the registrant and PPG Industries, Inc., dated as of September 22, 2011
     
10.5* #
 
OLED Technology License Agreement between the registrant and Pioneer Corporation, dated as of September 27, 2011
     
31.1*
 
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
     
31.2*
 
Certifications of Sidney D.  Rosenblatt, Chief Financial Officer, as required by Rule 13a-14(a) or Rule 15d-14(a)
   
32.1**
 
Certifications of Steven V. Abramson, Chief Executive Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section 1350 (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.  Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
Exhibit
   
Number
 
Description
     
32.2**
 
Certifications of Sidney D. Rosenblatt, Chief Financial Officer, as required by Rule 13a-14(b) or Rule 15d-14(b), and by 18 U.S.C. Section 1350 (This exhibit shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.  Further, this exhibit shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.)
 
*
 
Filed herewith.
**
 
Furnished herewith.
+
 
Filed as an exhibit to the registrant’s Current Report on Form 8-K, filed with the SEC on August 26, 2011.
#
 
Confidential treatment has been requested as to certain portions of this exhibit pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended.
 
 
Note: Any of the exhibits listed in the foregoing index not included with this report may be obtained, without charge, by writing to Mr. Sidney D. Rosenblatt, Corporate Secretary, Universal Display Corporation, 375 Phillips Boulevard, Ewing, New Jersey 08618.



SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized:


UNIVERSAL DISPLAY CORPORATION



Date: November 8, 2011
By:     /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer





Note:  Throughout this document, certain confidential material contained herein has been omitted and has been separately filed with the Commission. Each place where such an omission has been made is marked with an [***].

 
LIMITED-TERM OLED TECHNOLOGY LICENSE AGREEMENT
 

THIS LIMITED-TERM OLED TECHNOLOGY LICENSE AGREEMENT (this “ Agreement ”) is entered into effective as of August 1, 2011 (the “ Effective Date ”), by and between Universal Display Corporation (“ Universal Display ”), a Pennsylvania corporation with a place of business at 375 Phillips Blvd, Ewing, New Jersey 08618, U.S.A; and Panasonic Idemitsu OLED Lighting Co., Ltd. (“ Panasonic Idemitsu ”), a Japanese corporation with a place of business at 1048 Kadoma, Osaka 571-8686, JAPAN.  Each of Universal Display and Panasonic Idemitsu is referred to herein as a “ Party ,” and collectively as the “ Parties .”
 
 
BACKGROUND
 
WHEREAS, Universal Display has rights in certain patents and possesses certain know-how concerning organic light emitting devices (OLEDs) for solid-state lighting applications;
 
WHEREAS, Panasonic Idemitsu desires to obtain license rights to practice under these p atents and to use this know-how; and
 
WHEREAS, the Parties are entering into this Agreement in order to enable Panasonic Idemitsu to introduce OLED lighting products into the market for a limited period of time on the terms and conditions set forth herein.
 
NOW, THEREFORE, intending to be legally bound, each of the Parties hereby agrees as follows:
 
 
AGREEMENT
 
Article 1   Definitions
 
In addition to other terms defined elsewhere herein, the following terms shall have their corresponding meanings when used in this Agreement.
 
1.1   Know-How ” means unpatented technical information, data, specifications, plans, drawings, designs, blueprints, formulae, processes and other similar items of a trade secret or confidential nature, which is a Confidential Item (as defined below) of Universal Display.
 
1.2   Licensed Product ” means an OLED Lighting product sold or otherwise distributed by Panasonic Idemitsu for cash or other consideration, which product is (a) covered, in whole or in part, by any Valid Claim(s) of a Universal Display Patent; (b) manufactured using a process that is covered, in whole or in part, by any Valid Claim of a Universal Display Patent; and/or (c) manufactured using any of the Universal Display Know-How.
 

 
Page 1 of 14

 


1.3   Lighting ” means a source of direct or indirect illumination, which does not utilize addressable pixel elements smaller than [***] .
 
1.4   Net Sales Revenue
 
1.4.1   For Licensed Products sold by Panasonic Idemitsu to non-Affiliated third parties solely for monetary consideration, “Net Sales Revenue” means the gross amount invoiced or received, whichever occurs sooner, on account thereof, less the following where separately itemized on the customer invoice for the Licensed Products: (a) taxes and duties actually collected and remitted to the appropriate taxing authorities; (b) reasonable shipping and insurance costs actually paid or accrued for such purpose; and (c) refunds or credits actually given for returned or defective items.
 
1.4.2   For all other Licensed Products sold or otherwise transferred by Panasonic Idemitsu, (without exception of samples provided at no cost), “Net Sales Revenue” means the greater of (a) or (b), where (a) is the arm’s length transfer price recorded by Panasonic Idemitsu for such sale or transfer; and (b) is the average selling price at which Licensed Products of similar kind and quantity have been sold by Panasonic Idemitsu to non-Affiliated third parties during the same Reporting Period (as defined in Section 4.3 below), as calculated according to the preceding paragraph, or if no such selling price is available, the fair market value of such Licensed Products if and when such a market exists.  The  arm’s length transfer pricing referred to in clause (a) shall include all cost components fairly attributable to the Licensed Products being sold or otherwise transferred, and shall comply with the Japan National Tax Agency guidelines and other applicable laws, rules and regulations .
 
1.4.3   If either Party presents reasonable evidence that the amount calculated as set forth above does not fairly reflect the fair market value of a Licensed Product if and when such a market exists (such as evidence that the industry-wide average sales price of substantially similar products differs significantly from the price calculated herein, or evidence that additional consideration is being received based on the downstream sale of a Licensed Product), the Parties shall in good faith negotiate a more equitable method of calculating Net Sales Revenue with respect to the Licensed Product in question.
 
1.5   Term ” means the term of this Agreement, as specified in Article 8 below.
 
1.6   Universal Display Know-How ” means Know-How of Universal Display relating to the design or manufacture of OLED Lighting products.
 
1.7   Universal Display Patents ” means all patents and patent applications pertaining to OLED Lighting products that are issued, registered, granted, allowed or published in the world as of the Effective Date, and which Universal Display owns or has the right to license to Panasonic Idemitsu hereunder, together with such future patents and patent applications as are specified in Section 2.2 below.
 
1.8   Universal Display Technology ” means the Universal Display Patents and the Universal Display Know-How.
 

 
Page 2 of 14

 


1.9   Valid Claim ” means a claim of an issued, registered, granted, allowed or published patent or patent application, which claim has neither expired nor been finally, following expiration of all rights of appeal, held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction.
 
1.10   Affiliate ” means a corporation or other entity which directly or indirectly controls, is controlled by, or is under common control with the entity in question on or after the Effective Date, but only for so long as such control continues to exist.  “Control” shall be deemed to exist in the case of ownership, or the right to vote, fifty percent (50%) or more of the voting securities or other similar interests in an entity.
 
1.11   Confidential Item ” means information disclosed by a Party or its Affiliates (the “Discloser”) to another Party or its Affiliates (the “Recipient”), in written, oral, visual or electronic form, under this Agreement or another agreement between the Discloser and the Recipient either before or after the Effective Date, relating to the Discloser’s or its licensors’, suppliers’ or business partners’ technologies, compounds, research programs, operations and/or financial or business condition, including, without limitation, know-how, data, drawings, designs, specifications, formulations, processes, methods, equipment, software and pricing information (“Proprietary Information”), that is (i) disclosed in writing or other tangible form and marked as “Confidential”, “Proprietary” or with similar words at the time of disclosure, or (ii) orally or visually disclosed and identified as confidential or proprietary at the time of disclosure and confirmed as such in writing within thirty (30) days thereafter.  Notwithstanding the foregoing, “Confidential Items” of the Discloser shall not include any information that:
 
1.11.1   is approved by  the Discloser in writing for release by the Recipient without restriction;
 
1.11.2   the Recipient can demonstrate by written records was previously known to  the Recipient, other than through a prior disclosure by the Discloser, or to any third party without an obligation of confidentiality to  the Discloser;
 
1.11.3   is publicly known as of the date of this Agreement, or becomes public knowledge subsequent thereto, through no act or omission of  the Recipient or any third party receiving such information from or through  the Recipient;
 
1.11.4   is obtained by  the Recipient in good faith from a third party without the violation of any obligation of confidentiality; or
 
1.11.5   is independently developed by or on behalf of the Recipient without the benefit of the Discloser’s Confidential Items, as shown by competent written records.
 
Article 2   License Rights
 
2.1   Grant of License to Panasonic Idemitsu .  Subject to the remaining provisions of this Article 2, Universal Display hereby grants to Panasonic Idemitsu a worldwide, non-exclusive and non-transferable (except in connection with a permitted transfer of this Agreement as a whole) license, without rights to sublicense, under the Universal Display Patents, and to use the Universal Display Know-How, to manufacture, have manufactured (but only by Affiliates in
 

 
Page 3 of 14

 

accordance with Section 2.1.1 below), sell, offer for sale, import, export and otherwise dispose of Licensed Products.

2.1.1   Panasonic Idemitsu  may exercise its “have manufactured” rights granted under Section 2.1 above through Panasonic Electric Works Co., Ltd. and such other  entities that are Affiliates of Panasonic Idemitsu which have been approved by Universal Display in writing, but only for so long as such entities remain Affiliates of Panasonic Idemitsu.  Any such extension shall be pursuant to a written agreement between Panasonic Idemitsu and the relevant Affiliate, which written agreement shall obligate the Affiliate to abide by the scope of license and other applicable provisions of this Agreement.  In addition to its other rights or remedies hereunder, Universal Display shall be expressly identified in the written sublicense agreement as a third-party beneficiary thereof, entitled to enforce the scope of license and other applicable provisions of this Agreement directly against the Affiliate.  Panasonic Idemitsu shall identify to Universal Display in writing the name and business address of each Affiliate prior to its entry into such written agreement with the Affiliate, and shall use its best efforts to cause each such Affiliate to abide by the scope of license and other applicable provisions of this Agreement.
 
2.1.2   During the term of the license, Universal Display agrees not to assert any of the Universal Display Patents against Panasonic Idemitsu, its Affiliates or its customers based on their subsequent manufacture, sale, offer for sale, importation, exportation, use or other disposal of OLED lighting products incorporating the Licensed Products, provided such Licensed Products were manufactured and sold within the scope of the rights and restrictions outlined in this Agreement.
 
2.2   License Rights to Future Patents and Know-How .  To the extent it has the right to do so, Universal Display will expand Panasonic Idemitsu’s license rights under this Article 2 to include any additional patents, patent applications and Know-How of Universal Display pertaining to OLED Lighting products, which Universal Display owns or has the right to license to Panasonic Idemitsu hereunder, and which are issued, registered, granted, allowed published or generated during the Term, but excluding any such patents, patent applications or Know-How acquired by Universal Display through a merger, asset acquisition or other similar transaction unless separately agreed by the Parties in writing.
 
2.3   No Rights Respecting Certain OLED Chemicals .  Notwithstanding the foregoing, Panasonic Idemitsu is not authorized under this Agreement to sell or offer for sale any Licensed Products made using any chemical substance used or useful for the manufacture of OLEDs, the composition of matter of which is covered by a Valid Claim of a Universal Display Patent (a “ Universal Display Proprietary OLED Chemical ”), unless such Universal Display Proprietary OLED Chemical was purchased directly from Universal Display.  Panasonic Idemitsu shall not manufacture or purchase from a third party, or encourage any third party to manufacture or sell to Panasonic Idemitsu, any chemical substance that Panasonic Idemitsu knows, or has reason to know, is a Universal Display Proprietary OLED Chemical.
 
2.4   No Rights Respecting Certain OLED Manufacturing Equipment .  Notwithstanding the foregoing, Panasonic Idemitsu is not authorized under this Agreement to sell or offer for sale any Licensed Products made using any manufacturing equipment or machinery used or useful for the manufacture of OLEDs, the design or construction of which is
 

 
Page 4 of 14

 
covered by a Valid Claim of a Universal Display Patent (“ Universal Display Proprietary OLED Equipment ”), unless such Universal Display Proprietary OLED Equipment was purchased from an authorized Universal Display equipment vendor.  Panasonic Idemitsu shall not manufacture or purchase from a third party, or encourage any third party to manufacture or sell to Panasonic Idemitsu, any equipment or machinery that Panasonic Idemitsu knows, or has reason to know, is Universal Display Proprietary OLED Equipment.
 
2.5   Acknowledgement of Derivative Rights .  Panasonic Idemitsu acknowledges that certain of the Universal Display Technology is licensed by Universal Display from the Trustees of Princeton University (“ Princeton ”), the University of Southern California (“ USC ”) and the University of Michigan (“ Michigan ”), and, therefore, that Panasonic Idemitsu’s license rights under this Agreement with respect to such Universal Display Technology are subject to the reserved rights of and obligations to such third parties under their license agreements with Universal Display.  Panasonic Idemitsu further acknowledges that the U.S. Government has certain reserved rights with respect to those Universal Display Patents claiming inventions that were first conceived or reduced to practice under contracts between the U.S. Government and Universal Display or its licensors.  Universal Display hereby covenants to Panasonic Idemitsu that: (a) Universal Display shall comply in all material respects with the terms of its license agreement with such third-party licensors and its contracts with or awards from the U.S. Government as in either case are relevant to Panasonic Idemitsu’s exercise of the license rights granted by Universal Display hereunder; and (b) no additional consideration shall be owed by Panasonic Idemitsu to such third-party licensors or the U.S. Government on account of Panasonic Idemitsu’s exercise of such license rights.  Upon Panasonic Idemitsu’s request, Universal Display will provide Panasonic Idemitsu with copies (which may be reasonably redacted by Universal Display to avoid disclosing confidential information not relevant to this Agreement) of Universal Display’s agreement with these third-party licensors and of the applicable portions its relevant contracts with or awards from the U.S. Government.
 
2.6   Reservation of Rights .  Except for the license rights expressly granted to Panasonic Idemitsu under this Article 2, all rights to practice under the Universal Display Patents and to use the Universal Display Know-How are reserved unto Universal Display and its licensors.  No implied rights or licenses are granted to Panasonic Idemitsu hereunder.
 
Article 3   Patent Matters, Attribution and Samples
 
3.1   Patent Validity .  During the Term, Panasonic Idemitsu shall not, and shall ensure that its Affiliates do not, challenge or oppose, or assist others in challenging or opposing, in whole or in part, the issuance, validity, scope or enforceability of any of the Universal Display Patents licensed hereunder, nor shall Panasonic Idemitsu initiate or continue, or assist others in initiating or continuing, proceedings to have any of such Universal Display Patents cancelled or invalidated, in whole or in part, except that the foregoing shall not apply to the extent such prohibitions are contrary to law or regulation in the relevant patent jurisdiction.
 
3.2   Patent Marking .  Upon Universal Display’s request, Panasonic Idemitsu shall apply or cause to be applied to all Licensed Products intended for sale in the United States, or to their packaging, such reasonable markings or notices of the Universal Display Patents as may be requested in writing by Universal Display in order to reasonably protect Universal Display’s
 

 
Page 5 of 14

 

  rights and interests therein under the laws of the United States; provided however, that Panasonic Idemitsu shall be required to apply such markings or notices to the products or their packaging only to the extent that Panasonic Idemitsu applies similar markings or notices of Panasonic Idemitsu’s or its Affiliates’ own patents to the products or their packaging in order to protect Panasonic Idemitsu’s rights and interests therein under laws of the United States.
 
3.3   Non-Use of Certain Names .  Panasonic Idemitsu shall not use the names of Princeton, USC or Michigan in connection with any products, promotion or advertising without the prior consent of Princeton, USC or Michigan, as applicable, except to the extent reasonably required by law.  Notwithstanding the foregoing sentence, Panasonic Idemitsu may state that its license rights hereunder are derivative of rights granted by Princeton, USC and Michigan to Universal Display under the license agreement among them.
 
3.4   Samples .  Upon Universal Display’s written request and at the lowest price offered by Panasonic Idemitsu to any non-Affiliate for such Licensed Products, including any taxes, duties or other governmental charges based on the sale, shipment, import, export or use of the Licensed Products (other than taxes based upon Panasonic Idemitsu’s net income), Panasonic Idemitsu shall supply Universal Display with [***] samples of each type of Licensed Product that Panasonic Idemitsu offers for sale to third parties.  Universal Display shall limit its requests for such samples to a reasonable number of different Licensed Products and Panasonic Idemitsu shall supply such samples promptly following Panasonic Idemitsu’s first sale of the Licensed Product to a third party.  Universal Display agrees to use such samples only (a) to verify compliance with the terms of this Agreement, and (b) for promotional purposes such as in displays at shareholder meetings, industry conferences or other similar venues (with appropriate attribution being given to Panasonic Idemitsu).
 
3.5   Amendments to the Universal Display Patents  To the extent applicable law requires Universal Display to obtain Panasonic Idemitsu’s approval for amendments to the specifications of any Universal Display Patent licensed hereunder, Panasonic Idemitsu shall promptly approve all such reasonable amendments proposed by Universal Display.
 
Article 4   Consideration
 
4.1   Pre-paid Royalties .  In consideration of the license rights granted by Universal Display hereunder, Panasonic Idemitsu shall pay to Universal Display running royalties at a rate of [***] percent [***] on account of Net Sales Revenue from Panasonic Idemitsu’s worldwide sales or other disposition of Licensed Products.  Panasonic Idemitsu shall pay to Universal Display a non-refundable license fee of [***] U.S. Dollars [***] as a prepayment of such running royalties for cumulative Net Sales Revenue up to the threshold amount of [***] U.S. Dollars [***] (the “ Threshold Sales Amount ”).  Said license fee is due and payable to Universal Display in three (3) installments of [***] each, the first installment being due within forty-five (45) days following the Effective Date, the second being due by July 31, 2012, and the third being due by July 31, 2013.  Upon payment in full of the license fee to Universal Display, the license rights granted hereunder shall be fully paid-up for Panasonic Idemitsu’s worldwide sales or other disposition of Licensed Products for cumulative Net Sales Revenue up to the Threshold Sales Amount.
 

 
Page 6 of 14

 

 
 
4.2   Additional Royalties .  If and when cumulative Net Sales Revenue exceeds the Threshold Sales Amount, Panasonic Idemitsu shall pay to Universal Display running royalties at a rate of [***] percent [***] on account of Net Sales Revenue from Panasonic Idemitsu’s worldwide sales or other disposition of Licensed Products in excess of the Threshold Sales Amount.  No multiple royalties shall be due because any Licensed Product, or its manufacture, sale, other disposition or usage, is or may be covered by more than one Universal Display Patent licensed to Panasonic Idemitsu hereunder.  Both Parties acknowledge and agree that the royalty rates and the methods by which they are to be calculated and paid hereunder have been determined through arms length negotiations between the Parties, and that such rates and methods have been agreed upon because they are mutually convenient, reasonable and appropriate notwithstanding whether and to what extent any of the Universal Display Patents have been issued, granted, allowed or registered, or have expired, in any particular country in which Licensed Products are made, sold or used, or whether the Universal Display Patents encompass each and every feature of any particular Licensed Product.
 
4.3   Reports .  Within sixty (60) days following the end of each Reporting Period (as defined below), Panasonic Idemitsu shall submit to Universal Display a written report, in English, indicating (a) the number and size of each Licensed Product sold or otherwise distributed by Panasonic Idemitsu during such period, and (b) Panasonic Idemitsu’s reasonably detailed calculation of Net Sales Revenues on account of such sales or other disposition of Licensed Products and, if applicable, the royalties due and owing to Universal Display on account thereof.  Upon Universal Display’s written request with good justification, both parties will negotiate in good faith that Panasonic Idemitsu submit a written report, in English, indicating such other information as Universal Display may reasonably request of Panasonic Idemitsu which is pertinent to ensuring compliance with the scope of license provisions under Article 2 above.  As used herein, the Reporting Period shall initially be a six month period beginning on April 1 st and October 1 st of each year; provided, however, that if and when cumulative Net Sales Revenue from Panasonic Idemitsu’s worldwide sales or other disposition of Licensed Products exceeds the Threshold Sales Amount, the Reporting Period shall become a three month period beginning on January 1 st , April 1 st , July 1 st and October 1 st of each year.
 
4.4   Payment of Royalties.   Within sixty (60) days following the end of each Reporting Period during the Term (and if the Term ends in the middle of a Reporting Period, within sixty (60) days following the end of the Term), Panasonic Idemitsu shall pay directly to Universal Display the royalties due and payable with respect to Licensed Products sold or otherwise disposed of during such period, if any.
 
Article 5   Payment Terms; Audit Rights
 
5.1   Payment .  Payment shall be made to Universal Display, without setoff or deduction of any kind, by wire transfer using the following wire instructions:
 
[***]

Without limiting its other rights or remedies on account of any late payment, Universal Display may require Panasonic Idemitsu to pay interest on any late payment at a per annum rate equal to
 

 
Page 7 of 14

 


 
the Prime Rate as published in The Wall Street Journal on the date payment is due, plus [***] percent [***] .
 
5.2   Payment Authorization and Withholding Taxes .  Panasonic Idemitsu shall secure all authorizations required for payment to Universal Display hereunder, and shall bear any transfer fees, taxes and any other charges associated therewith.  Both Parties shall cooperate to file such tax exemption forms and other documentation as is necessary to avoid any withholding from amounts payable to Universal Display hereunder.
 
5.3   Currency Conversion and Restriction .  Any royalties due hereunder based on Licensed Products sold or otherwise disposed of by Panasonic Idemitsu outside of the United States shall be payable in U.S. Dollars at the rate of exchange for the currency of the country in which such sales or usage occurs, which rate of exchange shall equal the exchange rate as published in The Wall Street Journal on the last business day of the calendar quarter for which payment is being made.  All royalties shall be paid to Universal Display without deduction of currency exchange fees or other similar amounts.  If at any time the legal restrictions of countries outside of the United States prevent Panasonic Idemitsu from paying Universal Display any amounts due hereunder, or otherwise upon Universal Display’s written instruction, Universal Display may direct Panasonic Idemitsu to make all or any portion of these payments to Universal Display’s accounts established at banks or depositories in one or more countries other than the United States.
 
5.4   Records; Audit and Inspection .  Panasonic Idemitsu shall keep accurate and complete records relating to all Licensed Products made and sold or otherwise distributed hereunder for a period of three (3) years.  An independent certified public accountant selected by Universal Display and approved by Panasonic Idemitsu (such approval not to be unreasonably withheld), together with such technical support staff as such accountant reasonably deems necessary, shall have the right to audit such records and inspect such of Panasonic Idemitsu’s materials, equipment and manufacturing processes as are reasonably necessary in order to verify Panasonic Idemitsu’s compliance with its obligations hereunder.  Universal Display shall give reasonable advance notice of any such audit or inspection to Panasonic Idemitsu, and such audit or inspection shall be conducted during Panasonic Idemitsu’s normal business hours and in a manner that does not cause unreasonable disruption to Panasonic Idemitsu’s conduct of its business.  The results of any such audit or inspection shall be deemed a Confidential Item of Panasonic Idemitsu and shall not be disclosed by Universal Display except as may be necessary for Universal Display to enforce its rights and interests hereunder.  If the audit or inspection reveals that Panasonic Idemitsu has underpaid any royalties due to Universal Display, Panasonic Idemitsu shall immediately pay to Universal Display all unpaid royalties, plus interest on the unpaid amounts from the date payment was initially due at the rate specified in Section 5.1 above.  Universal Display shall be responsible for paying the fees and expenses charged by the accountant and/or technical support staff for conducting any audit or inspection hereunder; provided, however, that if the unpaid royalties exceed [***] percent [***] of the total royalties that should have been paid by Panasonic Idemitsu during the audited period, Panasonic Idemitsu shall promptly reimburse Universal Display for the reasonable fees and expenses charged by such accountant.  Nothing herein shall limit any other rights or remedies available to Universal Display on account of Panasonic Idemitsu’s breach of its obligations under this Agreement.
 

 
Page 8 of 14

 

 
 
Article 6   Confidentiality and Publicity
 
6.1   Incorporation by Reference .  The provisions of sections 1, 2, 6 and 8 through 10 of the Mutual Non-Disclosure Agreement entered into by the Parties effective as of June 15, 2011 (the “ NDA ”) are incorporated into this Agreement by reference.  For purposes of this Agreement, the “Stated Purpose” shall include the implementation and administration of this Agreement.  The obligations of each Party under the provisions of the NDA incorporated herein shall continue to be in effective during the term of this Agreement and for a period of four (4) years thereafter.
 
6.2 Publicity .  Each Party may issue a press release, or the Parties may agree to issue a joint press release, describing the general nature of this Agreement.  In addition, either Party may disclose in its public filings such of the terms of this Agreement as are reasonably required for such party to comply with applicable securities laws and regulations, including, without limitation, by filing an appropriately redacted copy of this Agreement in connection therewith.  Subject to the foregoing, neither Party shall make or originate any publication, publicity, news release or announcement relating to this Agreement, or the activities described herein or the terms hereof, without the prior written consent of the other Party.
 
6.3  Universal Display’s Licensors .  Notwithstanding the foregoing, Universal Display shall have the right to provide an unredacted copy of this Agreement, along with copies of all Royalty Reports, to each of Princeton, USC and Michigan; provided that in such case Universal Display shall first have caused such third-party licensors to agree in writing to handle and maintain such items in accordance with the provisions of this Article 6, or provisions substantially similar thereto.
 
Article 7   Representations and Warranties; Disclaimers and Limitations of Liability
 
7.1   Warranties by Both Parties .  Each Party represents and warrants to the other that such Party has the right, power and authority to enter into this Agreement and to perform its obligations hereunder, and that such performance will not violate any other agreement or understanding by which such Party is bound.
 
7.2   Further Warranty by Universal Display .  Universal Display additionally represents and warrants to Panasonic Idemitsu that Universal Display owns or has sufficient rights in the Universal Display Technology to grant the license rights granted to Panasonic Idemitsu hereunder.
 
7.3   Disclaimer of Additional Warranties .  ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT, VALIDITY, QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED BY EACH PARTY.  In particular, Universal Display makes no representation or warranty that Panasonic Idemitsu will be able to manufacture, sell or use any Licensed Products without obtaining additional license rights from third parties.
 
7.4   Required Disclaimer of Princeton, USC and Michigan .  PRINCETON, USC AND MICHIGAN MAKE NO REPRESENTATIONS AND WARRANTIES AS TO THE
 
 
Page 9 of 14

 
PATENTABILITY AND/OR DISCOVERIES INVOLVED IN ANY OF THE UNIVERSAL DISPLAY PATENTS LICENSED HEREUNDER.  PRINCETON, USC AND MICHIGAN MAKE NO REPRESENTATION AS TO PATENTS NOW HELD OR WHICH WILL BE HELD BY OTHERS IN ANY FIELD AND/OR FOR ANY PARTICULAR PURPOSE.  PRINCETON, USC AND MICHIGAN MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
 
7.5   Limitation on Certain Damages .  IN NO EVENT SHALL UNIVERSAL DISPLAY BE LIABLE TO PANASONIC IDEMITSU, OR TO ANY THIRD PARTY CLAIMING THROUGH PANASONIC IDEMITSU, WHETHER AS A RESULT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING UNDER OR IN CONNECTION WITH THIS AGREEMENT.  The foregoing shall not limit Universal Display’s liability for any breach of the provisions of Article 6 respecting Confidential Items of Panasonic Idemitsu.
 
7.6   Essential Part of the Bargain .  The Parties acknowledge that the disclaimers and limitations of liability set forth in this Article 7 reflect a deliberate and bargained for allocation of risks between them and are intended to be independent of any exclusive remedies available under this Agreement, including any failure of such a remedy to achieve its essential purpose.
 
Article 8   Term and Termination
 
8.1   Term .  The term of this Agreement shall commence on the Effective Date and shall continue, unless terminated sooner as permitted hereunder, until July 31, 2014.  Except as may otherwise be agreed upon by the Parties in writing, all licenses granted by Universal Display under this Agreement shall expire immediately upon expiration or termination of this Agreement.
 
8.2   Termination for Breach .  Either Party may terminate this Agreement on written notice to the other Party if the other Party materially breaches any of its obligations under this Agreement and fails to cure such breach within sixty (60) days following written notice thereof by the terminating Party.
 
8.3   Termination for Challenge of Patents .  Universal Display may terminate this Agreement on written notice to Panasonic Idemitsu if Panasonic Idemitsu or any of its Affiliates asserts or assists another in asserting (including through the use of a “dummy” person or entity), before any court, patent office or other governmental agency, that any of the Universal Display Patents are invalid or unenforceable, should be cancelled or invalidated in whole or in part, or should otherwise not be granted, allowed or issued in whole or in part (each, a “ Patent Challenge ”).  Such termination shall [***] , and such termination shall be without reduction in any royalties or other amounts due to Universal Display hereunder.  Should Panasonic Idemitsu contest or otherwise allege that such termination or the terms thereof are contrary to law and/or unenforceable, then, if the Patent Challenge is fully or substantially unsuccessful, Panasonic Idemitsu shall reimburse Universal Display, promptly on demand, for all attorneys’ fees, costs and out-of-pocket expenses reasonably incurred by Universal Display or its licensors of such Universal Display Patents in resisting or responding to the Patent Challenge.  The foregoing shall
 
 
Page 10 of 14

 
be in addition to, and not in lieu of, any other rights or remedies that may be available to Universal Display, at law or equity, including, without limitation, actions for injunctive relief and the recovery of damages.
 
8.4   Termination for Change in Control.   Universal Display may terminate this Agreement on written notice to Panasonic Idemitsu if Panasonic Idemitsu undergoes a Change in Control.  A “Change in Control” of Panasonic Idemitsu shall be deemed to have occurred if there is a change in ownership of securities representing [***] percent [***] or more of the voting capital stock of Panasonic Idemitsu, or of other interests having majority voting rights with respect to the election of the board of directors or similar governing authority of Panasonic Idemitsu, or of any other power by contract or in any other form which entitles the holder thereof to majority voting rights with respect to management decisions of Panasonic Idemitsu.  Provided, however, that this paragraph shall not apply to change of ownership of securities at the moment possessed by Panasonic Electric Works Co., Ltd. into one of its Affiliates within Panasonic Corporation group.
 
8.5   Other Termination .  Either Party may terminate this Agreement on written notice to the other Party if the other Party permanently ceases conducting business in the normal course, becomes insolvent or is adjudicated bankrupt, makes a general assignment for the benefit of its creditors, admits in writing its inability to pay its debts as they become due, permits the appointment of a receiver for its business or assets, or initiates or becomes the subject of any bankruptcy or insolvency proceedings which proceedings, if initiated involuntarily, are not dismissed with sixty (60) days thereafter.
 
8.6   Survival .  The following provisions of this Agreement shall survive four (4) years after the expiration or termination of this Agreement:  (a) any payment or reporting obligations of Panasonic Idemitsu; (b) any audit or inspection rights of Universal Display; and (c) any other provisions necessary to interpret the respective rights and obligations of the Parties hereunder.  Any termination of this Agreement shall be in addition to, and not in lieu of, any other rights or remedies available to the other Party under this Agreement, at law or in equity.
 
Article 9   Miscellaneous
 
9.1   Independent Contractors .  This Agreement is not intended by the Parties to constitute, create, give effect to, or otherwise recognize a joint venture, partnership, or formal business organization of any kind.  Each Party hereto shall act as an independent contractor, and neither shall act as an agent of the other for any purpose.  Neither Party has the authority to assume or create any obligation, express or implied, on behalf of the other.
 
9.2   Notices .  Any notices pertaining to the administration of this Agreement or any breach or alleged breach thereof shall be in writing and shall be deemed effectively given upon receipt of such notices by the recipient.  Such notices shall be given by personal delivery, certified mail with postage prepaid and return receipt requested, or prepaid delivery using a recognized private courier, to each Party at its address set forth below; provided, however, that the Parties may agree to exchange information by confirmed email or facsimile correspondence in lieu of the methods described above.  Either Party may change its address for such notices at any time by means of a notice given in the manner provided in this paragraph.
 
 
Page 11 of 14

 
All Reports and any other financial notices, to:
 
Universal Display Corporation
 
Panasonic Idemitsu OLED Lighting Co., Ltd.
375 Phillips Boulevard
 
1048 Kadoma, Osaka 571-8686, JAPAN
Ewing, New Jersey 08618, U.S.A.
 
Attn: [***]
Attn: [***]
 
Fax No.: [***]
Fax No.: [***]
 
Tel No.: [***]
Tel No.: [***]
 
E-mail: [***]
E-mail: [***]
   

All other notices and communications:

[same as above]
 
[same as above]
Attn: [***]
 
Attn: [***]
Fax No.: [***]
 
Fax No.: [***]
Tel No.: [***]
 
Tel No.: [***]
E-mail: [***]
 
E-mail: [***]

9.3   Non-Assignment .  Panasonic Idemitsu may not assign or transfer any of its rights or delegate any of its obligations hereunder, by application of law or otherwise, without the prior written consent of Universal Display.  Universal Display may assign or transfer this Agreement, in its entirety and on written notice to Panasonic Idemitsu, to a successor in interest to all or substantially all of Universal Display’s business or assets to which this Agreement relates, subject to the successor agreeing in writing to assume all of the obligations of Universal Display under this Agreement.  Any attempted assignment, transfer or delegation in violation thereof shall be null and void and without force and effect.  Nothing herein shall confer any rights upon any person other than the Parties hereto and their respective permitted successors and assigns.
 
9.4   Equitable Relief .  In the event of a Party’s actual or reasonably anticipated infringement or unauthorized use of the other Party’s patents or Know-How licensed hereunder, or breach of the provisions of Article 6 respecting the other Party’s Confidential Items, the other Party may seek to obtain injunctive or other equitable relief as may be necessary to restrain such activity.  Such relief shall be in addition to, and not in lieu of, any other rights or remedies available to the other Party under this Agreement, at law or in equity.
 
9.5   Choice of Law .  This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, U.S.A., without respect to its rules on the conflict of laws.  Any law or regulation providing that the language of a contract shall be construed against the drafter shall also not apply.
 
9.6   Dispute Resolution.   The Parties shall reasonably endeavor to settle amicably any dispute, controversy, or difference which may arise between the parties hereto out of or in relation to this Agreement.  If settlement is not reached between the Parties within sixty (60) days following the initiation of settlement discussions, [***] .   Nothing herein shall limit either Party’s ability to seek injunctive or other forms of relief in any available judicial forum for (a) unauthorized practice under such Party’s patents or other intellectual property rights; or (b) breach of the provisions of Section 6.1 of this Agreement respecting confidentiality.
 
 
Page 12 of 14

 
9.7 Severability .  In the event that any term of this Agreement is held to be invalid, illegal, or unenforceable, such invalidity, illegality, or unenforceability shall not affect any other portion of this Agreement, and there shall be deemed substituted for such term other term(s) that are permitted by applicable law and that will most fully realize the intent of the Parties as expressed in this Agreement.
 
9.8 No Waivers .  The failure of either Party to enforce, or any delay in enforcing, any right, power or remedy that such Party may have under this Agreement shall not constitute a waiver of any such right, power or remedy, or release the other Party from any of its obligations under this Agreement, except by a written document signed by the Party against whom such waiver or release is sought to be enforced.
 
9.9  Entire Agreement; Amendments .  This Agreement constitutes the entire understanding and agreement of the Parties respecting the subject matter hereof and, except for the NDA, supersedes any and all prior agreements, arrangements or understandings between the Parties, whether written or oral, relating thereto.  This Agreement may not be amended or supplemented in any way except by a written document signed by both of the Parties.
 
9.10  Counterparts .  This Agreement may be executed by the Parties hereto in separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
 

 
Page 13 of 14

 


IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives.

Universal Display Corporation
 
Panasonic Idemitsu OLED Lighting Co., Ltd.
By:            /s/ Steven V. Abramson
 
By:            /s/ Kazuo Kamada
Signature
 
Signature
Steven V. Abramson
 
Kazuo Kamada
Printed Name
 
Printed Name
President & CEO
 
President                                                     
Title
 
Title
8/9/11            
 
Aug. 23, 2011
Date
 
Date
 




Note:  Throughout this document, certain confidential material contained herein has been omitted and has been separately filed with the Commission. Each place where such an omission has been made is marked with an [***].

AMENDED AND RESTATED

OLED MATERIALS SUPPLY AND SERVICE AGREEMENT


THIS AGREEMENT (the “ Agreement ”) between PPG INDUSTRIES, INC. (" PPG "), a Pennsylvania corporation having its principal place of business at One PPG Place, Pittsburgh, Pennsylvania 15272, and UNIVERSAL DISPLAY CORPORATION (" UDC "), a Pennsylvania corporation having its principal place of business at 375 Phillips Boulevard, Ewing, New Jersey 08618, each a “ Party ” and collectively the “ Parties ,” is effective as of October 1, 2011 (the “ Effective Date ”).

WHEREAS, PPG and UDC previously entered into an OLED Materials Supply and Service Agreement effective as of January 1, 2006, as subsequently amended (the “ Original Agreement ”); and

WHEREAS, PPG and UDC desire to amend and restate the Original Agreement and continue the relationship of the Parties under the terms of this Agreement as of the Effective Date.

NOW, THEREFORE, intending to be legally bound, PPG and UDC agree as follows:


ARTICLE 1 – DEFINITIONS

Whenever used in this Agreement, unless otherwise clearly indicated in the context, the following terms shall have the meanings as defined in this Article.  As used herein, the singular includes the plural and vice versa, and the words “shall” and “will” are each understood to be imperative or mandatory in nature and are interchangeable with one another.

1933 Act ” means the Securities Act of 1933, as amended.

1934 Act ” means the Securities Exchange Act of 1934, as amended.

Ancillary Development Chemical ” means a Development OLED Chemical that UDC does not currently, and does not intend during the Term, to resell to third parties for their manufacture of OLEDs for commercial sale.

 
Page 1 of 65

 


Analytical Services ” means analytical services provided or to be provided by PPG with respect to the development, production or supply of OLED Chemicals hereunder.

Batch Sheet ” means PPG’s standard written operator instructions for the manufacture of Products or purification or conversion of Third-Party OLED Materials, and/or one or more Intermediates in the Synthetic Pathway for such Products, which instructions are intended to embody the equipment-specific information for manufacturing the Products or purification or conversion of Third-Party OLED Materials and/or Intermediates at PPG’s manufacturing facility.

Calendar Quarter ” means the three-month period beginning on each of January 1, April 1, July 1 and October 1 of a year.

Commercial OLED Chemical ” means an OLED Chemical supplied or to be supplied by PPG to UDC pursuant to a Purchase Order hereunder and following the establishment of a Validated Process for such OLED Chemical, which OLED Chemical (a) is being supplied to UDC with the understanding that UDC will be reselling it to third parties for their manufacture of OLEDs for commercial sale, (b) is being supplied to UDC with the understanding that UDC will be reselling it to third parties for their formulation into solution or suspension form for the manufacture of OLEDs for commercial sale,   or (c) is in fact resold to a third party for any such purpose.

Commercial OLED Chemical Vesting Date ” has the meaning given in Section 6.4.5.

Commission ” means the Securities and Exchange Commission.

Competitive OLED Chemical ” means an OLED Chemical or Intermediate that is not a Product.

Confidential Information ” of a Party shall include all trade secret, confidential and/or proprietary information of such Party, whether of a technical, engineering, operational, financial or marketing nature (including, without limitation, their respective proprietary materials), that is (i) in writing and marked as “Trade Secret,” “Confidential,” “Proprietary” or with words of a similar nature; or (ii) orally or visually disclosed and clearly identified as “Trade Secret,” “Confidential” or “Proprietary” at the time of such disclosure and confirmed in writing as such within thirty (30) days following such oral or visual disclosure.  Notwithstanding the foregoing, the information in each Batch Sheet and Process Development Technical Report shall be deemed Confidential Information of UDC; provided , however , that, for the avoidance of doubt, to the extent that any such Batch Sheet or Process Development Technical Report references any standard operating procedure of PPG, the actual content of such standard operating procedure will not be considered Confidential Information of UDC and will not be disclosed to UDC hereunder or to third parties pursuant to Section 5.2, unless the standard operating

 
Page 2 of 65

 


procedure relates to the usage of New OLED Equipment as defined in Section 6.4.6 below.

Contract Year ” means any calendar year beginning January 1 st and ending on December 31 st during the Term.

Development OLED Chemical ” means an OLED Chemical and/or Intermediate supplied or to be supplied by the Process Development Team to UDC hereunder, pursuant to a Purchase Order or Statement of Work and prior to the establishment of a Validated Process for such OLED Chemical, which OLED Chemical is being supplied to UDC with the understanding that UDC will not be reselling it to third parties for their manufacture of OLEDs for commercial sale.

Developed Technology ” means all inventions, discoveries, Know-How and materials, patentable or unpatentable, that are conceived, created, made or reduced to practice by the Process Development Team (alone or with UDC personnel) in their performance of work under agreed-upon Statements of Work.  This includes all OLED Chemicals and Intermediates, their compositions of matter, their Synthetic Pathways and relevant detailed process descriptions, their Material Specifications and any specifications for raw materials used to produce them, their uses in all fields of application, and their associated analytical characterization techniques.  “Developed Technology” shall also encompass all “Developed Technology” under the Original Agreement.  Furthermore, for purposes of clarification, the Know-How embodied in any Batch Sheet or Process Development Technical Report for an OLED Chemical or Intermediate is encompassed within Developed Technology.

Development Program ” means the joint research and development program undertaken or to be undertaken by PPG and UDC pursuant to this Agreement, as such program is detailed in one or more Statements of Work for the Process Development Team, which Program is or shall be directed to (i) Process Development; and (ii) such other items as are agreed upon by the Parties in a Statement of Work.

Disclosing Party ” has the meaning given in Section 4.1.

EH&S Services ” means the environmental, health and safety services provided or to be provided by PPG with respect to the development, production or supply of OLED Chemicals hereunder, including, without limitation, toxicity testing and chemicals inventory registration.

Intermediate ” means a material that occurs somewhere in a Synthetic Pathway between the introduction of the basic precursor raw materials and the creation of one or more unrefined OLED Chemicals.

Know-How ” means trade secrets and other unpatented proprietary technical and/or scientific information, data, specifications, plans, drawings, designs, copyrights, blueprints, formulae, processes and other similar items and materials.

 
Page 3 of 65

 



Material Specifications ” means, with respect to each OLED Chemical and/or Intermediate produced or supplied, or to be produced or supplied hereunder, the written analytical and visual specifications for such OLED Chemical and/or Intermediate, and for its packaging, storage and shipment, as such specifications may be changed by written agreement of the Parties from time to time.

New OLED Equipment ” has the meaning given in Section 6.4.6.

OLED Chemicals ” means organic or organometallic molecules or compounds positioned between the two electrodes in a device that radiates light by applying electrical current or voltage to the electrodes.

Patents ” means United States and foreign patents and patent applications, together with all divisions, continuations, continuations-in-part, reissues, re-examinations, renewals and extensions of the same.

Person ” or “ person ” means any natural person, corporation, partnership, limited liability company, proprietorship, association, trust or other legal entity.

PPG’s OLED Material Conversion Costs ” means all of PPG’s actual costs of producing and supplying Development OLED Chemicals or Pre-Commercial OLED Chemicals to UDC under an agreed-upon Statement of Work or Purchase Order (excluding the costs of raw materials and Third-Party OLED Materials purchased under subsection 6.2.1 below and Intermediates produced under subsection 6.2.2 below, all of which shall be invoiced separately to UDC under Section 9.1 below), the applicable categories of which shall be specified on Exhibit A-2 attached hereto, as the same may be amended by mutual written agreement of the Parties from time to time.

PPG’s Commercial OLED Material Costs ” means all of PPG’s actual costs of producing and supplying Commercial OLED Chemicals to UDC under an agreed-upon Purchase Order (including the costs of raw materials and Third-Party OLED Materials purchased under subsection 6.2.1 below and Intermediates produced under subsection 6.2.2 below), the applicable categories of which shall be specified on Exhibit A-3 attached hereto, as the same may be amended by mutual written agreement of the Parties from time to time.

PPG’s Process Development Costs ” means all of PPG’s actual, fully-loaded man-hour costs of conducting Process Development work under an agreed-upon Statement of Work and budget for such work, the applicable categories of which shall be specified on Exhibit A-4 attached hereto, as the same may be amended by mutual written agreement of the Parties from time to time.

Pre-Commercial OLED Chemical ” means an OLED Chemical supplied or to be supplied by PPG to UDC pursuant to a Purchase Order hereunder and following the establishment of a Validated Process for such OLED Chemical, which OLED chemical

 
Page 4 of 65

 

is being supplied to UDC with the understanding that UDC does not intend to resell it to third parties for their manufacture of OLEDs for commercial sale; provided, however, that if an ordered or supplied quantity of any Pre-Commercial OLED Chemical is in fact resold to a third party for such purpose, it shall be reclassified as a Commercial OLED Chemical, whereupon there shall be a corresponding additional charge or credit to UDC to reflect any cost differences as set forth below.

Primary Development Chemical ” means a Development OLED Chemical that UDC does not currently, but that UDC intends during the Term to, resell to third parties for their manufacture of OLEDs for commercial sale.

Princeton License Agreement ” means that Amended License Agreement by and among UDC, The Trustees of Princeton University (“ Princeton University ”) and the University of Southern California (“ USC ”), dated as of October 9, 1997, as amended.

Process Development ” means the exploration, identification, development and scale-up, pursuant to a Statement of Work, of (i) one or more new or improved Synthetic Pathways for manufacturing OLED Chemicals in quantities sufficient for supply on a commercial scale and on a cost-effective basis, including any processes intended to qualify as Validated Processes; (ii) new or improved Material Specifications for such OLED Chemicals; and (iii) new or improved analytical methodologies, data and data analyses for characterizing such OLED Chemicals.

Process Development Team ” means a team of one or more qualified research and process development chemists, technicians, engineers and/or supervisors employed or utilized by PPG in the Specialty Synthesis Group of its Optical Products business, or any successor to such group or business, which individuals PPG, in its sole discretion, shall select and assign from time to time during the Term to perform Process Development work hereunder.

Process Development Technical Report ” means a document prepared by the Process Development Team, which document details for a particular OLED Chemical, in a manner sufficiently comprehensive so as to facilitate and assist a reasonably competent specialty chemicals manufacturer to manufacture such OLED Chemical in commercial-scale quantities and according to its corresponding Material Specifications, one or more of the following, as applicable in view of the relevant Statement(s) of Work and subject to Section 11.5: (i) the viable Synthetic Pathway(s) and relevant detailed process descriptions for manufacturing such OLED Chemical in quantities appropriate for commercial-scale sales by UDC, including any processes intended to qualify as Validated Processes; (ii) the Material Specifications for such OLED Chemical and any associated Intermediates; (iii) raw materials required for the manufacture of such OLED Chemical and its associated Intermediates by such Synthetic Pathway(s), including the specifications for such raw materials and any existing and potential suppliers of such raw materials and current Certificates of Analysis for such raw materials; (iv) PPG’s current procedures for the handling of such OLED Chemical and its associated Intermediates and their raw materials, together with EH&S information pertaining

 
Page 5 of 65

 

thereto; (v) the analytical methodologies, data and data analyses for characterizing such OLED Chemical and its associated Intermediates and their raw materials; and (vi) a reasonably detailed description of problems encountered by PPG during Process Development work on such OLED Chemical that in PPG’s opinion are significant, including any material failed approaches and solutions or proposed solutions thereto.

Product ” means any Development OLED Chemical, Pre-Commercial OLED Chemical or Commercial OLED Chemical.

Purchase Order ” means a written order from UDC to PPG, or an instruction under a blanket written order from UDC to PPG, including email correspondence confirmed by an authorized representative of each Party, for the purchase of a Product, or for the performance of any Analytical Services or EH&S Services, but excluding any preprinted terms and conditions therein.

Receiving Party ” has the meaning given in Section 4.1.

Records ” has the meaning given in Section  2.8.1.

Rule 144 ” means Rule 144 promulgated by the Commission pursuant to the 1933 Act.

Securities ” means the shares of UDC Common Stock issuable to PPG pursuant to this Agreement.

Statement of Work ” means one or more agreed-upon written protocols, plans or other documents, including email correspondence confirmed by an authorized representative of each Party, describing the work to be performed by the Process Development Team, as the same may be amended from time to time in writing by mutual agreement of the Parties.

Sublimation ” or “ Sublimate ” means the conversion of an unrefined OLED Chemical from solid to vapor, and its subsequent de-sublimation from vapor to solid under appropriate temperature and pressure conditions to recover the desired sublimated OLED Chemical, with the purpose of such conversion being to enhance the purity of such OLED Chemical.

Synthetic Pathway ” means generalized process step(s) for the conversion of precursor materials and/or Intermediates to other Intermediates and/or OLED Chemicals, including, without limitation, the structural formulas for such precursor materials and/or Intermediates, and the general processing conditions for synthesis and purification of such Intermediates and/or OLED Chemicals (e.g., solvent usage, temperature conditions, etc.).

 
Page 6 of 65

 


Third-Party OLED Material ” means an Intermediate or unrefined OLED Chemical, produced by a party other than PPG, to be subjected to Sublimation and/or other additional processing hereunder.

UDC Common Stock ” means the common stock of UDC, $0.01 par value per share.

UDC Chemical Know-How ” means any and all Know-How relating to OLED Chemicals or methods of producing OLED Chemicals, or that might reasonably be useful in connection with producing OLED Chemicals, that UDC owns or otherwise is authorized to disclose and license or sublicense to PPG hereunder, including, without limitation, any such Know-How constituting Developed Technology and any such Know-How acquired or licensed by UDC from Princeton University or USC under the Princeton License Agreement, or under other agreements, whether prior to or after the Effective Date.

UDC Chemical Patents ” means any and all Patents, whether or not currently existing, that claim or cover any OLED Chemicals or methods of producing OLED Chemicals, or any methods or processes that might reasonably be useful in connection with producing OLED Chemicals, and that UDC is authorized to license or sublicense to PPG hereunder, including, without limitation, any such Patents claiming Developed Technology and any such Patents acquired or licensed by UDC from Princeton University or USC under the Princeton License Agreement, or under other agreements, whether prior to or after the Effective Date.

UDC Proprietary Materials for Chemicals ” means all UDC Chemical Patents, UDC Chemical Know-How and Developed Technology.

Validated Process ” means a process, including a Synthetic Pathway, for manufacturing an OLED Chemical, in quantities appropriate for commercial-scale sales by UDC, so as to meet its corresponding Material Specifications and UDC’s criteria for qualifying the material for use in OLED devices, which process has been successfully proven reproducible in three consecutive pilot batch manufacturing runs at PPG’s facility.

Waste ” means any “hazardous substance,” “hazardous material” and/or “hazardous waste” as provided under any environmental law, rule or regulation, as well as any other waste material, pollutant and/or contaminant of any kind, including, without limitation, any routine process waste or any by-product arising from the manufacture of any OLED Chemical hereunder.


ARTICLE 2 – DEVELOPMENT TEAMS

2.1.            Development Team .  PPG shall maintain the Process Development Team to work on the tasks set forth in Statements of Work.  PPG shall sufficiently staff the

 
Page 7 of 65

 

Process Development Team so as to reasonably ensure the timely and proper completion of such tasks.

2.2            Team Management .  The Process Development Team shall report to PPG’s Manager, Applied Technology for Optical Materials, who shall communicate periodically with UDC’s Vice President Technology Commercialization to discuss the direction and performance of the Process Development work.

2.3            Reserved .

2.4            Statements of Work and Budgets .

2.4.1            Reserved .

2.4.2            Process Development Work .  The Parties shall in good faith mutually agree upon Statements of Work and budgets for Process Development work on an as-needed basis prior to the commencement of such work.  PPG shall in good faith agree to perform all Process Development work reasonably requested by UDC hereunder, provided, however, PPG in its reasonable discretion may refuse to perform certain Process Development Work if (i) PPG does not have and cannot reasonably reassign sufficient staffing to perform the work, (ii) PPG does not have appropriate capital equipment and facilities reasonably available to perform the work, or (iii) the chemical nature of the materials involved is such that PPG is not reasonably equipped to manage their associated chemical hazards.  If there is a problem that can be circumvented through outsourcing any of the Process Development Work, then the Parties shall use commercially reasonable efforts to pursue and facilitate such outsourcing.  The Parties acknowledge and agree that each Statement of Work that includes the services of one or more of PPG's computational chemists, including, without limitation, [***], shall contain a commitment by UDC for a minimum amount of time to be spent by any such computational chemist in connection with the services to be provided under such Statement of Work.

2.4.3            Changes .  Upon either Party’s request, the Parties will in good faith discuss and endeavor to agree upon revisions to any Statement of Work and/or budget for the Development Program.  However, such Statements of Work and budgets may be amended only by mutual written agreement of the Parties, which may include email correspondence confirmed by an authorized representative of each Party.

2.4.4            Certain Development Work .  Consistent with past practice under the Original Agreement, PPG shall make reasonably available to UDC the services of Jun Deng and other computational chemists.  The parties shall develop a mutually agreeable Statement of Work regarding the amount of time these individuals will be able to devote to providing services to UDC.  The provision of such services shall continue as long as these individuals are employed by PPG, and PPG shall give UDC reasonable advance notice if and when PPG is no longer able to offer UDC the services of these individuals.  In such event, the Parties shall cooperate in good faith to find an

 
Page 8 of 65

 

alternative resource for comparable services.  For purposes of this Agreement, these individuals shall be deemed members of the Process Development Team and the services they provide shall be deemed Process Development Work, and UDC shall pay PPG for such services in accordance with Sections 6.4.2 and 9.2.

2.4.5           PPG shall be solely responsible for all salary and other compensation of its employees and/or researchers in connection with the performance of any work under this Agreement, including, without limitation, all tax withholding with respect thereto and payment, if any, of employment-related taxes and workers’ compensation insurance premiums.

2.5            Reserved .

2.6            Reserved .

2.7            Party Responsibilities .

2.7.1           PPG’s responsibilities under the Development Program shall include, without limitation, using commercially reasonable efforts to do the following:

(i)  
Reserved.

(ii)  
Reserved.

(iii)  
Reserved.

(iv)  
PPG shall direct the Process Development Team to perform Process Development work.

(v)  
PPG shall direct the Process Development Team to supply UDC with Development OLED Chemicals under a Statement of Work.

(vi)  
PPG shall direct the Process Development Team to provide UDC with Process Development Technical Reports for Development OLED Chemicals upon UDC’s request.

(vii)  
PPG shall direct the Process Development Team to disclose to UDC all Developed Technology, by periodically providing copies of laboratory notebooks at a reasonable frequency requested by UDC, or by such other means as the Parties may agree upon in writing.

2.7.2           UDC’s responsibilities under the Development Program shall include, without limitation, using commercially reasonable efforts to do the following:

(i)  
UDC shall direct its personnel to perform their obligations as specified in a Statement of Work.

 
Page 9 of 65

 


(ii)  
UDC shall maintain a qualified team to reasonably evaluate in OLED applications any Development OLED Chemicals supplied by the Process Development Team.  UDC shall report the results of such evaluations to the Process Development Team.

(iii)  
UDC shall direct its personnel to cooperate with the Process Development Team in performance of their responsibilities under the Development Program.

(iv)  
For OLED Chemicals, including Third-Party OLED Materials, transferred by UDC to PPG’s Process Development Team for Process Development work pursuant to a Statement of Work, UDC shall direct its personnel to provide the Process Development Team with such of the reasonably available UDC Chemical Know-How as is necessary in connection with PPG’s performance hereunder.

(v)  
UDC shall be responsible, in its sole discretion, for protecting and maintaining the intellectual property rights to Developed Technology as set forth in Section 3.4 below.

2.7.3           Each Party agrees to the following responsibilities under this Agreement:

 
(i)
The Parties’ researchers will work together in a team environment using their respective expertise and Know-How to facilitate performance of the Development Program.

(ii)  
While working at the other Party’s facilities, each Party’s chemists and other personnel shall: (a) at all times comply with all of the other Party’s safety, security and mutually agreed confidentiality policies and procedures; and (b) limit their activities solely to assisting the other Party in the conduct of the Development Program.

(iii)  
The Parties shall work together in a jointly cooperative manner in support of Product sales by UDC and the timely availability of Products meeting current or future requirements of the OLED industry.

2.8            Recordkeeping and Reporting .

2.8.1           During the Term, PPG shall direct the Process Development Team to diligently maintain tangible records of work conducted under the Development Program (“ Records ”).  These Records shall be kept in bound or electronic laboratory notebooks, each page of which shall be timely dated, signed and witnessed.  PPG will retain the Records for two (2) years beyond the Term.

 
Page 10 of 65

 



2.8.2           PPG shall provide UDC with such reports and other supporting documentation as UDC may reasonably request in connection with monitoring PPG’s charges for the Development Program.

2.8.3           During the Term and for at least two (2) years thereafter, UDC shall have the right to examine Records kept by PPG hereunder.  Each such examination shall take place during normal business hours of PPG and on at least ten (10) business days’ advance written notice to PPG.  Each such examination shall be at a location selected by PPG and in accordance with procedures reasonably acceptable to PPG, including, without limitation, procedures designed to protect any Confidential Information of PPG.  PPG shall not be required to permit examination of its Records more often than once during any Calendar Quarter.

2.9            Other Research Work .

2.9.1           PPG acknowledges that UDC intends to continue working with Princeton University, USC and others to explore and develop new and improved OLED Chemicals, and that PPG’s work under the Development Program may involve work on such chemicals, to the extent set forth in a Statement of Work.

2.9.2           Except in connection with conducting the Development Program hereunder, during the Term and for [***] months thereafter, PPG shall not conduct or fund any research program specifically directed to developing OLED Chemicals for use in OLEDs, whether on its own or in collaboration with any other person; provided, however, that nothing in this Agreement shall prohibit PPG from continuing to perform work on its photochromic and electrochromic development programs.


ARTICLE 3 – INTELLECTUAL PROPERTY

3.1            Developed Technology .  All Developed Technology shall be owned solely by UDC, and PPG hereby assigns and transfers any and all right, title and interest it may have in and to such Developed Technology to UDC.  Upon UDC’s request, PPG shall execute and deliver to UDC all instruments and other documents, and shall take such other actions as may be reasonably necessary so that UDC may protect and defend its rights in and to the Developed Technology.  Subject to the express terms of this Agreement, UDC shall have no obligation of accounting to PPG with respect to any Developed Technology.  UDC shall bear all costs associated with patenting and protecting the Developed Technology.

3.2            Other Technology .

3.2.1           All inventions, discoveries, Know-How and materials, that are not Developed Technology, patentable or unpatentable, that are conceived, created, made or reduced to practice under this Agreement (“ Other Technology ”), if conceived,

 
Page 11 of 65

 

created, made or reduced to practice solely by the personnel of one Party, shall be owned solely by that Party.  Each Party shall bear all costs associated with patenting and protecting its solely-owned Other Technology.

3.2.2           All Other Technology conceived, created, made or reduced to practice jointly by the personnel of both Parties shall be owned jointly by both Parties.  Subject to the express terms of this Agreement, neither Party shall have any obligation of accounting to the other Party with respect to any jointly-owned Other Technology.  The Parties shall in good faith agree upon and implement procedures for the preparation, filing, prosecution and maintenance of patent applications and patents claiming any jointly-owned Other Technology, and shall allocate responsibility for the costs and expenses associated with such patent activities.  Should either Party elect not to pay its fair share of such costs and expenses for patents in any country of the world, that Party shall, upon request, assign to the other Party all of such Party’s rights to such patents in said country.

3.2.3           Upon either Party’s request, the other Party shall execute and deliver to such Party all instruments and other documents, and shall take such other actions as may be reasonably necessary so that such Party may protect and defend its rights in and to any Other Technology.

3.3            License Grants to PPG .

3.3.1           UDC hereby grants to PPG, during the Term and subject to the terms and conditions set forth herein, a worldwide, royalty-free, non-exclusive, non-transferable (except as permitted under Section 21.2 below) license, with the right to sublicense under subsection 3.3.4 below, to practice under any and all UDC Chemical Patents, and to use, improve, enhance and modify any and all unpatented UDC Proprietary Materials for Chemicals, for the sole purposes of (i) performing PPG’s obligations under the Development Program as contemplated hereunder; (ii) producing and selling OLED Chemicals to UDC as contemplated hereunder; and (iii) providing Analytical Services and EH&S Services as requested by UDC hereunder.

3.3.2           UDC hereby further grants to PPG a worldwide, perpetual, royalty-free, non-exclusive, non-transferable (except as permitted under Section 21.2 below) license, with the right to sublicense as permitted under subsection 3.3.4 below, to practice under any and all Patents claiming Developed Technology and all Know-How encompassed by Developed Technology, solely for PPG’s own use in its current and future business, but not otherwise in competition with UDC with respect to OLEDs or OLED Chemicals.

3.3.3           UDC shall not grant rights to others that will adversely affect PPG’s license contemplated under this Section 3.3.

3.3.4           The licenses granted to PPG under this Agreement shall extend to any division of or subsidiary controlled by PPG.  Any sublicenses, in whole or in part, to

 
Page 12 of 65

 

other Persons shall be subject to UDC’s prior written approval, such approval not to be withheld unreasonably; provided, however, that UDC, in its sole discretion, may withhold approval of sublicenses other than those for purposes of permitting such third Parties to practice under the applicable Patents and/or Know-How on PPG’s behalf and/or for PPG’s benefit or account ( e.g. , for purposes of exercising the equivalent of “have made” or “have sold” rights as such rights are generally understood, or performing manufacturing activities on PPG’s behalf with respect to Products to be supplied to UDC hereunder).  PPG shall provide UDC with written notice of the names and addresses of each such sublicensee, as well as a full, unredacted copy of the sublicense agreement and all subsequent amendments and modifications thereof, before or within a reasonable period of time after PPG enters into such sublicense.  Each sublicense granted by PPG hereunder shall (i) expressly provide that such sublicense is nontransferable and nonassignable, (ii) prohibit the initial sublicensee from granting any further licenses or sublicenses thereunder, (iii) expressly provide that UDC is a third-party beneficiary of the sublicense agreement with rights to enforce its terms directly against the sublicensee, and (iv) obligate the sublicensee to abide by the terms and conditions of this Agreement applicable to sublicensees.

3.3.5           Except for the license and other rights expressly granted or promised to PPG under this Agreement, the Parties retain their respective rights to their respective Patents and Know-How.

3.4            Acknowledgment of Derivative Rights .  Notwithstanding anything to the contrary in this Agreement, PPG acknowledges that some of its rights to certain UDC Chemical Patents derive from the Princeton License Agreement.  Each Party agrees that PPG’s rights to said UDC Chemical Patents under this Agreement shall be a sublicense under and subject to the provisions of the Princeton License Agreement.

3.5            Patent Procurement, Maintenance and Enforcement .

3.5.1           The desirability of applying for, prosecuting and maintaining Patents claiming the Developed Technology (and the countries in which Patents should be applied for, prosecuted and maintained) shall be determined by UDC in its sole and absolute discretion.  If UDC decides to obtain Patent protection for any Developed Technology, PPG shall reasonably cooperate with UDC in preparing, filing and prosecuting applications for such Patents and in maintaining any Patents issuing thereon.  UDC shall bear all expenses incurred in preparing, filing and prosecuting such Patent applications and in maintaining any resulting Patents.

3.5.2           UDC shall provide PPG with copies of all Patent applications claiming any Developed Technology before they are filed, in order for PPG to promptly review said applications to be certain that no PPG Confidential Information is being disclosed without PPG’s prior approval.  If PPG claims that its Confidential Information is disclosed in an application submitted for review, UDC shall not file such application until the claim has been resolved to the reasonable satisfaction of PPG.  The Parties shall in good faith attempt to resolve any such claim as expeditiously as possible.

 
Page 13 of 65

 



3.5.3           Each Party shall promptly notify the other Party of any known or reasonably suspected infringement or misappropriation of UDC Proprietary Materials for Chemicals.

3.5.4           UDC shall protect and enforce all Patents and Patent applications claiming any Developed Technology, at its sole expense and in its sole and absolute discretion.  PPG shall reasonably assist UDC in its efforts to protect and/or enforce such Patents and Patent applications at UDC’s sole cost and expense.


ARTICLE 4 – CONFIDENTIALITY

4.1            General Obligations .  Each Party (in such capacity, the “ Receiving Party ”) shall review and maintain Confidential Information of the other Party (in such capacity, the “ Disclosing Party ”) in accordance with the following terms and conditions:

4.1.1           The Receiving Party agrees to treat all Confidential Information of the Disclosing Party as confidential and not to disclose such Confidential Information to any other person, or use such Confidential Information for any purpose other than to perform its obligations or exercise its rights hereunder, except as expressly permitted by the Disclosing Party in writing.

4.1.2           The Receiving Party shall make only such copies of the Confidential Information of the Disclosing Party as are reasonable for the Receiving Party’s performance of its obligations or exercise of its rights hereunder.

4.1.3           At all times, the Receiving Party shall keep and maintain all Confidential Information of the Disclosing Party in a safe and secure place with reasonable safeguards to insure that unauthorized persons do not have access to such Confidential Information.  Upon discovery of any unauthorized disclosure or use of Confidential Information of the Disclosing Party, the Receiving Party shall immediately notify the Disclosing Party and take all reasonable steps to prevent its further unauthorized disclosure or use.

4.1.4           The Receiving Party is prohibited from disclosing Confidential Information of the Disclosing Party to third parties unless such other person has a need-to-know such Confidential Information in connection with the Receiving Party’s performance of its obligations or exercise of its rights under this Agreement.  In addition, disclosure of such Confidential Information to any third party shall be permitted only after such third party has agreed in writing to abide by provisions of confidentiality and restrictive use no less stringent than those set forth herein.  The Receiving Party shall be responsible for enforcing such provisions against such third party.

4.1.5           With respect to all Confidential Information of the Disclosing Party in the Receiving Party’s possession or control (including, without limitation, all copies

 
Page 14 of 65

 

and summaries thereof and regardless of the format in which such Confidential Information is stored), the Receiving Party, promptly upon the Disclosing Party’s request, shall either:  (i) return all such Confidential Information to the Disclosing Party, or (ii) destroy all such Confidential Information and certify the same to the Disclosing Party in writing.  Notwithstanding the foregoing sentence, the Receiving Party may retain one copy of each tangible item of Confidential Information of the Disclosing Party in a secure location solely for purposes of enforcement of this Agreement; provided, however, that all such Confidential Information shall continue to be governed in all respects by the other provisions of this Article.  The provisions of this Section 4.1.5 shall not apply to any Developed Technology.

4.2            Exceptions .  Notwithstanding anything to the contrary herein, the provisions of this Article shall not apply with respect to any Confidential Information of the Disclosing Party that:

4.2.1           is already in or subsequently enters the public domain through no fault of the Receiving Party;

4.2.2           is supplied by the Disclosing Party to another person without a duty of confidentiality;

4.2.3           is known to the Receiving Party or is in its possession (as shown by tangible evidence) prior to receipt from the Disclosing Party;

4.2.4           is developed independently by the Receiving Party (as shown by competent written records) without reliance on any Confidential Information of the Disclosing Party;

4.2.5           is lawfully received by the Receiving Party from another person without a duty of confidentiality to the Disclosing Party; or

4.2.6           is disclosed by the Receiving Party pursuant to judicial order or governmental regulation or administrative process so long as the Receiving Party notifies the Disclosing Party promptly before the disclosure and cooperates with the Disclosing Party in the event that the Disclosing Party decides to contest or limit the disclosure.

4.3            Other Persons .  To the extent any person that is subject to the restrictions set forth in this Article is not a Party to this Agreement, the terms of this Article 4 shall apply to such person to the same extent as if he, she or it were a Party hereto.

4.4            Injunctive Relief .  In the event of any breach or threatened breach by any person of any provision of this Article 4, the Party harmed or likely to be harmed by such breach or threatened breach shall be entitled to seek injunctive or other equitable relief restraining such person from engaging in conduct that would constitute a breach of the obligations of such person under this Article 4.  Such relief, if granted, shall be in

 
Page 15 of 65

 

addition to and not in lieu of any other remedies that may be available, at law or equity, including an action for the recovery of damages.

4.5            Survival .  The obligations of confidentiality pursuant to this Article 4 will survive termination or expiration of this Agreement for a period of ten (10) years after the date of expiration or termination.


ARTICLE 5 – APPOINTMENT AND EXCLUSIVE OLED MATERIAL SUPPLY

5.1            Exclusive Appointment .  Subject to the terms and conditions of this Agreement, UDC hereby appoints PPG as its exclusive supplier of, and PPG hereby agrees to manufacture and sell to UDC, all of UDC's requirements for OLED Chemicals that (i) are developed solely by UDC and are materials that UDC intends during the Term to resell to third parties for their manufacture of OLEDs for commercial sale; or (ii) are or were developed jointly by UDC and PPG through Process Development work conducted hereunder or under the Original Agreement (collectively, “ Covered OLED Chemicals ”).  UDC shall not sell or otherwise supply Covered OLED Chemicals for use in OLEDs, except those provided by PPG to UDC hereunder.

5.2            Exceptions .  The obligations and restrictions under Section 5.1 above shall not apply under the following circumstances:

5.2.1           UDC’s requirements for the Covered OLED Chemical are in excess of such quantities as PPG is able to reasonably manufacture, alone or in the aggregate with other Covered OLED Chemicals, using its current or anticipated capital equipment and facilities.  For each current Covered OLED Chemical, such maximum quantity has been separately agreed to in writing by the Parties and each of UDC and PPG agrees that such maximum quantity is sufficient for UDC’s reasonably foreseeable needs.  For future Covered OLED Chemicals, or if UDC’s expected requirements for a current Covered OLED Chemical increase substantially, the Parties shall discuss and in good faith endeavor to agree upon a new or revised maximum quantity for the Covered OLED Chemical.  If PPG is to perform Process Development work on the Covered OLED Chemical, PPG shall provide UDC with PPG’s proposed maximum quantity for the Covered OLED Chemical and the Parties shall endeavor to reach such agreement prior to or promptly following UDC’s request for PPG to commence such Process Development work.  If there is a problem that can be circumvented through PPG’s outsourcing of any of the manufacturing process steps, or through the purchase of a Third-Party OLED Material, then the Parties shall use commercially reasonable efforts to pursue such an alternative approach and the foregoing obligations and restrictions shall continue to apply unless the Parties, despite their good faith efforts, are unable to agree on a viable alternative.

5.2.2           PPG’s pricing or projected pricing for commercial-scale quantities of the Covered OLED Chemical is in excess of that which allows UDC to resell the Covered OLED Chemical for a reasonable profit and UDC has good reason to believe

 
Page 16 of 65

 

that it can obtain the Covered OLED Chemical from another source at pricing that would enable UDC to resell the Covered OLED Chemical for such a profit.  For each current Covered OLED Chemical, PPG pricing or projected pricing for commercial-scale quantities has been separately agreed to in writing by the Parties and each of UDC and PPG agrees that such pricing or projected pricing is currently sufficient for UDC to resell the Covered OLED Chemical for a reasonable profit.  For other Covered OLED Chemicals, or if the pricing at which UDC is able to resell a current Covered OLED Chemical decreases substantially, the Parties shall discuss and in good faith endeavor to agree upon reduced pricing or projected pricing for commercial-scale quantities of the Covered OLED Chemical prior to UDC obtaining the Covered OLED Chemical from another source.  This shall include, without limitation, commercially reasonable efforts to: (i) renegotiate pricing with suppliers of raw materials or Third-Party OLED Materials used to produce the Covered OLED Chemical, (ii) develop alternative, lower-cost suppliers of such raw materials or Third-Party OLED Materials, (iii) outsource additional manufacturing process steps for the Covered OLED Chemical, (iv) perform agreed-upon additional Process Development work to lower PPG’s costs for the Covered OLED Chemical, and (v) revise the multipliers charged by PPG for the Covered OLED Chemical.

5.2.3           PPG is regularly unable to provide commercial-scale quantities of the Covered OLED Chemical that meet its corresponding Material Specifications and pass UDC’s OLED device qualification testing and the Parties, despite their good faith efforts, are unable to timely agree upon and implement a plan for the situation to be remedied.  If there is a problem that can be circumvented through PPG’s outsourcing of any of the manufacturing process steps, or through the purchase of a Third-Party OLED Material, then the Parties shall use commercially reasonable efforts to pursue such an alternative approach and the foregoing obligations and restrictions shall continue to apply unless the Parties, despite their good faith efforts, are unable to agree on a viable alternative.

5.2.4           The Covered OLED Chemical cannot be manufactured by PPG and supplied to UDC for resale to third parties for use in OLEDs without infringing or otherwise violating the Patent or other proprietary rights of a third party.

5.2.5           The Covered OLED Chemical is only being obtained by UDC in limited quantities for demonstration, testing, evaluation and/or research and development purposes.

5.2.6           The Covered OLED Chemical is designed or intended to be used [***].

5.2.7           UDC and PPG otherwise mutually agree that the Covered OLED Chemical will not be subject to the foregoing obligations and restrictions.

5.2.8           UDC, after using commercially reasonable efforts to preserve the exclusive appointment of PPG under Section 5.1, reasonably determines that it is

 
Page 17 of 65

 

important, to obtain or preserve the business or one or more of its customers, for UDC to [***], whether through [***], in order to meet the needs of such customer(s) [***].  In such event, UDC shall provide PPG with advance written notice prior to the effective date of any such [***], said notice to be provided as far in advance as is reasonably practicable.  In the event that, following such notice period, UDC enters into such [***], UDC and PPG will in good faith negotiate [***], taking into consideration the terms of [***]; provided that, if reasonably acceptable to PPG, [***].

5.2.9           Due to [***], the Covered OLED Chemical is required to be manufactured [***] and PPG is unable or unwilling to manufacture the Covered OLED Chemical [***].  If the problem can be circumvented through PPG’s outsourcing of any of the manufacturing process steps, or through the purchase of a Third-Party OLED Material, then the Parties shall use commercially reasonable efforts to pursue such an alternative approach and the foregoing obligations and restrictions shall continue to apply unless the Parties, despite their good faith efforts, are unable to agree on a viable alternative.

For clarification, subject to Section 11.5, UDC shall be entitled to share Process Development Technical Reports and Batch Sheets with third parties as and to the extent deemed appropriate by UDC, such that PPG shall not claim any information contained therein is Confidential Information of PPG.

5.3            Other OLED Chemical Sales by PPG .

5.3.1           During the Term and for [***] months thereafter, PPG shall not sell or supply Products to persons other than UDC, or assist or authorize any other person to sell or supply Products to persons other than UDC.

5.3.2           During the Term and for [***] months thereafter, PPG shall not sell or supply Competitive OLED Chemicals for any OLED-related uses to persons other than UDC, or assist or authorize any other person to sell or supply Competitive OLED Chemicals for any OLED uses to persons other than UDC.

5.3.3           Should PPG, during the Term or within [***] months thereafter, learn that any person to whom PPG is selling any Competitive OLED Chemical for non-OLED uses is using such Competitive OLED Chemical for OLED uses, PPG agrees to immediately cease supplying such person with such Competitive OLED Chemical unless otherwise agreed in writing by UDC.  Nothing in this Agreement, by implication or otherwise, authorizes PPG to use any UDC Proprietary Materials for Chemicals and/or any Confidential Information of UDC in manufacturing, purifying, analyzing or distributing Products or Competitive OLED Chemicals to persons other than UDC, either during or following the Term.


 
Page 18 of 65

 


ARTICLE 6 – PRODUCTS AND SERVICES

6.1            General .

6.1.1           The OLED Chemicals to be supplied pursuant to this Agreement are Products.  PPG shall use commercially reasonable efforts to allocate sufficient resources and adopt sufficient planning procedures to fulfill its obligations to supply Products to UDC hereunder in a timely manner.

6.1.2           The maximum quantity of each current Product that PPG may be required to supply to UDC during any Calendar Quarter has been separately agreed to in writing by the Parties.  The Parties will cooperate in good faith to agree in writing upon such maximum quantity for future Products, or if either Party proposes any changes to a then-existing maximum quantity; provided that, for the avoidance of doubt, in the event that the maximum quantity of a Product required by UDC increases, then, subject to Section 5.2, PPG shall have the exclusive right to supply such additional quantity of Product.

6.1.3           All Products supplied by PPG hereunder shall be manufactured, packaged, stored and shipped according to and in compliance with their corresponding Material Specifications, and in accordance with manufacturing practices as implemented by PPG with respect to other, similar products manufactured by PPG.

6.1.4           The Parties will cooperate in good faith to control PPG’s costs and expenses for each Product supplied to UDC hereunder, and shall use their reasonable best efforts to reduce such costs to the fullest extent reasonably practicable in light of the Product’s corresponding Material Specifications and UDC’s required volumes and lead times, including, without limitation, the cost of raw materials, Third-Party OLED Materials and Intermediates.  PPG shall provide UDC with such reports and other supporting documentation as UDC may reasonably request in connection with monitoring such costs and expenses and PPG’s efforts to control the same.

6.1.5           The Parties recognize that detailed and continuing exchanges of information shall be necessary in order to optimize the administration of this Agreement and PPG’s supply of Products to UDC, consistent with the respective rights and obligations of the Parties hereunder.  To that end, each Party shall designate a representative (and notify the other Party of the individual so designated) responsible for exchanging information and for resolving issues relating to the forecasting, ordering, production, shipment and sales of Products which may arise under this Agreement.  The designated representative of each Party shall conduct planning meetings (which may be by teleconference if practicable) periodically and as may be necessary to address any issues that may arise.

 
Page 19 of 65

 


6.2            Raw Materials, Intermediates and Third-Party OLED Materials .

6.2.1            PPG’s Purchase of Raw Materials and Third-Party OLED Materials .  Except as otherwise set forth below, PPG will purchase and maintain a commercially reasonable inventory of raw materials and Third-Party OLED Materials in order to accommodate each Quarterly Product Forecast (as defined in Section 7.1).  Unless otherwise specifically agreed by each Party in writing, PPG shall be responsible administratively for ordering and arranging for the delivery of all raw materials and Third-Party OLED Materials required for Process Development and the manufacture of said Products to PPG’s facility, and PPG shall arrange for the conversion of such raw materials and Third-Party OLED Materials into said Products which PPG shall supply to UDC as set forth herein.  Unless otherwise agreed by each Party in writing, PPG shall also serve as the technical interface with the supplier of such raw materials and Third-Party OLED Materials for quality control and related purposes.  During the Term, PPG shall use commercially reasonable efforts to obtain raw materials hereunder at lower costs, through both standard cost reduction measures and aggressive, extraordinary raw material strategies including, without limitation, should PPG develop and implement raw material recycling techniques that lead to significant cost savings.  [***]

(i)            Raw Materials for Products Other Than Commercial OLED Chemicals .  Upon written approval by UDC to the Manager, Applied Technology for Optical Materials of PPG, PPG will purchase all raw materials for Products other than Commercial OLED Chemicals for UDC’s account.  As used in this Agreement, “for UDC’s account” shall mean that PPG will invoice UDC for the material in question according to Section 9.1 below; however, in all other respects the material shall be purchased and maintained by PPG as if PPG had acquired the material on its own for the manufacture of Products to be supplied to UDC hereunder; provided that, notwithstanding the foregoing, the risk of loss for any material purchased for UDC’s account hereunder shall transfer to UDC upon delivery to PPG, except to the extent that any loss thereafter is caused by the negligence or fault of PPG.

(ii)            Raw Materials for Commercial OLED Chemicals .  In order to reasonably ensure the manufacture and supply of Commercial OLED Chemicals described in each Quarterly Product Forecast, PPG will purchase and maintain at its facility a commercially reasonable inventory of raw materials.  Subject to clause (v) below, PPG will invoice, and UDC will pay for, such raw materials on a Purchase Order-by-Purchase Order basis when UDC makes payment for the completed batch of Product.  However, should UDC specifically request that PPG purchase and maintain an inventory of one or more critical raw materials above and beyond that which is maintained by PPG as described above, PPG shall maintain said additional inventory at such levels as UDC and PPG, from time to time, shall agree in good faith and in writing.  Such additional inventory of raw material (“ Additional Commercial Raw Material ”) shall be for UDC’s account.

(iii)            Third-Party OLED Materials – Intermediates .  Where the Third-Party OLED Material is an Intermediate, unless otherwise agreed by the Parties in

 
Page 20 of 65

 

writing, such Third-Party OLED Material shall be treated, for purposes of this Section 6.2.1, as if it were a raw material covered under clause (i) or clause (ii) above (and clause (v) below), as applicable.

(iv)            Third-Party OLED Materials – Unrefined OLED Chemicals .  Where the Third-Party OLED Material is an unrefined OLED Chemical, unless otherwise agreed by the Parties in writing, such Third-Party OLED Material shall be treated, for purposes of this Section 6.2.1, as if it were a raw material covered under clause (i) or clause (ii) above (and clause (v) below), as applicable.

(v)            Unused Raw Material Inventory .  In the event that any raw material (excluding any Additional Commercial Raw Material) purchased and inventoried by PPG pursuant to clauses (ii), (iii) or (iv) above is not converted to a Commercial OLED Chemical within twelve (12) months following the date of receipt by PPG due to a failure by UDC to submit one or more Purchase Orders that meet the forecasted Products set forth in the applicable Quarterly Product Report, unless otherwise agreed by the Parties, PPG shall invoice, and UDC shall pay for, such unused raw material (each, an “ Unused Raw Material ”) in accordance with Section 9.1, but without any multiplier being applied.

6.2.2            PPG’s Production of Intermediates .  PPG will recommend to UDC, in writing and on a quarterly basis, the production and maintenance of inventories of Intermediates based upon each Quarterly Product Forecast to be provided by UDC.

(i)            Intermediates for Products Other Than Commercial OLED Chemicals .  Upon written approval by UDC to the Manager, Applied Technology for Optical Materials of PPG, PPG will produce and maintain a reasonable inventory of Intermediates for Products other than Commercial OLED Chemicals for UDC’s account.

(ii)            Intermediates for Commercial OLED Chemicals .  As a general matter, PPG shall be responsible for producing Intermediates sufficiently in advance so as to reasonably ensure the timely manufacture and supply of Commercial OLED Chemicals hereunder.  However, should UDC specifically request that PPG produce and maintain an inventory of one or more Intermediates above and beyond that which is usual and customary for the production of a particular Commercial OLED Chemical, PPG shall maintain said additional inventory at such levels as UDC and PPG, from time to time, shall agree in good faith and in writing.  Such additional inventory shall be for UDC’s account.

6.2.3            Maintenance and Records .  All raw materials and Third-Party OLED Materials purchased by PPG for UDC’s account will be maintained separate from other PPG materials and shall be used solely for the production of Products for UDC hereunder.  PPG will provide UDC with a report summarizing its inventory of raw materials and Third-Party OLED Materials within thirty (30) days prior to the start of each Calendar Quarter and will maintain records as to disposition of such raw materials and Third-Party OLED Materials for a period of six (6) months following the close of

 
Page 21 of 65

 

each Contract Year.  Upon at least thirty (30) days’ prior written notice to PPG, UDC may engage an independent third party to audit such records, subject to PPG’s reasonable confidentiality limitations.

6.2.4            Disposal of Unused Inventory .  If (a) any inventory of raw materials or Third Party OLED Materials obtained pursuant to Section 6.2.1 or (b) any inventory of Intermediates produced pursuant to Section 6.2.2 is not converted to an OLED Chemical within twelve (12) months following receipt or production by PPG, as the case may be, and such inventory is no longer required, then UDC, at its option, shall either (i) pay for disposal of the inventory; (ii) have the inventory shipped to UDC at UDC’s sole cost and expense; or (iii) in the case of raw materials, to the extent possible, return such inventory for credit from supplier of such inventory; provided that, with respect to any inventory of Unused Raw Material, UDC shall have paid in full for all such inventory pursuant to Section 9.1 (but without any multiplier being applied) prior to its disposal.

6.3            Material Specifications .  As a general matter, all Material Specifications shall be proposed by PPG but are subject to final comment and revision and written approval by UDC.  Once approved, the Material Specifications for a given OLED Chemical or Intermediate may be changed only by written agreement of the Parties, which agreement in the case of PPG shall not be unreasonably withheld.  The Parties shall endeavor to establish and agree upon changes to the Material Specifications in a manner designed to ensure that all Products are of high quality and purity, are fit for use in connection with OLEDs, and can be manufactured at a commercially reasonable price; provided however that the Parties are only agreeing to use their good faith efforts to achieve the foregoing goals and, subject thereto, neither Party makes any representation or warranty with respect to the Material Specifications.  With respect to Development OLED Chemicals that are the subject of Process Development, the Parties shall in good faith attempt to agree upon the Material Specifications for such Development OLED Chemicals as part of the Process Development work.  The Parties acknowledge that they will promptly and in good faith agree upon a representative Material Specification in a mutually acceptable format.

6.4            Services and Charges .  Except as otherwise set forth herein, upon UDC’s request by a written Statement of Work and/or Purchase Order, PPG shall supply the following OLED Chemicals and services to UDC, for the charges set forth herein:

6.4.1            Reserved .

6.4.2            Process Development Work .  UDC shall pay PPG at the rate of [***] times PPG’s Process Development Costs for all Process Development work performed by chemists on the Process Development Team.  If supplied to UDC, Development OLED Chemicals produced by chemists on the Process Development Team shall be without added charge for the materials themselves.

 
Page 22 of 65

 


6.4.3            Development OLED Chemicals .

(i)           For the supply of each Development Chemical produced (including, without limitation, Sublimed) by PPG personnel other than chemists on the Process Development Team, UDC shall pay PPG at the rate of [***] times PPG’s OLED Material Conversion Costs.

(ii)           For clarification, the amounts specified above do not include the cost of raw materials and Third-Party OLED Materials purchased for UDC’s account in accordance with subsection 6.2.1 above, or Intermediates produced for UDC’s account in accordance with subsection 6.2.2 above, for which UDC shall pay PPG at PPG’s cost according to Section 9.1 below.

6.4.4            Pre-Commercial OLED Chemicals .  For the supply of each Pre-Commercial OLED Chemical, UDC shall pay PPG at the rate of [***] times PPG’s OLED Material Conversion Costs.  For clarification, these amounts do not include any costs for raw materials and Third-Party OLED Materials purchased for UDC’s account in accordance with subsection 6.2.1 above, or for Intermediates produced for UDC’s account in accordance with subsection 6.2.2 above, for which UDC shall pay PPG at PPG’s cost according to Section 9.1 below.

6.4.5            Commercial OLED Chemicals .

(i)           For the supply of each Commercial OLED Chemical, during each Contract Year, UDC shall pay PPG at the rate of [***] times PPG’s Commercial OLED Material Cost.  For clarification, these amounts include all costs for raw materials and Third-Party OLED Materials purchased for UDC’s account in accordance with subsection 6.2.1 above, and for Intermediates produced for UDC’s account in accordance with subsection 6.2.2 above.

(ii)           Notwithstanding the foregoing, the rate applied to the cost of each raw material purchased by PPG for the production of Commercial OLED Chemicals shall be as follows: (a) commencing on the later of (1) the Effective Date or (2) the date of [***] (such date, the " Commercial Raw Material Vesting Date ") and continuing through [***] months following the Commercial Raw Material Vesting Date, [***] times PPG’s Commercial OLED Material Cost for such raw material, (b) during [***] months following the Commercial Raw Material Vesting Date (to the extent applicable), [***] times PPG's Commercial OLED Material Cost for such raw material, (c) during [***] months following the Commercial Raw Material Vesting Date (to the extent applicable), [***] times PPG's Commercial OLED Material Cost for such raw material, and (d) during [***] months following the Commercial Raw Material Vesting Date (to the extent applicable), [***] times PPG's Commercial OLED Material Cost for such raw material.  For the avoidance of doubt, no multiplier shall be applied to [***].

(iii)           Notwithstanding the foregoing, the rate applied to the cost of each Third-Party OLED Material purchased by PPG for the production of Commercial

 
Page 23 of 65

 

OLED Chemicals shall be as follows:  (a) commencing on the later of (1) the Effective Date or (2) the date of [***] (such date, the " Commercial Third-Party OLED Material Vesting Date ") and continuing through [***] months following the Commercial Third-Party OLED Material Vesting Date, [***] times PPG’s Commercial OLED Material Cost for such Third-Party OLED Material, (b) during [***] months following the Commercial Third-Party OLED Material Vesting Date (to the extent applicable), [***] times PPG’s Commercial OLED Material Cost for such Third-Party OLED Material, (c) during [***] months following the Commercial Third-Party OLED Material Vesting Date (to the extent applicable), [***] times PPG’s Commercial OLED Material Cost for such Third-Party OLED Material, and (d) during [***] months following the Commercial Third-Party OLED Material Vesting Date (to the extent applicable), [***] times PPG’s Commercial OLED Material Cost for such Third-Party OLED Material.

(iv)           For clarification, in the case of unrefined Commercial OLED Chemicals or Intermediates produced by PPG and, to the extent mutually agreed upon by the Parties (such agreement not to be unreasonably withheld), provided to a third party for [***] or other processing steps, the rate applied to PPG’s Commercial OLED Material Cost for the [***] or other processing steps performed by the third party shall follow the schedule set forth in clause (iii) above.

(v)           For clarification, the “date of [***]” as used above shall be the date that [***].

6.4.6            Depreciation of Certain OLED Equipment .

(i)           Prior to the start of each Contract Year, PPG shall prepare and submit to UDC a proposed rolling [***] year forecast of any additional capital equipment that PPG reasonably believes it needs to purchase for use in the manufacture of Commercial OLED Chemicals in the quantities expected to be required by UDC based on a rolling [***] year forecast of UDC’s requirements for known Products, which such forecast will be provided by UDC to PPG not less than sixty (60) days prior to the start of each Contract Year.  The parties will then discuss and may revise the forecast based on [***].  Capital equipment purchased by PPG according to a forecast mutually agreed upon by both parties through the process described above shall be referred to herein as " New OLED Equipment ."

(ii)           PPG shall prepare a depreciation schedule for each item of New OLED Equipment and provide a copy of such schedule to UDC.  The schedule shall be prepared [***].  The total depreciation amount for each item of New OLED Equipment shall be referred to herein as the " New Equipment Depreciation Value .”  The annual depreciation cost for each item of New OLED Equipment shall be referred to as the “ Annual Depreciation Cost .”

(iii)           Prior to the beginning of each Contract Year, PPG shall calculate a unit depreciation cost for the year based on the Annual Depreciation Cost for that year for all New OLED Equipment (the “ Unit Depreciation Cost ”).  The Unit

 
Page 24 of 65

 

Deprecation Cost shall be based on relevant factors, including, to the extent applicable, [***].  The Unit Depreciation Cost will be included in the costs charged to UDC for each applicable unit of Product supplied to UDC hereunder from and after the date the New OLED Equipment begins to be used for the manufacture of each such Product.  Notwithstanding the foregoing, the rate applied to the Unit Depreciation Cost will be [***] times PPG’s OLED Material Conversion Costs or PPG’s Commercial OLED Material Cost, as applicable.

(iv)           If PPG uses any New OLED Equipment for purposes other than the manufacture of OLED Chemicals for supply to UDC hereunder, the New Equipment Depreciation Value, Annual Depreciation Cost and Unit Depreciation Cost shall all [***].  If, after the New OLED Equipment is fully depreciated, PPG continues to use such equipment for the manufacture of OLED Chemicals for UDC hereunder, UDC shall not be charged any further depreciation amounts for the usage of such equipment.

6.4.7            Analytical Services .  PPG shall recommend and provide Analytical Services that are reasonably within the scope of PPG’s capabilities on a Purchase Order basis.  UDC shall pay PPG for such Analytical Services at the rate of [***] times PPG’s actual costs to provide such services.  For clarification, UDC shall not be required to pay separately for Analytical Services in connection with (i) Process Development work, or (ii) the supply of Commercial OLED Chemicals, all such amounts being included in the charges under Article 2, Section 6.4.2 and Section 6.4.5, respectively.

6.4.8            Environmental, Health & Safety Services .  PPG shall recommend and provide EH&S Services that are reasonably within the scope of PPG’s capabilities on a Purchase Order basis.  UDC shall pay PPG for such EH&S Services at the rate of [***] times PPG’s actual out-of-pocket costs to provide such services.

6.5           Reserved.

6.6            Cost Components .

6.6.1           PPG shall determine the particular amounts to be included in the various costs identified in Exhibits A-2 through A-4 in a manner consistent with past practice under the Original Agreement, and so as to conform with generally accepted practices in the specialty chemicals industry.  Should PPG, in performing any services or providing any Products hereunder, incur any substantial costs in connection with an equipment malfunction, processing error or other similar occurrence that are beyond those which is foreseeable and customary, the amounts associated therewith shall not be included in such costs.

6.6.2           The various costs identified in Exhibits A-2 through A-4 shall be reset as of the beginning of each Contract Year and, unless otherwise agreed by the Parties in writing, shall remain in effect for the remainder of such Contract Year.  PPG shall notify UDC of all such cost adjustments at least thirty (30) days prior to the date on

 
Page 25 of 65

 

which the adjustment is to take effect and, upon UDC’s request, PPG shall provide UDC with a reasonably detailed written justification for the adjustment.


ARTICLE 7 – FORECASTS, ORDERS, PLANNING & DELIVERY

7.1            Forecasts .  For planning purposes only, UDC shall provide to the Manager, Applied Technology for Optical Materials of PPG a non-binding twelve (12) month rolling forecast of its requirements for known Products at least fifteen (15) days prior to the start of each Calendar Quarter (each such quarterly forecast, a “ Quarterly Product Forecast ”).  Notwithstanding the above, should UDC become aware of any material change in any Quarterly Product Forecast of its requirements for any Product, UDC shall notify PPG promptly after becoming aware of such change.

7.2            Lead Times .  PPG shall provide a report in writing to UDC at least thirty (30) days prior to the start of each Calendar Quarter specifying PPG’s lead times required to supply each Product based on the information available to PPG at the time.  The Parties will use their reasonable best efforts to reduce the lead times for each Product to be supplied to UDC hereunder to the fullest extent reasonably practicable in light of cost considerations and UDC’s forecasted needs.  Any increase in lead times over those indicated in a prior report shall be justified by PPG in writing.  Notwithstanding the above, should PPG become aware of any material change in lead times for any Product, PPG shall notify UDC within five (5) business days of becoming aware of such change.

7.3            Purchase Orders .

7.3.1           UDC shall issue Purchase Orders for all Products, except that Development OLED Chemicals to be supplied pursuant to a Statement of Work shall be supplied according thereto.  Each Purchase Order shall identify the requested quantity and shipping date for the Product, along with any other information reasonably requested by PPG.  Unless otherwise agreed to in writing by PPG, the requested shipping date shall not reflect a shorter period than the current lead time for the Product.

7.3.2           UDC shall issue separate Purchase Orders for all Process Development to be performed under a Statement of Work, Analytical Services, EH&S Services and UDC-approved raw material and Third-Party OLED Material purchases.

7.4            Acceptance of Orders .  PPG shall promptly accept each Purchase Order issued by UDC, provided such Purchase Order is consistent in all material respects with the terms of this Agreement and any applicable Statement of Work.

7.5            Delivery, Title and Risk of Loss .  PPG shall deliver OLED Chemicals to UDC F.O.B., PPG’s facility, freight absorbed and paid by PPG.  Title and risk of loss for all OLED Chemicals shall transfer from PPG to UDC upon delivery to the carrier at PPG’s facility.

 
Page 26 of 65

 



7.6            Inconsistencies; Preprinted Terms .  To the extent of any conflict or inconsistency between this Agreement and any Purchase Order, confirmation, acceptance or other similar document exchanged hereunder, the provisions of this Agreement shall govern.  No preprinted terms of any Purchase Order, confirmation, acceptance or other similar document exchanged hereunder shall have any effect unless separately agreed to in writing by the Parties.


ARTICLE 8 – INSPECTION, ACCEPTANCE, REJECTION AND REPLACEMENT

8.1            Shipment Documentation; Certificate of Analysis .  Each shipment of a Product hereunder shall be accompanied by (i) a packing slip describing the shipment and referencing any UDC Purchase Order or other identifying number; and (ii) an accurate certificate of analysis, or other mutually agreed-upon quality control data (a " Certificate of Analysis "), demonstrating that the Product complies with its corresponding Material Specifications.

8.2            Batch Samples .  Unless and until the Parties otherwise agree in writing, upon completing production of any batch of Product ordered hereunder, PPG shall promptly make a batch sample available to UDC for inspection and acceptance testing.  For each batch of any Product produced by PPG hereunder, PPG shall maintain quality control samples and records for a period of two (2) years following the date of production.  Such samples and records shall be available for review and testing by UDC or its designees on reasonable advance notice and during PPG’s normal business hours.

8.3            UDC Testing of Samples .

8.3.1           Unless UDC elects by written notice to PPG otherwise, UDC shall conduct OLED device tests on each batch sample provided by PPG hereunder in order to verify that the Product contributes the properties required for the OLED device to function effectively.  Regardless of real or apparent compliance of the batch sample with its corresponding Material Specifications, UDC reserves the right to reject any batch of Product that does not contribute said properties; provided, however, that UDC shall not reject any batch of Product due to an alteration of its intended use.  UDC shall promptly provide PPG with written notice of the results of its testing of each batch sample.

8.3.2           Should UDC reject any batch of Product based on its testing of a batch sample as set forth above, the Parties shall promptly discuss the matter and attempt to determine the source of the problem.  In any event, PPG shall promptly rework or replace the batch of Product as and to the extent instructed by UDC, and PPG shall ship to UDC a new batch sample for testing as set forth above.  All non-conforming Product that cannot be reworked shall be disposed of by PPG in accordance with all applicable laws, rules, regulations and other requirements.

 
Page 27 of 65

 


8.3.3           This process of testing batch samples and reworking or replacing any rejected batches of Product shall be repeated until UDC instructs PPG otherwise.  Any rejection by UDC shall apply only to the batch of Product affected.

8.4            Quantity Tolerances .  Unless otherwise mutually agreed to in writing by the Parties, the amount of any Product delivered hereunder may not vary by more than [***] percent [***] from the amount specified in the Purchase Order.

8.5            Container Labels .  All Product containers will be labeled with the identity and net weight of the Product contained therein and shall indicate the production date and lot number for such Product.  The actual weight of the Product in the container shall not deviate from the weight shown on the container’s label by more than one-half (0.5) gram.  PPG shall apply to all containers containing Products supplied hereunder such notices of the UDC Chemical Patents as may be reasonably requested by UDC in writing, in order to protect UDC’s rights and interests therein.

8.6            Trademarks .  All trademarks, trade names and designs utilized on the packaging for Products supplied under this Agreement shall be chosen by UDC; provided, however, that UDC must obtain prior written approval to use any PPG trademarks, trade names and designs.  All rights to the respective trademarks, trade names and designs of each Party shall remain with that Party.  Except as otherwise agreed to by the Parties in writing, each Party assumes all responsibility for use of its trademarks, trade names or designs, or any portions thereof, appearing on the packaging for or on other written materials distributed with the Products supplied hereunder.

8.7            Shipments, Inspection and Acceptance .

8.7.1           PPG shall use commercially reasonable efforts to ship the entire requested quantity of each Product to UDC by the requested shipping date.  However, no shipment shall be sent prior to UDC’s written confirmation that testing of the batch sample was successful unless UDC has elected by written notice to PPG not to test a batch sample for the Product shipment.

8.7.2           Upon receipt of each Product shipment, UDC shall inspect the shipment for any shortage or other visible defects.  Should UDC detect a problem, UDC shall promptly provide PPG with written notice thereof, which notice shall specify the nature of the problem.  Such written notice shall be provided to PPG within ninety (90) days following the date of receipt of the shipment by UDC; otherwise, UDC shall be deemed to have accepted the shipment subject to its right of revocation under Section 8.8 below.

8.7.3           Promptly following such notice, the Parties shall discuss the matter and attempt to determine the source of the problem.  In any event, PPG shall promptly (i) make up any shortage, or (ii) rework or replace any non-conforming portion of the shipment, in each case as and to the extent instructed by UDC.  If a portion of the

 
Page 28 of 65

 

shipment is to be reworked or replaced, PPG first shall ship to UDC a new batch sample for testing as set forth in Section 8.3 above unless UDC elects by written notice to PPG not to test a batch sample.  All non-conforming Product shall be returned to PPG unless otherwise agreed by the Parties.  Any non-conforming Product that cannot be reworked shall be disposed of by PPG or UDC, as applicable, in accordance with all applicable laws, rules, regulations and other requirements.

8.8            Revocation of Acceptance .

8.8.1           The Parties acknowledge that UDC may elect not to test each Product shipment prior to using the shipment or selling all or any portion of it to a third party.  Consequently, should UDC subsequently learn that any portion of the Product shipment does not meet its corresponding Material Specifications as indicated in the Certificate of Analysis, or that its properties in an OLED are not consistent with those of the batch sample originally tested by UDC, UDC shall have the right to provide written notice to PPG revoking UDC’s acceptance of the shipment.  Such notice shall be provided within ten (10) business days of UDC’s learning of the problem, and in any event within one (1) year of the date of receipt of the shipment by UDC; otherwise UDC shall be deemed to have waived its right to revoke acceptance of the shipment.

8.8.2           Promptly following such notice, the Parties shall discuss the matter and attempt to determine the source of the problem.  In any event, PPG shall promptly replace any non-conforming portion of the shipment as and to the extent instructed by UDC.  Prior to sending any replacement shipment of Product, PPG first shall ship to UDC a new batch sample for testing as set forth in Section 8.3 above unless UDC elects by written notice to PPG not to test a batch sample.  UDC shall be responsible for ensuring that any non-conforming Product is disposed of in accordance with all applicable laws, rules, regulations and other requirements.

8.9            Responsibility for Costs .  Any reworking or replacement of Product batches or shipments, or portions thereof, under this Article 8 shall be performed by PPG.  Following a root cause investigation of the problem that is reasonably satisfactory to each Party, any reworking or replacement shall be charged as follows: (i) if the problem is due to negligence on the part of UDC, the cost of reworking or replacement shall be charged to UDC on a cost-plus basis; (ii) if the problem is due to negligence on the part of PPG, the cost of reworking or replacement shall be borne by PPG; and (iii) if the problem cannot fairly be attributed to negligence on the part of either Party, the cost of reworking or replacement shall be negotiated by the Parties on a per batch or per shipment basis and charged to PPG or UDC, as the case may be.  The cost of any reworking or replacement shall include the cost of any raw materials or Third-Party OLED Materials required for reworking or replacement of the batch or shipment in question.  Notwithstanding the foregoing sentence, if, pursuant to Section 8.3.1, UDC has elected by written notice to PPG not to test a batch sample then such reworking or replacement shall be at UDC’s cost and UDC shall receive no credit even if the problem is due to negligence on the part of PPG.

 
Page 29 of 65

 


8.10            Entire Remedy .  This Article 8 states UDC’s sole remedy and PPG’s sole responsibility with respect to any short, defective or non-conforming shipment of Product provided to UDC hereunder.  However, the foregoing sentence shall not apply with respect to claims of bodily injury or damage to tangible property resulting from the negligence or willful misconduct of PPG.


ARTICLE 9 – INVOICES AND PAYMENT TERMS

9.1            Raw Materials, Intermediates and Third-Party OLED Materials .  PPG shall invoice UDC for all raw materials and Third-Party OLED Materials purchased for UDC’s account in accordance with subsection 6.2.1 above, and for all Intermediates produced for UDC’s account in accordance with subsection 6.2.2 above, in each case within fifteen (15) days following the end of each month.  All such invoices are subject to reasonable confirmation by UDC and shall be due and payable, within thirty (30) days from date of receipt by UDC, in 100% cash.

9.2            Process Development, Development OLED Chemicals and Pre-Commercial OLED Chemicals .  PPG shall invoice UDC for all amounts payable for UDC-approved services in accordance with subsection 2.6.1 above, for Process Development work in accordance with subsection 6.4.2 above, for the supply of all Development OLED Chemicals in accordance with subsection 6.4.3 above, and for the supply of all Pre-Commercial OLED Chemicals in accordance with subsection 6.4.4 above (such collective amounts referred to herein as “ PPG’s Processing Charges ”), as follows:

9.2.1            Election of Payment .

(i)           UDC shall have the right and option to pay PPG’s Processing Charges for each Calendar Quarter in up to 50% in shares of UDC Common Stock, as specified in Article 15 below, and the remainder in cash.  Notwithstanding the foregoing, if the Ten-Day Average (as defined in Section 15.2 below) is less than [***] (as such price shall be adjusted to account for stock splits and dividends or other distributions paid in shares of stock), then UDC shall be required to pay PPG’s Processing Charges for such Calendar Quarter in 100% cash.  Furthermore, if UDC has already prepaid a portion of PPG’s Processing Charges for such Calendar Quarter in shares of UDC Common Stock, UDC shall be required to pay the balance of PPG’s Processing Charges for such Calendar Quarter in 100% cash.

(ii)           Within fifteen (15) days following the commencement of first and third Calendar Quarters of each Contract Year, UDC may exercise the right set forth in clause (i) of this Section 9.2.1 to pay a portion (not to exceed 50% in any Calendar Quarter) of PPG’s Processing Charges for the Calendar Quarter and the subsequent Calendar Quarter in shares of UDC Common Stock by providing PPG with written notice of its intention to exercise such right, and if so the portion, up to 50% of the Processing Charges in each such Calendar Quarter, to be paid in such manner.  If

 
Page 30 of 65

 

no such notice is provided to PPG during this time period, UDC shall be deemed to have elected to pay PPG’s Processing Charges for such Calendar Quarter and the subsequent Calendar Quarter in 100% cash.

9.2.2            Invoicing and 100% Cash Payment .  If UDC has elected, is deemed to have elected, or is required to pay PPG’s Processing Charges for a Calendar Quarter, or any portion thereof, in 100% cash, within fifteen (15) days following the end of such Calendar Quarter, PPG shall provide UDC with an invoice for the actual dollar amount of PPG’s Processing Charges for such Calendar Quarter, less any credits for UDC’s prior prepayment, if any, of any portion of such amount in shares of UDC Common Stock.  Upon UDC’s request, PPG shall provide a reasonably detailed breakdown of all of PPG’s Processing Charges, which shall be subject to reasonable confirmation by UDC.  All such invoiced amounts shall be due and payable within fifteen (15) days from the date of receipt of the invoice by UDC.

9.2.3            Invoicing and Partial Payment in Shares .  If UDC has elected and is permitted to pay PPG’s Processing Charges for a Calendar Quarter and the subsequent Calendar Quarter in up to 50% in shares of UDC Common Stock, within fifteen (15) days following the end of such Calendar Quarter, PPG shall provide UDC with an invoice for: (i) the actual dollar amount of PPG’s Processing Charges for such Calendar Quarter; and (ii) the expected dollar amount of PPG’s Processing Charges for the subsequent Calendar Quarter, including the portion of such amount(s) that is to be paid in shares of UDC Common Stock.  Upon UDC’s request, PPG shall provide a reasonably detailed breakdown of all of PPG’s Processing Charges, which shall be subject to reasonable confirmation by UDC.  The cash portion of all such invoiced amounts shall be due and payable within fifteen (15) days from the date of receipt of the invoice by UDC.  The share portion of all such invoiced amounts shall be handled in accordance with the provisions of Article 15 below.

9.2.4            Excessive Prepayments .  Any prepayment of PPG’s Processing Charges for a Calendar Quarter in shares of UDC Common Stock that exceeds the actual amount of PPG’s Processing Charges for that Calendar Quarter shall first be applied to reduce the actual dollar amount of PPG’s Processing Charges for the subsequent Calendar Quarter, as specified in subsections 9.2.2 and 9.2.3 above.  If any portion of the prepaid amount still remains thereafter, it shall be repaid to UDC in cash within thirty (30) days following the end of the subsequent Calendar Quarter.

9.3            Commercial OLED Chemicals .  PPG shall invoice UDC for the supply of all Commercial OLED Chemicals in accordance with subsection 6.4.5 above upon the earlier of (i) the time of shipment under subsection 8.7.1 above; or (ii) thirty (30) days following shipment of a batch sample for OLED device testing under Section 8.2 above, which batch sample has not been rejected by UDC during such 30-day period based on UDC’s testing under Section 8.3 above.  All such invoices are subject to reasonable confirmation by UDC and shall be due and payable, within thirty (30) days from date of receipt by UDC, in 100% cash.

 
Page 31 of 65

 


9.4  
Depreciation of New OLED Equipment .

9.4.1           Within fifteen (15) days following the end of each Contract Year, PPG shall determine, for all items of New OLED Equipment, the extent to which the total Unit Depreciation Cost paid by UDC during such Contract Year exceeded or was less than the collective Annual Depreciation Costs for such items of equipment for that Contract Year.  If the total Unit Depreciation Costs paid by UDC were less than the collective Annual Depreciation Costs, PPG shall [***].  If the total Unit Depreciation Costs paid by UDC exceeded the collective Annual Depreciation Costs, PPG shall [***].

9.4.2           If this Agreement is renewed beyond the Initial Term, the process described in Section 9.4.1 above shall continue during the renewal period.  Otherwise, within thirty (30) days following the expiration or termination of this Agreement, PPG shall [***].

9.4.3           PPG and UDC shall discuss and in good faith agree on a disposition for each item of New OLED Equipment if and when it is no longer useful for the manufacture of OLED Chemicals for supply to UDC hereunder.  It is understood and agreed that any proceeds from the further usage or other disposition of the New OLED Equipment shall be [***].

9.5            Analytical Services and EH&S Services .  PPG shall invoice UDC for Analytical Services in accordance with subsection 6.4.7 above, and for EH&S Services in accordance with subsection 6.4.8 above, in each case within fifteen (15) days following the end of each month.  All such invoices are subject to reasonable confirmation by UDC and shall be due and payable, within thirty (30) days from date of receipt by UDC, in 100% cash.

9.6            Late Payments .  At its discretion, PPG may charge UDC interest at the Prime Rate plus [***] percent [***], or the maximum rate permitted by law, whichever is lower, on all properly invoiced amounts not paid when due.  As used herein, the “Prime Rate” shall be the prime rate of interest as reported in The Wall Street Journal on the first business day immediately preceding the date on which the payment is made.

9.7            Books of Account; Examinations .  PPG shall keep books of account and supporting data and records consistent with its accounting policies and practices, which shall contain all particulars that may be reasonably necessary for the purpose of showing the amounts payable by UDC under this Article 9 (“ PPG’s Books of Account ”).  During the Term and for at least two (2) years thereafter, UDC shall have the right to examine PPG’s Books of Account.  Each such examination shall take place during normal business hours of PPG and on at least ten (10) business days’ advance written notice to PPG.  Each such examination shall be at a location selected by PPG and in accordance with procedures reasonably acceptable to PPG, including, without limitation, procedures designed to protect any Confidential Information of PPG.  PPG shall not be required to permit examination of its Books of Account more often than once during any Calendar Quarter.

 
Page 32 of 65

 




ARTICLE 10 – QUALITY CONTROL; PRODUCTION FACILITIES

10.1            Production Quality Control .  PPG shall analyze and control its production to achieve and maintain a state of predictable stability of the Products.  UDC may request PPG to provide quality control records, including, without limitation, the following:  (i) the existing quality assurance control or similar plan of PPG as attached hereto as Exhibit B; (ii) periodic quality assurance surveys by UDC of PPG’s production facility; and/or (iii) a report to UDC of statistically analyzed data which demonstrates the state of predictable stability of the processes involved.

10.2            Production Changes .  PPG shall inform UDC in writing of the occurrence or expected occurrence of material events that might reasonably be expected to affect the quality, quantity, cost or any other material aspect of any Product manufactured or processed hereunder, including, without limitation, any changes in manufacturing conditions or quality control procedures relating to the manufacture or processing of the Product.  Following its delivery to UDC of the foregoing written notice, PPG shall, upon UDC’s written request, supply test data and/or samples of Products produced hereunder to UDC and otherwise reasonably cooperate with UDC, in order to permit UDC to evaluate the possible effects of such events and verify that PPG will continue to be able to supply Products as required hereunder.  PPG shall not change raw material suppliers, the composition, manufacturing location, or process used to produce any Pre-Commercial OLED Chemical or Commercial OLED Chemical from that utilized when the OLED Chemical was originally approved by UDC, without UDC’s prior written consent.

10.3            Testing and Inspection .  UDC shall have the right, upon reasonable advance notice and during regular business hours, to test OLED Chemicals being produced by PPG hereunder, and, upon reasonable advance notice, to visit, inspect and audit the facilities at which such OLED Chemicals are produced, as well as all relevant records being maintained by PPG in connection therewith.  Upon prior approval by PPG, such approval not to be unreasonably withheld, purchasers or prospective purchasers of Products from UDC may visit these facilities with UDC for substantially similar purposes.  All persons visiting, inspecting or auditing any PPG facilities shall be required to comply with PPG’s generally applicable policies and procedures with respect thereto, including, without limitation, executing PPG’s standard form confidentiality agreement prior to the visit, inspection or audit.


ARTICLE 11 – WARRANTIES AND LIMITATIONS OF LIABILITY

11.1            Mutual Representations and Warranties .  Each Party represents and warrants to the other as follows:

11.1.1                      It has the requisite corporate right, power and authority to enter into and perform this Agreement.

 
Page 33 of 65

 



11.1.2                      The execution, delivery and performance of this Agreement by it will not (i) result in the breach of, constitute a default under or interfere with any contract or other instrument or obligation, whether written or oral, to which it is currently bound; or (ii) violate any writ, order, injunction, decree, or any law, statute, rule or regulation applicable to it.

11.1.3                      It shall, to its knowledge following reasonable inquiry, comply in all material respects with all applicable laws, rules, regulations and other governmental requirements relating to or affecting its performance under this Agreement, and shall obtain and maintain all governmental permits, licenses and consents required in connection therewith.

11.2            Additional UDC Representations and Warranties .  UDC further represents and warrants to PPG that:

11.2.1                      It owns or has, and shall retain, sufficient rights in the UDC Proprietary Materials for Chemicals to grant the licenses, sublicenses and other rights granted to PPG pursuant to Section 3.3 above.

11.2.2                      It is unaware of any alleged invalidity of the UDC Chemical Patents licensed to PPG hereunder, and it will immediately notify PPG in writing of its receipt of any written notices to the contrary.

11.2.3                      It will not, without PPG’s prior written consent which shall not be unreasonably withheld, resell any Development OLED Chemical to other persons for their manufacture of OLEDs for commercial sale.

11.3            Additional PPG Representations and Warranties .  PPG further represents and warrants to UDC that:

11.3.1                      It has or will have sufficient rights to assign to UDC the Developed Technology pursuant to Section 3.1 above; and

11.3.2                      It will not, knowingly, manufacture any Product for supply to UDC hereunder utilizing any process known or suspected by PPG to be covered by a Patent of PPG or any third party.

11.4            Intellectual Property Warranty; Indemnity .  Notwithstanding any other provision of this Agreement, UDC warrants to PPG that each Third-Party OLED Material supplied to PPG by UDC hereunder shall be supplied in such a manner so as not to infringe any valid and enforceable U.S. or non-U.S. patent, trademark, copyright, trade secret or other intellectual property or proprietary rights of any third party.  UDC shall indemnify and hold harmless PPG from and against any and all claims, damages, judgments, costs and expenses, and out-of-pocket losses, including without limitation reasonable attorney’s fees, arising from or related to any such infringement or alleged

 
Page 34 of 65

 

infringement.  UDC shall further defend or settle, at its own option and expense, any claim, suit or proceeding brought against PPG alleging such infringement.  PPG shall notify UDC promptly in writing of the commencement of such claim, suit or proceeding and shall give UDC authority, information, and a reasonable amount of assistance for the defense or settlement thereof, and UDC shall pay all of PPG’s out-of-pocket expenses in connection therewith.  In its sole discretion, PPG may participate in any such suit or proceeding with counsel of its own choice, at its own expense.  PPG shall not settle or compromise any such claim, suit or proceeding without the prior written consent of UDC, which shall not be unreasonably withheld.  At no cost or obligation to PPG, UDC shall keep PPG informed of the progress of any suit including any settlement negotiations.

11.5            Additional PPG Disclaimer; Indemnity .  In situations where PPG provides to UDC, or to any third party on UDC’s behalf, any Process Development information or information pertaining to the manufacture of Products as contemplated under subsections 2.4.2, 5.2.1, 5.2.2, 5.2.3, or 6.2.1 (last sentence of opening paragraph only) above, or under Section 18.6 (Transition Assistance), or through any Process Development Technical Report or Batch Sheet prepared by PPG hereunder, PPG agrees to use commercially reasonable efforts to ensure that such information is substantially accurate and complete.  Subject thereto, PPG disclaims all representations and warranties as to such information, and UDC shall indemnify and hold harmless PPG from and against any and all claims, damages, judgments, costs and expenses, and out-of-pocket losses, including without limitation reasonable attorney’s fees, arising from property damage, physical injury or death caused by UDC’s or any third party’s reliance on such information.  UDC shall further defend or settle, at its own option and expense, any claim, suit or proceeding brought against PPG alleging such property damage, physical injury or death.  PPG shall notify UDC promptly in writing of the commencement of such claim, suit or proceeding and shall give UDC authority, information, and a reasonable amount of assistance for the defense or settlement thereof, and UDC shall pay all of PPG’s out-of-pocket expenses in connection therewith.  In its sole discretion, PPG may participate in any such suit or proceeding with counsel of its own choice, at its own expense.  PPG shall not settle or compromise any such claim, suit or proceeding without the prior written consent of UDC, which shall not be unreasonably withheld.  At no cost or obligation to PPG, UDC shall keep PPG informed of the progress of any suit including any settlement negotiations.

11.6            Disclaimer of Additional Warranties .  EXCEPT FOR THE EXPRESS WARRANTIES CONTAINED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES TO THE OTHER, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF TITLE, NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.  ALL SUCH OTHER REPRESENTATIONS AND WARRANTIES ARE HEREBY DISCLAIMED.

11.7            Limitation on Certain Damages .  EXCEPT FOR OUT-OF-POCKET AMOUNTS PAYABLE TO THIRD PARTIES AS SET FORTH IN SECTIONS 11.4

 
Page 35 of 65

 

(INTELLECTUAL PROPERTY WARRANTY; INDEMNITY) AND 11.5 (ADDITIONAL PPG DISCLAIMER; INDEMNITY), IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY SPECIAL, INDIRECT, PUNITIVE OR CONSEQUENTIAL DAMAGES OF ANY KIND (INCLUDING LOST PROFITS, BUSINESS OR GOODWILL) IN CONNECTION WITH THIS AGREEMENT OR ANY MATTER COVERED BY THIS AGREEMENT, REGARDLESS OF WHETHER SUCH LIABILITY IS BASED ON BREACH OF CONTRACT, TORT, STRICT LIABILITY, BREACH OF WARRANTY OR ANY OTHER THEORY, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

11.8            Special Disclaimer .  PRINCETON UNIVERSITY AND USC MAKE NO REPRESENTATIONS AND WARRANTIES AS TO THE PATENTABILITY AND/OR DISCOVERIES INVOLVED IN ANY OF THE UDC CHEMICAL PATENTS.  PRINCETON UNIVERSITY AND USC MAKE NO REPRESENTATION AS TO PATENTS NOW HELD OR WHICH WILL BE HELD BY OTHERS IN ANY FIELD AND/OR FOR ANY PARTICULAR PURPOSE.  PRINCETON UNIVERSITY AND USC MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.


ARTICLE 12 – REGULATORY COMPLIANCE; HEALTH AND SAFETY

12.1            General .

12.1.1                      PPG shall comply in all material respects with all applicable domestic governmental requirements for, and where required obtain or provide, all registrations, permits, notices, reports, licenses, and supplier notifications with respect to its production, sale, packaging and delivery of Products hereunder.  PPG shall promptly provide UDC with copies of any such documents of a material nature.

12.1.2                      PPG shall recommend and provide, as EH&S Services hereunder, assistance in preparing and filing the forms required for compliance with non-U.S. laws, such as registrations, permits, notice reports, licenses and supplier notifications with respect to PPG’s production, sale, packaging and delivery of Products by UDC outside the U.S.  Such services will be performed, in part, by an outside consultant selected by PPG in such a manner as PPG would use to select a consultant for its own similar purposes, subject to UDC’s consent, and PPG makes no representation or warranty, regarding the quality of any such services provided by said consultant.  UDC will indemnify and defend PPG from and against any liability arising from any such services provided by said consultant.

12.2            Material Safety Data Sheets .  PPG shall be responsible for preparing and delivering to UDC Material Safety Data Sheets for all Products supplied hereunder, as may be required under the Occupational Safety and Health Act, regulations promulgated thereunder and any similar state “right-to-know” laws that are currently in force or that may be enacted in the future.  UDC shall be responsible for delivering such

 
Page 36 of 65

 

Material Safety Data Sheets to those persons to whom UDC sells or otherwise supplies the Product.  PPG shall update such Material Safety Data Sheets as necessary to comply with all material legal requirements, and shall promptly provide UDC with such updated Material Safety Data Sheets, which UDC shall deliver to those persons to whom UDC sells or otherwise supplies the Products.  PPG shall be listed as the emergency contact on all container labels and Material Safety Data Sheets for Products supplied hereunder.  In addition, during the term of this Agreement and for twenty-four (24) months thereafter, PPG shall be responsible for emergency response in the case of any emergencies or other incidents involving the Products supplied hereunder.  The Parties shall cooperate in good faith to transition responsibility for such activities to UDC or its designee prior to the end of such period.

12.3            Employees and Training .  Each Party shall become reasonably familiar with the OLED Chemicals supplied hereunder and with any raw materials used and/or Wastes generated by such Party during the course of producing, packaging, handling and/or using such OLED Chemicals.  Each Party shall be responsible for informing its employees of any known or reasonably ascertainable chemical hazards associated with the OLED Chemicals supplied hereunder, and with any such raw materials or Wastes that its employees may handle, and each Party shall provide its employees with reasonable training in the proper methods of handling such items.

12.4            Notice of Government Action .  Each Party shall promptly notify the other of any information or notice it has or becomes aware of, including, without limitation, any threatened or pending action by any governmental authority, concerning the health and/or environmental risks posed by any OLED Chemical supplied hereunder, or any raw material used or Waste generated during the course of producing or packaging such OLED Chemical, including, but not limited to, information concerning any known or suspected side effects, injuries, toxicity, sensitivity reactions, complaints, alleged defects or other adverse experiences (including the severity thereof) associated with exposure to or use of such items.


ARTICLE 13 – WASTE DISPOSAL

Except as otherwise provided in this Agreement, PPG shall be solely responsible for the lawful management (including, without limitation, the emission, release and disposal) of all Wastes generated in connection with the manufacture and supply of OLED Chemicals under this Agreement.  PPG shall handle, accumulate, label, package and ship such Wastes in material compliance with all applicable federal, state and local laws, rules, regulations and orders.


ARTICLE 14 – INDEMNIFICATION AND INSURANCE

14.1            Environmental Indemnification .  Subject to Section 14.2 below, PPG shall indemnify, defend and hold harmless UDC, its affiliates and their respective officers,  
 
 
Page 37 of 65

 
directors, members, employees, agents and representatives (each, an “ Indemnified Party ”), from and against any and all claims, demands, liabilities, damages, judgments, penalties, fines, costs, and expenses (including, but not limited to, reasonable attorneys’ fees; collectively “ Claims ”) incurred by, or rendered against, each such Indemnified Party arising out of any alleged or actual bodily injury to persons, or damage to property, the environment or natural resources, at a facility of PPG or any of its sublicensees, or at a facility or location chosen by PPG or any of its sublicensees for their disposal of Wastes generated in connection with the manufacture of OLED Chemicals supplied under this Agreement, or any other facility or location at which such Wastes are ultimately disposed or come to be located.

14.2            Indemnification Procedures .  UDC shall promptly notify PPG in writing, specifying the nature of any Claim, the total monetary amount sought, and any other relief sought.  Each Indemnified Party shall cooperate with PPG in all reasonable respects in connection with the defense and/or settlement of the Claim.  Any compromise or settlement of a Claim must be approved in writing by both Parties, which approval shall not be unreasonably withheld.  Any Indemnified Party’s failure to give timely notice or to provide copies of documents or to furnish relevant data in connection with any Claim shall not constitute a defense (in part or in whole) to any claim for indemnification for such Party, except and only to the extent that such failure results in material prejudice to PPG.  Each Indemnified Party, upon written notice to PPG, shall have the right to employ separate counsel at its own expense and participate in the defense of the Claim.

14.3            Insurance Requirements .  Each Party shall maintain its standard general liability insurance or its self-insurance practices to protect against covered damages, costs or fees (including reasonable attorney’s fees) arising out of or relating to any property damage, bodily injury, sickness, disease or death, caused directly by any negligent act or omission of either Party’s personnel while on premises at the other Party’s facility, and will name the other Party as an additional insured under such insurance.  The insured will provide the other Party with a certificate of such insurance, showing the other as an additional insured, and notify the other of any material changes to the relevant insurance policies.


ARTICLE 15 – UDC COMMON STOCK

15.1            Timing of Share Issuance .  Shares in payment for invoices provided under subsection 9.2.3 above shall be delivered within fifteen (15) days following UDC’s receipt of such invoices.

15.2            Issuance of Shares .  The number of shares of UDC Common Stock to be issued in full or partial payment of any invoiced amount shall equal the quotient of (i) the invoiced amount to be paid in shares, divided by (ii) the Ten-Day Average.  As used herein, the “ Ten-Day Average ” shall equal the average closing price for UDC Common Stock, as set forth in the NASDAQ Global Market listing of The Wall Street Journal, for
 
 
Page 38 of 65

 
the ten (10) trading days prior to the close of the Calendar Quarter immediately preceding the date of issuance.

15.3            Representations of PPG .

15.3.1                       Purchase Entirely for Own Account .  The Securities to be received by PPG pursuant to this Agreement will be acquired for investment for PPG’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof that would violate any applicable federal securities laws, and PPG has no immediate intention of selling, granting any participation in, or otherwise distributing the same except to the extent the same are included in a Registration Statement (as hereinafter defined).  By executing this Agreement, PPG further represents that PPG does not have any contract, undertaking, agreement or arrangement with any person to sell, transfer or grant participations to such person or to any third person, with respect to any of the Securities, other than as provided herein.  PPG represents that it has full power and authority to enter into this Agreement.

15.3.2                       Accredited Status .  PPG is an “accredited investor” within the meaning of Commission Rule 501 of Regulation D, as presently in effect.

15.3.3                       Restricted Securities .  PPG understands that the Securities it is receiving are characterized as “restricted securities” under the federal securities laws inasmuch as they are being acquired from UDC in a transaction not involving a public offering, and that under such laws and applicable regulations such Securities may be resold without registration under the 1933 Act only in certain limited circumstances.  In this connection, PPG represents that it is familiar with Commission Rule 144, as presently in effect, and understands the resale limitations imposed thereby and by the 1933 Act.

15.3.4                       Legends .  It is understood that the certificates evidencing the Securities that may be issued pursuant to this Agreement shall, unless otherwise expressly agreed by the Parties, bear the following legend:

“These securities have not been registered under the Securities Act of 1933, as amended.  They may not be sold, offered for sale, pledged or hypothecated in the absence of a registration statement in effect with respect to the securities under such Act or an opinion of counsel satisfactory to the Corporation that such registration is not required or unless sold pursuant to Rule 144 of such Act.”
 
and any other legend required by any applicable state securities laws.  To the extent that such legends are no longer applicable, UDC shall instruct its transfer agent to remove the legends upon request by PPG.

 
Page 39 of 65

 
 
15.4
Certain Covenants of UDC .

15.4.1                       Authorized Shares .  All shares of UDC Common Stock issued to PPG in accordance with Section 9.2 above shall be duly authorized, validly issued fully-paid and non-assessable.

15.4.2                       Listing .  UDC shall promptly secure the listing of the Securities upon The NASDAQ Global Market or such other national securities exchange or automated quotation system, if any, upon which shares of UDC Common Stock are then listed (subject to official notice of issuance).  So long as PPG owns any of the Securities, UDC shall maintain, so long as any other shares of UDC Common Stock shall be so listed, such listing of all UDC Common Stock, and shall comply in all respects with UDC’s reporting, filing and other obligations under the bylaws or rules of the National Association of Securities Dealers and such exchanges, as applicable.

15.4.3                       Reports Under 1934 Act .  With a view to making available to PPG the benefits of Rule 144 and any successor or other rule or regulation of the Commission that may at any time permit PPG to sell the Securities to the public without registration, UDC agrees to: (i) make and keep public information available, as those terms are understood and defined in Rule 144, at all times; (ii) file with the Commission in a timely manner all reports required of UDC under the 1934 Act; and (iii) furnish to PPG, so long as PPG owns any Securities, forthwith upon request (a) a written statement by UDC that it has filed with the Commission in a timely manner all reports required of UDC under the 1934 Act, (b) a copy of the most recent annual or quarterly report of UDC and such other reports and documents so filed by UDC, and (c) such other information as may be reasonably requested in availing PPG of any rule or regulation of the Commission which permits the selling of any Securities without registration.

15.5            Certain Sales .

15.5.1                       Short Sales .  During the Term, PPG shall not, and shall cause its affiliates to not, engage in or encourage any third party to engage in any “short sales” (as such term is defined in Rule 3b-3 of the 1934 Act) of UDC Common Stock or any other UDC securities.

15.5.2                       Prohibited Sales During Certain Periods .  During the thirty (30) day period following the end of each Calendar Quarter during the Term (each a “ PPG Restricted Period ”), PPG shall not offer, sell or contract to sell shares of UDC Common Stock received hereunder or previously under the Original Agreement, or any securities convertible into or exchangeable or exercisable for any share of UDC Common Stock, to the extent that the number of shares of UDC Common Stock subject to such offer, sale or contract to sell would exceed, on any one (1) day during such PPG Restricted Period, twenty-five percent (25%) of the average daily trading volume of shares of UDC Common Stock for the ninety (90) day period immediately preceding the PPG Restricted Period (the “ PPG Volume Limit ”); provided however that the PPG Volume
 
 
Page 40 of 65

 
Limit shall not apply to any private placement of shares of UDC Common Stock by PPG.  During each PPG Restricted Period, PPG shall not enter into any swap or hedge arrangement that transfers, in whole or in part, any of the economic consequences of ownership of shares of UDC Common Stock in excess of the PPG Volume Limit, or publicly disclose the intention to make any offer, sale or contract to sell or to enter into any swap or hedge in excess of the PPG Volume Limit.

15.6            Reserved.


ARTICLE 16 – REGISTRATION RIGHTS

16.1            Registration of the Securities .

16.1.1                      Within thirty (30) days following the date any Securities are delivered to PPG as set forth in Section 15.1 above, UDC shall prepare and file with the Commission one or more registration statements (on Form S-3, or other appropriate form of registration statement) under the 1933 Act (each a “ Registration Statement ”), together with such state law qualifications and other compliances with applicable law, at the sole expense of UDC, in respect of PPG, so as to permit public offering and resale of such Securities (hereinafter, the “ Registrable Securities ”) under the 1933 Act by PPG.

16.1.2                      UDC shall use commercially reasonable efforts to cause each Registration Statement to be declared effective by the Commission as promptly as is practicable, but in any event within one hundred twenty (120) days following the filing date thereof and within five (5) days after Commission clearance.

16.1.3                      UDC will cause each Registration Statement or any post-effective amendment filed under this Article 16 to remain continuously effective under the 1933 Act until the earliest of (i) the date that none of the Registrable Securities covered by such Registration Statement are outstanding; (ii) the date that all of the Registrable Securities covered by such Registration Statement have been sold by PPG pursuant to such Registration Statement; (iii) the date that PPG receives an opinion of counsel to UDC, which counsel shall be reasonably acceptable to PPG, that the Registrable Securities may be sold under the provisions of Rule 144 without limitation as to volume or a requirement of “brokers transactions”; (iv) the date that all of the Registrable Securities covered by such Registration Statement have been otherwise transferred to persons who may trade such shares without restriction under the 1933 Act, and UDC has delivered a new certificate or other evidence of ownership for such Registrable Securities not bearing a restrictive legend; or (v) the date that all of the Registrable Securities covered by such Registration Statement may be sold without any time, volume or manner limitations pursuant to Rule 144(k) or any similar provision then in effect under the 1933 Act in the opinion of counsel to UDC, provided such counsel is reasonably acceptable to PPG.  If, under Commission rules or policies of the Commission staff, any of the Registrable Securities for any reason cannot be included in a Registration Statement initially filed by UDC and must be included in a separate
 
 
Page 41 of 65

 
registration statement, UDC shall file all such additional registration statements as may be needed to permit PPG to offer and resell to the public all of the Registrable Securities, and the term “Registration Statement” shall for purposes of this Agreement be deemed to include all such additional registration statements.

16.1.4                      All fees, disbursements and out-of-pocket expenses and costs incurred by UDC in connection with the preparation and filing of each Registration Statement under this Article 16, and in complying with applicable federal and state securities laws (including, without limitation, all attorneys’ and accountants’ fees of UDC), shall be borne by UDC.  PPG shall bear the cost of underwriting and/or brokerage discounts, fees and commissions, if any, applicable to its sale of the Registrable Securities and the fees and expenses of its counsel.  PPG and its counsel shall have a reasonable period, of not less than two (2) business days for each Registration Statement filed hereunder and for each amendment or subsequently filed Registration Statement, to review the proposed Registration Statement or any amendment thereto, prior to filing with the Commission, and UDC shall provide PPG with copies of any comment letters received from the Commission and each written response thereto with respect thereto within two (2) business days of receipt or sending thereof.  UDC shall make reasonably available for inspection by PPG, any underwriter participating in any disposition pursuant to such Registration Statement, and any attorney, accountant or other agent retained by PPG or any such underwriter all financial and other records, pertinent corporate documents and properties of UDC and its subsidiaries, and cause UDC’s officers, directors and employees to be reasonably available for discussions with and to supply all information reasonably requested by such PPG or any such underwriter, attorney, accountant or agent in connection with each Registration Statement, in each case, as is customary for similar due diligence examinations; provided, however, that all records, information and documents that are designated in writing by UDC, in good faith, as confidential, proprietary or containing any material non-public information shall be kept confidential by PPG and any such underwriter, attorney, accountant or agent (pursuant to an appropriate confidentiality agreement in the case of any such underwriter or agent), unless such disclosure is made pursuant to judicial process in a court proceeding (after first giving UDC an opportunity promptly to seek a protective order or otherwise limit the scope of the information sought to be disclosed) or is required by law, or such records, information or documents become available to the public generally or through a third party not in violation of an accompanying obligation of confidentiality; and provided further that, if the foregoing inspection and information gathering would otherwise unreasonably disrupt UDC’s conduct of its business, such inspection and information gathering shall, to the maximum extent reasonably practicable, be coordinated on behalf of PPG and the other persons entitled thereto by one firm of counsel reasonably acceptable to PPG and such other persons.  To the extent necessary, UDC shall qualify any of the Registrable Securities for sale in such states as such PPG reasonably designates, except that UDC shall not be required to qualify in any state which will require an escrow relating to UDC and/or the sellers of Registrable Securities, or which will require UDC to qualify to do business in such state or require UDC to file therein any general consent to service of process.  UDC, at its expense, will supply PPG with copies of each
 
 
Page 42 of 65

 
Registration Statement and the prospectus included therein and other related documents in such quantities as may be reasonably requested by PPG.

16.1.5                      If UDC delivers to PPG a certificate signed by UDC’s President and Chief Operating Officer and Chief Financial Officer to the effect that (i) UDC is aware of nonpublic information concerning UDC that has not been disclosed in a Registration Statement either by incorporation of 1934 Act filings by UDC or by information included directly in such Registration Statement, and (ii) in the good faith judgment of UDC, the disclosure of such information in such Registration Statement may have a material adverse effect on the business, operations, properties, assets, prospects or condition (financial or otherwise) of UDC, then, PPG agrees not to effect any sales of Registrable Securities pursuant to such Registration Statement until such time as PPG (a) is advised in writing by UDC that the use of the applicable prospectus contained in such Registration Statement may be resumed, (b) has received copies of a supplemental or amended prospectus, if applicable, containing such information and (c) has received copies of one or more additional or supplemental filings, if any, which are incorporated or deemed to be incorporated by reference in such prospectus and which contain such information.  UDC agrees to, as promptly as practicable, prepare any supplement or amendment to the applicable prospectus or to make any additional or supplemental filings so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain any untrue statement of material fact or omit to state any fact necessary to make the statements therein not misleading.

16.2           PPG’s Obligations .

16.2.1               Cooperation with UDC .  PPG will cooperate with UDC in all respects in connection with this Article 16, including, without limitation, by timely supplying all information reasonably requested by UDC (which shall include all information regarding PPG and proposed manner of sale of the Registrable Securities required to be disclosed in a Registration Statement), and by executing and returning to UDC or its counsel all documents reasonably requested in connection with the registration and sale of the Registrable Securities.

16.2.2               “Market Stand-Off” Agreement .  Unless otherwise consented to in writing by the managing underwriter, PPG shall not effect any public sale or distribution of equity securities of UDC, or any securities convertible into or exchangeable or exercisable for such securities, during the seven (7) days prior to and the ninety (90) days after any underwritten registered public offering of UDC Common Stock or other UDC securities (except as part of such underwritten registered public offering) if PPG is a selling stockholder in such underwritten registered public offering.  UDC may impose stop-transfer instructions with respect to the shares of UDC Common Stock or other UDC securities subject to the foregoing restriction until the end of any such period.

16.3           Registration Procedures .  In addition to the requirements of Section 16.1 above, UDC shall (except as otherwise expressly provided in this Agreement), as expeditiously as possible, subject to PPG’s compliance with subsection 16.2.1 above:

 
Page 43 of 65

 
16.3.1                      prepare and file with the Commission such amendments and supplements to each Registration Statement and the prospectus used in connection therewith as may be necessary to keep such Registration Statement effective and to comply with the provisions of the 1933 Act with respect to the sale or other disposition of all Securities covered by such Registration Statement (including prospectus supplements with respect to the sales of securities on a delayed or continuous basis in connection with a registration statement pursuant to Rule 415 promulgated under the 1933 Act);

16.3.2                      take all lawful action such that (i) each Registration Statement and any amendment thereto does not, when it becomes effective, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, not misleading; and (ii) the prospectus forming part of each Registration Statement, and any amendment or supplement thereto, does not, at any time during the period set forth in subsection 16.1.3 above, include an untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading;

16.3.3                      prior to the filing with the Commission of any Registration Statement (including any amendments thereto) and the distribution or delivery of any prospectus (including any supplements thereto), (i) provide draft copies thereof to PPG and reflect in such documents all such comments as PPG (and its counsel) reasonably may propose; and (ii) furnish to PPG such numbers of copies of a prospectus including a preliminary prospectus or any amendment or supplement to any prospectus, as applicable, in conformity with the requirements of the 1933 Act, and such other documents, as PPG may reasonably request in order to facilitate the public sale or other disposition of the Registrable Securities;

16.3.4                      to the extent necessary, register and qualify the Securities covered by a Registration Statement under applicable state securities laws, do any and all other acts and things which may be reasonably necessary or advisable to enable PPG to consummate the public sale or other disposition in such jurisdictions within the United States of America of the Registrable Securities, except that UDC shall not be required to qualify in any state which will require an escrow relating to UDC and/or the sellers of Registrable Securities, or which will require UDC to qualify to do business in such state or require UDC to file therein any general consent to service of process;

16.3.5                      subject to the provisions of subsection 16.1.5 above, (i) notify PPG, at any time when a prospectus included in a Registration Statement is required to be delivered under the 1933 Act, upon becoming aware of the happening of any event as a result of which the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; and (ii) prepare and file
 
 
Page 44 of 65

 
a curative amendment or 1934 Act filing deemed incorporated by reference in such Registration Statement under applicable provisions of this Article 16 as promptly as is reasonably practicable;

16.3.6                      notify PPG (and, in the event of an underwritten offering, the managing underwriters) of: (i) the issuance by the Commission or any state authority of any stop order or other suspension of the effectiveness of a Registration Statement, or the initiation of any proceeding for such purpose, or threat (to the extent known by UDC) at the earliest practicable time and take all lawful and reasonable action to effect the withdrawal, rescission or removal of such stop order or other suspension and (ii) the receipt of any notification with respect to the suspension of the qualification of UDC Common Stock for sale in any jurisdiction, or the initiation or treat (to the extent known by UDC) for such purpose;

16.3.7                      cooperate with PPG to facilitate the timely preparation and delivery of certificates for the Securities to be offered pursuant to a Registration Statement and enable such certificates for the Securities to be in such denominations or amounts, as the case may be, as PPG reasonably may request and to be registered in such names as PPG may request, and, within three (3) business days after a Registration Statement that includes Securities is declared effective by the Commission, deliver and/or cause legal counsel selected by UDC to deliver to the transfer agent for the Securities (with copies to PPG) an appropriate instruction and, to the extent necessary, an opinion of such counsel;

16.3.8                      take all such other lawful actions as are reasonably necessary to expedite and facilitate the disposition by PPG of the Securities in accordance with the intended methods therefor provided in the prospectus and as is otherwise customary for issuers to perform under the circumstances;

16.3.9                      in the event of an underwritten offering pursuant to this Section 16, (i) promptly include or incorporate in a prospectus supplement or post-effective amendment to a Registration Statement such information as the managing underwriters reasonably agree should be included therein to the extent UDC does not reasonably object thereto, (ii) make all required filings of such prospectus supplement or post-effective amendment as soon as is reasonably practicable after being notified of the matters to be included or incorporated in such prospectus supplement or post-effective amendment, and (iii) enter into an underwriting agreement, in usual and customary form and subject to reasonable negotiation by its counsel, with the managing underwriters of such offering and perform its obligations under such underwriting agreement;

16.3.10              cause all Securities registered pursuant to this Section 16 to be listed timely on each securities exchange or quotation system on which similar securities issued by UDC are then listed;

16.3.11              if Securities are being sold in an underwritten offering, enter into such agreements (including an underwriting agreement) and take all such other actions
 
 
Page 45 of 65

 
in connection therewith as are reasonably requested in order to expedite or facilitate the disposition of the Securities, and in such connection (i)(A) make such representations and warranties to PPG and to the underwriters, in form, substance and scope as are customarily made by issuers in such agreements and (B) notify PPG and the underwriters if such representations and warranties cease to be true and correct in any material respect prior to the completion of all transactions contemplated by such agreements; (ii) obtain opinions of counsel to UDC and updates thereof (which counsel and opinions (in form, substance and scope) shall be reasonably satisfactory to PPG and the managing underwriters) addressed to such parties and covering such matters as are customarily covered in opinions requested in underwritten offerings and such other matters as may be reasonably requested by PPG or the managing underwriters; and (iii) obtain "comfort" letters and updates thereof from the independent registered public accounting firm of UDC (and, if necessary, any other independent certified public accountants of any subsidiary of UDC or of any business acquired by UDC for which financial statements and financial data are, or are required to be, included in a Registered Statement), addressed to PPG and the underwriters, in form, substance and scope which shall be reasonably satisfactory to PPG and the underwriters and covering matters of the type customarily covered in "comfort" letters in connection with such underwritten offerings;

16.3.12              maintain a transfer agent and CUSIP number for the UDC Common Stock; and

16.3.13              reasonably cooperate with PPG to carry out the intent of this Section 16.

16.4            Rank .  UDC shall not be precluded from granting registration rights to other persons, provided that no such grant shall interfere with or purport to delay or subordinate any of PPG’s rights under this Agreement.

16.5            Indemnification .

16.5.1              UDC shall indemnify, defend and hold harmless PPG, and any underwriter (as defined in the 1933 Act) for PPG, and each person, if any, who controls PPG or underwriter within the meaning of the 1933 Act or 1934 Act (“ Selling Person ”) against any losses, claims, damages or liabilities, joint or several (which shall, for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees), to which the Selling Person may become subject, under the 1933 Act, the 1934 Act, any state securities law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in a Registration Statement, or any related preliminary prospectus, final prospectus or amendment or supplement thereto; or (ii) the omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading; or (iii) any violation or alleged violation by UDC of the 1933 Act, 1934 Act, or any state securities law, or any rules or
 
 
Page 46 of 65

 
regulations of governmental agencies promulgated thereunder; provided, however, that UDC will not be liable in any such case to the extent that any such loss, claim, damage or liability arises out of or is based upon an untrue statement or alleged untrue statement or omission or alleged omission made in such Registration Statement, preliminary prospectus, final prospectus or amendment or supplement thereto in reliance upon, and in conformity with, written information furnished to UDC by the Selling Person, specifically for use in the preparation thereof.  This Section shall not inure to the benefit of any Selling Person with respect to any person asserting such loss, claim, damage or liability who purchased the Securities which are the subject thereof if, and to the extent such loss or other claim arises from the fact or alleged fact that, the Selling Person failed to send or give (in violation of the 1933 Act or the rules and regulations promulgated thereunder) a copy of the prospectus contained in such Registration Statement to such person at or prior to time required under the 1933 Act, where the Selling Person was obligated to do so under the 1933 Act or the rules and regulations promulgated thereunder.  This indemnity agreement will be in addition to any liability which UDC may otherwise have.

16.5.2              PPG shall cause each Selling Person, severally and not jointly, to agree in writing to indemnify and hold harmless UDC, and each officer, director of UDC or person, if any, who controls UDC within the meaning of the 1933 Act, against any losses, claims, damages or liabilities (which shall, for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees) to which UDC or any such officer, director or controlling person may become subject under the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) any untrue statement or alleged untrue statement of any material fact contained in a Registration Statement, or any related preliminary prospectus, final prospectus or amendment or supplement thereto; or (ii) the omission or the alleged omission of a material fact required to be stated therein or necessary to make the statements therein not misleading, but in each case only to the extent that such untrue statement or alleged untrue statement or omission or alleged omission was made in such Registration Statement, preliminary prospectus, final prospectus or amendment or supplement thereto in reliance upon, and in conformity with, written information furnished to UDC by such Selling Person, specifically for use in the preparation thereof.  This indemnity agreement will be in addition to any liability which the Selling Person may otherwise have.  Notwithstanding anything to the contrary herein, the Selling Person shall not be liable under this Section for any amount in excess of the net proceeds to such Selling Person as a result of the sale of Securities pursuant to such Registration Statement.

16.5.3              Promptly after receipt by an indemnified party under this Section 16.5 of notice of the commencement of any action, such indemnified party will, if a claim in respect thereof is to be made against the indemnifying party under this Section 16.5, notify the indemnifying party of the commencement thereof; but the omission so to notify the indemnifying party will not relieve the indemnifying party from any liability which it may have to any indemnified party except to the extent of actual prejudice demonstrated by the indemnifying party.  In case any such action is brought against any
 
 
Page 47 of 65

 
indemnified party, and where it notifies the indemnifying party of the commencement thereof, the indemnifying party will be entitled to participate in and, to the extent that it may wish, jointly with any other indemnifying party similarly notified, assume the defense thereof.  Subject to the provisions herein stated and after notice from the indemnifying party to such indemnified party of its election so to assume the defense thereof, the indemnifying party will not be liable to such indemnified party under this Section 16.5 for any legal or other expenses subsequently incurred by such indemnified party in connection with the defense thereof other than reasonable costs of investigation, unless the indemnifying party shall not pursue the action to its final conclusion.  The indemnified party shall have the right to employ separate counsel in any such action and to participate in the defense thereof, but the fees and expenses of such counsel shall not be at the expense of the indemnifying party if the indemnifying party has assumed the defense of the action with counsel reasonably satisfactory to the indemnified party; provided that if the indemnified party is the Selling Person, the fees and expenses of such counsel shall be at the expense of the indemnifying party if (i) the employment of such counsel has been specifically authorized in writing by the indemnifying party, or (ii) the named parties to any such action (including any impleaded parties) include both the Selling Person and the indemnifying party and the Selling Person shall have been advised by such counsel that there may be one or more legal defenses available to the indemnifying party different from or in conflict with any legal defenses which may be available to the Selling Person (in which case the indemnifying party shall not have the right to assume the defense of such action on behalf of the Selling Person, it being understood, however, that the indemnifying party shall, in connection with any one such action or separate but substantially similar or related actions in the same jurisdiction arising out of the same general allegations or circumstances, be liable only for the reasonable fees and expenses of one separate firm of attorneys for the Selling Person, which firm shall be designated in writing by the Selling Person).  No settlement of any action against an indemnified party shall be made without the prior written consent of the indemnified party, which consent shall not be unreasonably withheld.  All fees and expenses of the indemnified party (including reasonable costs of defense and investigation in a manner not inconsistent with this subsection and all reasonable attorneys’ fees and expenses) shall be paid to the indemnified party, as incurred, within ten (10) business days of written notice thereof to the indemnifying party (regardless of whether it is ultimately determined that an indemnified party is not entitled to indemnification hereunder; provided, that the indemnifying party may require such indemnified party to undertake to reimburse all such fees and expenses to the extent it is finally judicially determined that such indemnified party is not entitled to indemnification hereunder).

16.5.4              In order to provide for just and equitable contribution under the 1933 Act in any case in which (i) the indemnified party makes a claim for indemnification pursuant to this Section 16.5 but is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that the express provisions of this Section 16.5 provide for indemnification in such case; or (ii) contribution under the 1933 Act may be required on
 
 
Page 48 of 65

 
the part of any indemnified party, then UDC and the applicable Selling Person shall contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (which shall, for all purposes of this Agreement, include, but not be limited to, all reasonable costs of defense and investigation and all reasonable attorneys’ fees), in either such case (after contribution from others) on the basis of relative fault as well as any other relevant equitable considerations.  The relative fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by UDC on the one hand or the applicable Selling Person on the other hand, and the Parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission.  UDC and the Selling Person agree that it would not be just and equitable if contribution pursuant to this Section 16.5 were determined by pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in this subsection.  The amount paid or payable by an indemnified party as a result of the losses, claims, damages or liabilities (or actions in respect thereof) referred to above in this Section 16.5 shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.  Notwithstanding the provisions of this subsection, in no case shall any Selling Person be liable or responsible for any amount in excess of the net proceeds received by such Selling Person from the offering of Registrable Securities and UDC shall be liable and responsible for any amount in excess of such proceeds.  No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.

16.5.5              Notwithstanding any other provision of this Section 16.5, in no event shall (i) PPG be required to undertake liability to any person under this Section 16.5 for any amounts in excess of the dollar amount of the net proceeds to be received by PPG from the sale of such person’s Securities (after deducting any fees, discounts and commissions applicable thereto) pursuant to any Registration Statement under which such Securities are to be registered under the 1933 Act; and (ii) any underwriter be required to undertake liability to any person hereunder for any amounts in excess of the aggregate discount, commission or other compensation payable to such underwriter with respect to the Securities underwritten by it and distributed pursuant to such Registration Statement.

16.6           Liquidated Damages .  The Parties hereto agree that PPG will suffer damages if UDC fails to fulfill its obligations under subsection 16.1.1 or subsection 16.1.2 above, and that it would not be feasible to ascertain the extent of such damages.  Accordingly:

16.6.1                      if a Registration Statement is not filed within thirty (30) days after the date on which such Registration Statement is to be filed pursuant to subsection 16.1.1 above, UDC will be obligated to pay liquidated damages to PPG in the form of shares of UDC Common Stock in an amount equal to the quotient of [***] divided by the
 
 
Page 49 of 65

 
Average Price for each month or portion thereof during which such Registration Statement has not been filed after such thirty (30) day period; and

16.6.2                      if a Registration Statement has not been declared effective within one hundred twenty (120) days after the date of its filing, then UDC will be obligated to pay liquidated damages to PPG in the form of shares of UDC Common Stock in an amount equal to the quotient of [***] divided by the Average Price for each month or portion thereof during which such Registration Statement has not been declared effective after such one hundred twenty (120) day period.

16.6.3                      For purposes of this Section 16.6, the “ Average Price ” shall equal, for any month, the average closing price for UDC Common Stock, as set forth in the NASDAQ Global Market listing of The Wall Street Journal, for the ten (10) trading days prior to the close of the Calendar Quarter immediately preceding such month.

16.6.4                      Notwithstanding anything to the contrary in this Section16.6, UDC shall not be required to pay liquidated damages to PPG if PPG failed to comply with its obligations under Section 16.2.


ARTICLE 17 – RESERVED


ARTICLE 18 – TERM AND TERMINATION

18.1            Effect on Prior Agreements .  The Original Agreement is hereby terminated effective as of the Effective Date; provided, however, that the provisions of the Original Agreement pertaining to a reconciliation for actual work performed or OLED Chemicals provided during the fourth Calendar Quarter of 2010 shall continue in effect except as expressly modified by the terms of this Agreement.

18.2            Term .  The initial term of this Agreement (the “ Initial Term ”) shall be from the Effective Date through December 31, 2014.  Thereafter, the term of this Agreement shall be extended automatically for additional twelve (12) month periods (each, a “ Renewal Term ”; and collectively with the Initial Term, the “ Term ”) unless and until (i) PPG provides UDC with at least [***] months’ prior written notice, or (ii) UDC provides PPG with at least [***] months’ prior written notice, that this Agreement shall expire at the end of the Initial Term or the upcoming Renewal Term, as applicable.

18.3            Termination for Material Breach .  Either Party may terminate this Agreement if the other Party breaches any material term, condition or provision of this Agreement (including, without limitation, a material breach by UDC of any of its payment obligations under Article 9) and such breach continues uncured for a period of forty-five (45) days (thirty (30) days for nonpayment of amounts due and owing hereunder) after the breaching Party’s receipt of written notice specifying the nature of the breach from the terminating Party; provided, however that if such breach is not reasonably capable
 
 
Page 50 of 65

 
of cure within the applicable cure period, the breaching Party shall have an additional forty-five (45) days to cure such breach so long as the cure is commenced within the applicable cure period and is diligently pursued to completion thereafter.

18.4            Termination for Bankruptcy Events .  Either Party may terminate this Agreement in the event of the filing by or against the other Party of a proceeding under any bankruptcy or similar law, unless such proceeding is dismissed, within forty-five (45) days from the date of filing; the making by the other Party of a proceeding for dissolution or liquidation, unless such proceeding is dismissed within forty-five (45) days from the date of filing; the appointment of a receiver, trustee or custodian for all or part of the assets of the other Party, unless such appointment or application is revoked or dismissed within forty-five (45) days from the date thereof; the attempt by the other Party to make any adjustment, settlement or extension of its debts with its creditors generally; or the declared insolvency of the other Party.

18.5            Survival .  The rights and obligations of the Parties under Articles 3 (except subsection 3.3.1), 4, 11, 13, 16, 19 and 20, and Sections 2.8, 2.9, 5.3, 9.7, 12.2 (last sentence only), 12.4, 14.1, 14.2, 15.3, 15.4, 18.7, 21.8 and 21.13 of this Agreement, together with any other provisions that by their nature would be expected to survive the expiration or termination of this Agreement, shall survive such expiration or termination.

18.6            Transition Assistance .  Should either Party provide a notice of non-renewal under Section 18.2 above, upon UDC’s request and at UDC’s expense, in order to facilitate an orderly transition of the activities being conducted by PPG hereunder at such time, PPG shall reasonably assist UDC in transitioning such activities to UDC and/or to one or more third parties designated by UDC.  The Parties shall in good faith agree upon a written plan for such a transition and implement said plan sufficiently in advance of the date by which this Agreement is then-scheduled to expire so as to reasonably ensure that the transition will be completed by such date.

18.7            Reconciliation .  Within thirty (30) days after expiration or termination of this Agreement, PPG shall prepare and send to UDC a written statement reconciling to actual amounts any outstanding amounts for services provided or materials purchased by PPG that are properly chargeable to UDC but that have not yet been invoiced under this Agreement.  Subject to reasonable confirmation of such statement by UDC, within thirty (30) days thereafter, any amounts set forth in the statement shall be paid by the party owing such amounts in all cash.


ARTICLE 19 – NON-SOLICITATION

During the Term and for a period of two (2) years thereafter, neither Party shall, directly or indirectly, hire, retain or attempt to hire or retain any person who is known to be employed by the other Party at such time.


 
Page 51 of 65

 
ARTICLE 20 – NOTICES

All notices and requests in connection with this Agreement shall be in writing and shall be transmitted via facsimile, with a copy thereof promptly mailed, to the address(es) of the recipient as set forth below, or to such other address(es) as the recipient shall specify in a notice given hereunder.  Notices shall be deemed given on the date of confirmation of facsimile transmission, if such confirmation occurs on a business day of the recipient, or, if not, on the next succeeding business day of the recipient.

To PPG:
PPG Industries, Inc.
 
One PPG Place
 
Pittsburgh, PA 15272
 
Attn.:  [***]
 
Fax:  [***]

With a copy to:
PPG Industries, Inc.
 
440 College Park Drive
 
Monroeville, PA  15146
 
Attn.:  [***]
 
Fax:  [***]

To UDC:
Universal Display Corporation
 
375 Phillips Boulevard
 
Ewing, NJ 08618
 
Attn.:  [***]
 
Fax:  [***]

With a copy to:
Morgan, Lewis & Bockius LLP
 
1701 Market Street
 
Philadelphia, PA 19103-2921
 
Attn.:  [***]
 
Fax:  [***]


ARTICLE 21 – MISCELLANEOUS

21.1            Force Majeure .  If the performance of this Agreement by either Party should be prevented, delayed, restricted, or interfered with by any man-made or natural catastrophe, or any other circumstances outside the control of such Party and not due to its negligence that is recognized under international commercial practice as constituting a force majeure event, then the Party so affected shall, upon giving prompt notice of such event to the other Party, be excused from such performance to the extent of such prevention, delay, restriction, or interference, provided that the Party so affected shall use its best efforts to avoid or remove such causes of nonperformance and promptly resume performance hereunder when such causes have been removed.  
 
 
Page 52 of 65

 
Upon such circumstances arising, the Parties shall promptly consult as to what, if any, modification to the terms of the Agreement shall be required to arrive at an equitable solution; and, if such nonperformance appears likely to continue for a period of time in excess of thirty (30) days and the affected Party’s nonperformance appears likely to cause serious hardship to the other Party, such other Party may terminate this Agreement upon thirty (30) days’ prior written notice to the affected Party.

21.2            Assignment; Binding Effect .  Neither Party may assign or transfer to any person, firm, or corporation, any of its rights or obligations under this Agreement without the prior written consent of the other Party, except that either Party may assign this Agreement to an entity which acquires all or substantially all of its assets relating to the subject matter of this Agreement, or to an entity which merges or consolidates with it.  Any prohibited assignment of this Agreement or the obligations hereunder shall be null and void.  No permitted assignment shall relieve PPG or UDC of responsibility for the performance of any accrued obligations which it has prior to such assignment.  Any permitted assignment shall obligate the assignee or successor in interest of PPG or UDC to be bound by the terms and obligations of this Agreement.  Subject to the foregoing, all of the terms, conditions and provisions of this Agreement shall be binding upon and shall inure to the benefit of each Party’s permitted successors and assigns.

21.3            Third-Party Beneficiaries .  Except as expressly stated herein, nothing in this Agreement shall confer any rights upon any person other than the Parties hereto and their respective permitted successors and assigns.

21.4            Non-Use of Names .  PPG shall not use the names of Princeton University or USC in connection with any products, promotion or advertising without the prior consent of Princeton University or USC, except to the extent reasonably required by law.  Notwithstanding the foregoing sentence, PPG may state that certain of its rights hereunder are sublicense rights under the Princeton License Agreement.

21.5            Governing Law .  This Agreement will be governed by and construed in accordance with the laws of the Commonwealth of Pennsylvania, irrespective of its provisions regarding conflicts of laws.

21.6            Entire Agreement .  This Agreement, together will its Exhibits, constitutes the entire agreement between the Parties regarding the subject matter hereof.  Neither Party has made any representation, promises or warranties not herein expressly stated.  This Agreement may not be modified except by a written instrument signed by both Parties to this Agreement.

21.7            Waivers .  No waiver by any Party of any condition, or the breach of any term, covenant, agreement, representation, or warranty contained in this Agreement, in any one or more instances, shall be deemed to be a further or continuing waiver of any such condition or breach of any other term, covenant, agreement, representation, or warranty contained in this Agreement.

 
Page 53 of 65

 
21.8            Dispute Resolution .

21.8.1                      Except to the extent of a claim to enforce intellectual property rights or confidentiality obligations, and as a precondition to instituting any legal action permitted by the provisions below, any controversy, claim or dispute between the Parties arising out of or relating to the provision of this Agreement or the breach, termination or a validity thereof shall, upon written request of either Party, immediately be referred jointly for resolution to senior executives of each of the Parties who have authority to settle the controversy and who are at a higher level of management than the person(s) with direct responsibility for day-to-day administration of this Agreement.  Within fifteen (15) days after delivery of the written request of a Party, the receiving Party shall submit to the other a written response.  The request notice and the response shall each include: (i) a statement of the respective Party’s position and a summary of arguments supporting that position; and (ii) the name and title of any other person who will accompany the senior executive.  Within thirty (30) days after delivery of the disputing Party’s request notice, the senior executives of both Parties shall meet at a mutually acceptable time and place, and thereafter as often as they reasonably deem necessary, to attempt in good faith to resolve the controversy.  The Parties agree to honor all reasonable requests for information.  All negotiations pursuant to this provision are confidential and shall be treated as compromise and settlement negotiations for purposes of applicable rules of evidence.

21.8.2                      If the controversy has not been resolved by negotiation within forty-five (45) days of the disputing Party’s request notice, or if the Parties failed to meet within thirty (30) days of such request notice, the Parties agree to attempt to settle the dispute by mediation under the mediation procedure rules then in effect of the CPR Institute or any rules mutually agreed upon by the Parties.  Unless otherwise agreed, the Parties shall select a neutral mediator from the CPR Panels of Distinguished Neutrals.  All mediation proceedings are non-binding.

21.8.3                      This mediation must be concluded within any period mutually agreed upon by the Parties or if there is no such agreement, then within forty-five (45) days of the selection of the mediator.  Unless the Parties expressly agree otherwise, each Party shall bear its own costs, legal and expert fees incurred in mediation, and evenly share the costs of the mediator.  If after proceeding in good faith (i) the Parties are unable to agree on a neutral mediator within thirty (30) days of the failure of the senior executives to meet or to resolve the dispute in accordance with subsection 21.8.2 above, whichever is earlier; or (ii) with the assistance of a neutral mediator, the Parties do not resolve the dispute within the period prescribed in this subsection, the Parties may proceed in accordance with subsection 21.8.4 below.

21.8.4                      After exhausting the procedures set forth above, either Party may initiate litigation to resolve the dispute.  The litigation shall be commenced only in a state court or federal court located in Philadelphia or Pittsburgh, Pennsylvania and each Party hereto submits to the jurisdiction of the court in which such litigation is commenced.

 
Page 54 of 65

 
21.8.5                      In the event of any dispute involving termination of this Agreement by a Party, such termination shall be suspended for so long as the other Party is acting in good faith to resolve the dispute in accordance with the provisions of this Section 21.8; provided, however, that if the basis for termination concerns UDC’s non-payment of PPG’s charges for a particular service provided by PPG hereunder, PPG may suspend its continued provision of said service, without impacting the other obligations of either Party hereunder, until the matter is resolved to the reasonable satisfaction of both Parties.

21.8.6                      Nothing in this Section 21.8 shall prohibit either Party from seeking equitable relief to restrain or prevent a breach of this Agreement at any time.

21.9            Severability .  If the final judgment of a court of competent jurisdiction declares that any term or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making the determination of invalidity or unenforceability will have the power to reduce the scope, duration or area of the term or provision, to delete specific words or phrases, or to replace any invalid or unenforceable term or provision with a term or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision, and this Agreement will be enforceable as so modified after the expiration of the time within which the judgment may be appealed.

21.10            Independent Contractors .  In making and performing this Agreement, the Parties are acting and shall act as independent contractors.  Neither Party is, nor will be deemed to be, an agent, legal representative, joint venturer, partner or employee of the other Party for any purpose.

21.11            Press Releases .  The Parties shall agree on the language of any press releases or public disclosures regarding the existence of this Agreement and/or its terms and conditions prior to the issuance or release thereof.  Language that has been approved by either Party need not be reapproved for subsequent release by the other Party in the absence of notice to the contrary.  Nothing in this Section shall prevent either Party from complying with any applicable securities or other laws.

21.12            Counterparts .  This Agreement may be executed in two (2) or more counterparts, each of which shall be binding as of the date executed by both Parties, and all of which shall constitute one and the same instrument.  Each such copy shall be deemed an original, and it shall not be necessary in making proof of this Agreement to produce or account for more than one such counterpart.  This Agreement shall be deemed executed by the Parties when any one or more counterparts hereof, individually or taken together, bears the signatures of each of the Parties hereto.  This Agreement, once executed by a Party, may be delivered to the other Party by facsimile transmission of a copy thereof that bears the signature of the Party so delivering it.

 
Page 55 of 65

 
21.13            Export Control .

21.13.1                      The Parties acknowledge that they, as well as the products, services, and technology (“ Items ”) sold or otherwise transferred under this Agreement, may be subject to U.S. and other export controls, embargoes, sanctions and similar laws, regulations and requirements (“ Export Controls ”), as well as those additional requirements under PPG’s export policies, controls, and procedures that are set forth on Exhibit C attached hereto, as may be amended from time to time upon mutual written agreement of the Parties (“ PPG’s Export Compliance Requirements ”). 

21.13.2                      Each Party agrees to (1) comply with Export Controls to the extent applicable to such Party’s activities under this Agreement; (2) comply with their respective obligations under PPG’s Export Compliance Requirements; and (3) provide the other Party with all information and documentation deemed reasonably necessary by such other Party in order for such other Party to comply with all Export Controls as they relate to this Agreement and the transactions contemplated hereby.

21.13.3                      Each Party agrees to report to the other Party in writing, any suspected or actual violations of any Export Controls that involve Items or employees of such other Party or its subsidiaries (“ Reports ”), to the extent such reporting is legally permitted under applicable law.  Such Reports shall be provided to the person(s) designated by each Party in writing and using such methods as are reasonably identified by such Party in writing.

21.13.4                      Should either Party fail to comply with (1) Export Controls or (2) such Party’s obligations under PPG’s Export Compliance Requirements, the other Party reserves the right to take appropriate and customary action, including exercising such other Party’s rights to terminate this Agreement as permitted hereunder.  In addition, and notwithstanding any other provision of this Agreement, each Party agrees to indemnify, defend, and hold harmless the other Party, its officers, employees, agents, and representatives, from and against any and all claims, demands, suits, causes of action, out-of-pocket expenses (including reasonable attorneys’ fees), damages, fines and penalties, arising from, or allegedly arising from or related to, such Party’s failure to adhere to Export Controls or such Party’s obligations under PPG’s Export Compliance Requirements.

21.13.5                      The provisions of this Export Compliance section of the Agreement are in addition to any other provisions of the Agreement related to compliance with any laws or regulations.  To the extent that this section of the Agreement is inconsistent with any other provision of the Agreement, the Parties agree that the provisions of this section supersede any such inconsistent provision.  The Parties further agree that the obligations under this section survive the termination of this Agreement.


 
Page 56 of 65

 
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement by their duly authorized representatives as of the Effective Date.

UNIVERSAL DISPLAY CORPORATION
PPG INDUSTRIES, INC.
By:               /s/ Steven V. Abramson                                                  
By:               /s/ Richard C. Elias                                                  
NAME:             Steven V. Abramson                                             
NAME:             Richard C. Elias                                             
TITLE:               President                                                  
TITLE:              Sr. VP Optical + Specialty Materials                                                
DATE:               Sept 22, 2011                                                  
DATE:               9/14/11                                             
 
 
Page 57 of 65

 

Exhibit A-1

Reserved



 
Page 58 of 65

 

Exhibit A-2

PPG’s OLED Material Conversion Costs


Basis for Calculating Lab Reactor, Plant Reactor and Sublimator Unit Cost:
·  
Labor (Benefits, Employee Expenses, Training, Meeting Expenses, Payroll admin)
·  
Operating Supplies (solvents used during conversion of intermediates and products as well as purification, some filtration media, misc. lab supplies, office supplies, safety equipment)
·  
Manufacturing Unit Depreciation, less the applicable portion, if any, of the New Equipment Depreciation Value
·  
Maintenance
·  
Facilities Charges (Utilities and other service charges from group, storeroom, etc.)
·  
Software purchases and maintenance (DP services, computer center etc.)
·  
Professional Services (Safety, Process etc.)


 
Page 59 of 65

 

Exhibit A-3

PPG’s Commercial OLED Material Costs

Categories
·  
Raw Materials
·  
Conversion Cost as listed in Exhibit A-2
·  
Analytical Charges
·  
Packaging Cost
o  
Containers
o  
Shipping boxes
o  
Labor


 
Page 60 of 65

 

Exhibit A-4

PPG’s Process Development Costs

Basis for Calculating Chemist Hourly Rate Charge:
·  
Labor (Benefits, Employee Expenses, Training, Meeting Expense, Payroll admin)
·  
Facilities charges (Utilities and other service charges for group, storeroom, office and lab space, etc.)


 
Page 61 of 65

 

Exhibit B

PPG Quality Assurance Control Plan


Customer needs and expectations are determined through the use of the Gatekeeper process (Staged Gate Process).  This process monitors compliance of purchased and manufactured materials with applicable regulatory environmental, health, and safety requirements.  This process is also a guide to determining the specifications for purchased and manufactured materials along with writing standard procedures for safer and consistent manufacture/handling/storage/shipment of materials.  A lot number to provide traceability identifies critical raw materials, intermediates, and products.  Critical raw materials, critical isolated intermediates, and products are tested to monitor for compliance with applicable specifications.  Changes to written standard procedures are done through a documented Management of Change (MOC) process.   The MOC process identifies potential impacts on environmental, health, & safety and product quality along with standard procedures.  Customer notification is part of the MOC process.

 
Page 62 of 65

 


Exhibit C

Additional Export Compliance Policies, Controls & Procedures


U.S. Export Administration Regulations (“EAR”) require that exports for certain end-uses and end-users be licensed by the U.S. Bureau of Industry and Security (“BIS”) prior to export.  The following pages contain the current example of a Customer Activity Statement that PPG has designed to gather information needed to determine whether PPG might need to obtain a license from the U.S. Bureau of Industry and Security (“BIS”) prior to releasing any of UDC’s orders.  UDC will be asked to review this form carefully and complete it to the best of UDC’s knowledge.  Each year thereafter, UDC will be asked to confirm that the information on the form is still accurate.


 
Page 63 of 65

 


[Missing Graphic Reference]
 
 
Customer Activity Statement
PPG requires a general understanding of your business and how the merchandise you purchase from PPG business unit name will be used so that the proper export procedures may be followed.  Accordingly, please complete the following form:
Company Name:
 
Contact Name:
 
Street Address:
 
City:
 
State:
 
Postal Code:
 
Country:
 
Telephone:
 
Email:
 
   
Bill To:
 
Street Address:
 
City:
 
State:
 
Postal Code:
 
Country:
 
   
Ship To:
 
Street Address:
 
City:
 
State:
 
Postal Code:
 
Country:
 
 
 
1.   Please advise if your company is involved in any of the following activities by checking the applicable box.
 
If you answer “YES” to any of these activities, please provide the following information in the blank space directly below the activity:
(a) describe the specific activity (e.g., program, service provided, etc.) in detail, and
(b) confirm if and how any of the PPG products you purchase are used in conjunction with that activity.
 
Nuclear activities
This includes research on or development, design, manufacture, construction, testing or maintenance of any nuclear explosive device, nuclear reactor, facility for fabrication, conversion, processing or storage of nuclear fuel, components thereof, or other similar activities
YES      NO                                                      

 
Page 64 of 65

 
 
Chemical or biological weapons activities
This includes the design, development, production, stockpiling or use of chemical or biological weapons
YES      NO                                                      
 
Rocket systems activities
This includes the design, development, production or use of rocket systems including ballistic missile systems, space launch vehicles, sounding rockets, and unmanned air vehicles including cruise missile systems, target drones, and reconnaissance drones
YES      NO                                                      
 
Maritime nuclear propulsion activities
This includes any activity relating maritime nuclear propulsion plants, their land prototypes and facilities for their construction, support or maintenance
YES       NO                                                      
 
Military activities
This includes any activity with a non-U.S. military or defense organization or an entity owned or controlled by a non-U.S. military or defense organization (“non-U.S.” includes NATO and Coalition military forces)
YES       NO                                                      
 
 
2.  
Please specify below the specific uses you have planned for the PPG products you order.
Note : You MUST describe below what you plan on doing with the PPG products you purchase.

 


We confirm that the foregoing information is complete and accurate and that the individual signing below has authority to legally bind the company.

If the information concerning activities or uses changes for this or a future shipment, we will immediately advise PPG.

Signed on behalf of
 
(distributor/end user/customer)


 
(Signature)
 
(Title)
 
(Printed Name)
 
(Date)
 
(Email)
 
(Phone)





Note:  Throughout this document, certain confidential material contained herein has been omitted and has been separately filed with the Commission. Each place where such an omission has been made is marked with an [***].
 
OLED TECHNOLOGY LICENSE AGREEMENT
 

THIS OLED TECHNOLOGY LICENSE AGREEMENT (this “ Agreement ”) is entered into effective as of May 1, 2011 (the “ Effective Date ”), by and between Universal Display Corporation (“ Universal Display ”), a corporation duly organized and existing under and by virtue of the laws of Pennsylvania, U.S.A., having its principal office at 375 Phillips Boulevard, Ewing, New Jersey 08618, U.S.A.; and Pioneer Corporation (“ Pioneer ”), a corporation duly organized and existing under and by virtue of the laws and regulations of Japan, having its office at  1-1, Shin-ogura, Saiwa-ku, Kawasaki-shi, Kanagawa 212-0031, Japan.  Each of Universal Display and Pioneer is referred to herein as a “ Party ,” and collectively as the “ Parties .”

 
BACKGROUND
 
WHEREAS, Universal Display has rights in certain patents and possesses certain know-how concerning organic light emitting devices; and
 
WHEREAS, Pioneer desires to obtain license rights to practice under these patents and to use this know-how on the terms and conditions set forth herein.
 
NOW, THEREFORE, intending to be legally bound, each of the Parties hereby agrees as follows:
 
 
AGREEMENT
 
Article 1   Definitions
 
In addition to other terms defined elsewhere herein, the following terms shall have their corresponding meanings when used in this Agreement.
 
1.1   Affiliate ” means an entity under the control of a Party, whether directly or through one or more intermediaries.  For such purposes, “control” shall mean the ownership of securities representing more than fifty percent (50%) of the voting capital stock of the relevant entity, or of other interests having majority voting rights with respect to the election of the board of directors or similar governing authority of the relevant entity, or of any other power by contract or in any other form which entitles the holder thereof to majority voting rights with respect to management decisions of the relevant entity.
 
1.2   Know-How ” means unpatented technical information, data, specifications, plans, drawings, designs, blueprints, formulae, processes and other similar items of a trade secret or confidential nature.
 
1.3   Licensed Product ” means an OLED Light Source, or any portion thereof that consists minimally of a Permitted OLED Device, or any product that incorporates one or more of the foregoing, which item is (a) covered, in whole or in part, by any Valid Claim(s) of a
 

 
Page 1 of 21

 

  Universal Display Patent; (b) manufactured using a process that is covered, in whole or in part, by any Valid Claim of a Universal Display Patent; and/or (c) manufactured using any of the Universal Display Know-How.
 
1.4   Lighting ” means a source of direct or indirect illumination, including, but not limited to, a room, area or architectural lighting source, a backlight for an LCD display or other consumer electronics product, or a source of illumination for signage; provided, however, that the source of illumination shall not itself be intended to display movable or changeable images or information ( e.g. , a passive matrix or active matrix display).
 
1.5   Net Sales Revenue
 
1.5.1   For Licensed Products sold or leased by Pioneer or its Affiliates to non-Affiliated third parties solely for monetary consideration, “Net Sales Revenue” means the gross amount invoiced or received, whichever occurs sooner, on account thereof, less the following where separately itemized on the customer invoice for the Licensed Products: (a) taxes and duties actually collected and remitted to the appropriate taxing authorities; (b) reasonable shipping and insurance costs actually paid or accrued for such purpose; and (c) refunds or credits actually given for returned or defective items.
 
1.5.2   For all other Licensed Products sold, leased or otherwise transferred by Pioneer or its Affiliates, “Net Sales Revenue” means the greater of (a) or (b), where (a) is the arm’s length transfer price recorded by Pioneer or its Affiliate for such sale, lease or transfer; and (b) is the average selling price at which Licensed Products of similar kind and quantity have been sold by Pioneer or its Affiliates to non-Affiliated third parties during the same calendar quarter, as calculated according to the preceding paragraph, or if no such selling price is available, the fair market value of such Licensed Products.  The  arm’s length transfer pricing referred to in clause (a) shall include all cost components fairly attributable to the Licensed Products being sold, leased or otherwise transferred, and shall comply with the Japan National Tax Agency guidelines and other applicable laws, rules and regulations.
 
1.5.3   If either Party presents reasonable evidence that the amount calculated as set forth above does not fairly reflect the fair market value of a Licensed Product (such as evidence that the industry-wide average sales price of substantially similar products differs significantly from the price calculated herein, or evidence that additional consideration is being received based on the downstream sale or lease of a Licensed Product), the Parties shall in good faith negotiate a more equitable method of calculating Net Sales Revenue with respect to the Licensed Product in question.
 
1.6   OLED ” means a device consisting of two or more electrodes, at least one of which is transparent, together with one or more chemical substances deposited between these two electrodes, at least one of which is an organic or organometallic material, which device emits light when a voltage is applied across the electrodes.
 
1.7   OLED Light Source ” means a Permitted OLED Device, or a series of such devices, which OLED device(s) are intended for use in Lighting applications, together with the following elements: (a) encapsulation or packaging materials or coatings for protection of the
 

 
Page 2 of 21

 

  OLED device(s); (b) optical elements, coatings or enhancements added to the OLED device(s) for the purpose of affecting or modulating light output from the OLED device(s); (c) connectors, contacts or similar components attached to the OLED device(s) and designed to connect the OLED device(s) to an external power source or supply and/or other elements of a lighting fixture; (d) a supporting frame in direct contact with the OLED device(s) designed to stabilize or protect the OLED device(s) during shipment, installation or usage; (e) thermal elements, coatings, structures or enhancements attached to the OLED device(s) for purposes of reducing, dispersing or modulating the temperature of the OLED device(s); (f) control electronics or circuitry designed or utilized to adjust or correct light emission from the OLED device(s); and (g) power conversion components designed to allow the OLED device(s) to operate utilizing an external power source or supply (the power source or supply itself is not part of the OLED Light Source).  Two potential configurations of an OLED Light Source, by example only, are set forth in Exhibit A attached hereto.
 
1.8   Permitted OLED Device   means an OLED device in which all of the emissive layer materials are deposited by vacuum thermal evaporation.
 
1.9   Solution Processing Method ” means a fabrication method whereby one or more of the emissive layer materials in the OLED device are deposited while such materials are in solution (otherwise known as a “wet” processing method).
 
1.10   Term ” means the term of this Agreement, as specified in Article 8 below.
 
1.11   Universal Display Know-How ” means Know-How of Universal Display relating to the design or manufacture of an OLED Light Source, which Know-How has been or is in the future provided to Pioneer under other agreements between the Parties.
 
1.12   Universal Display Patents ” means all patents and patent applications pertaining to OLED Light Sources that are (1) issued, registered, granted, allowed, published or filed in the world as of the Effective Date, or (2) entitled to a priority date prior to the Effective Date, or (3) any divisions, continuations, continuations-in-part, reexaminations, renewals, extensions or reissues of (1) or (2) above, and which in the case of (1), (2) or (3) above, Universal Display owns or has the right to license to Pioneer hereunder, including, but not limited to, the issued, registered, granted, published, or filed patents and patent applications listed in Exhibit C , together with such future patents and patent applications as are specified in Section 2.3 below.
 
1.13   Universal Display Technology ” means the Universal Display Patents and the Universal Display Know-How.
 
1.14   Valid Claim ” means a claim of an issued, registered, granted, allowed or published patent or patent application, which claim has neither expired nor been finally, following expiration of all rights of appeal, held unpatentable, invalid or unenforceable by a court or other government agency of competent jurisdiction.
 
1.15   Service Part ” means a Licensed Product supplied to a customer upon request of the customer in return and as a replacement for a defective Licensed Product previously sold to such customer, and provided that the defective Licensed Product is replaced at no charge or without charging the customer more than the cost to Pioneer of the replacement Licensed
 

 
Page 3 of 21

 

  Product.  As used herein, “defective” means that the Licensed Product being replaced did not last for its expected useful life based on its published specifications.
 
1.16   Authorized Bank ” means the Bank of Tokyo-Mitsubishi UFJ, Ltd., or such other bank as the parties shall mutually agree upon in writing.
 
Article 2   License Rights
 
2.1   Grant of License to Pioneer .  Subject to the remaining provisions of this Article 2, Universal Display hereby grants to Pioneer a worldwide, royalty-bearing, non-exclusive and non-transferable (except in connection with a permitted transfer of this Agreement as a whole) license, without rights to sublicense, under the Universal Display Patents, and to use the Universal Display Know-How, solely to manufacture, have manufactured (but only in accordance with the following sentence), sell, offer for sale, lease, import, use or otherwise dispose of Licensed Products.  Pioneer’s “have manufactured” rights shall [***] .  Should Pioneer wish to extend its “have manufactured” rights for the manufacture of Permitted OLED Devices to others, [***] .
 
2.2   Extension of License to Certain Affiliates  Pioneer may extend the license rights granted to Pioneer under Section 2.1 above to Tohoku Pioneer Corporation (having its office at 4-3146-7 Hachimanpara, Yonezawa-shi, Yamagata 992-1128, Japan) and to such other  entities that are Affiliates of Pioneer, but only for so long as such entities remain Affiliates of Pioneer, and excluding any [***].  Should Pioneer wish to extend such license rights to others, [***].  Any extension of license rights shall be pursuant to a written agreement between Pioneer and the relevant Affiliate, which written agreement shall obligate the Affiliate to abide by the scope of license and other applicable provisions of this Agreement.  In addition to its other rights or remedies hereunder, Universal Display shall be expressly identified in the written sublicense agreement as a third-party beneficiary thereof, entitled to enforce the scope of license and other applicable provisions of this Agreement directly against the Affiliate.  Except for Tohoku Pioneer Corporation, Pioneer shall identify to Universal Display in writing the name and business address of each Affiliate prior to its entry into such written agreement with the Affiliate, and shall use its best efforts to cause each such Affiliate abide by the scope of license and other applicable provisions of this Agreement.
 
2.3   License Rights to Future Patents and Know-How .  To the extent it has the right to do so, Universal Display will expand Pioneer’s license rights under this Article 2 to include any additional patents, patent applications and Know-How of Universal Display pertaining to OLED Light Sources that are owned by or licensed to Universal Display and which are (1) issued, registered, granted, allowed, published or filed or generated during the first five (5) years of the Term, or (2) entitled to a priority date during the first five (5) years of the Term, or (3) any divisions, continuations, continuations-in-part, reexaminations, renewals, extensions or reissues of (1) or (2) above, but in the case of (1), (2) or (3) above   excluding any such patents, patent applications or Know-How acquired by Universal Display through a merger, asset acquisition or other similar transaction unless separately agreed by the Parties in writing.  Universal Display shall periodically update Exhibit C to include any such additional patents and patent applications that are issued, registered, granted, allowed or published or filed.
 

 
Page 4 of 21

 

 
 
2.4   No Rights Respecting Certain OLED Chemicals .  Notwithstanding the foregoing, Pioneer and its Affiliates are not authorized under this Agreement to sell or offer for sale any Licensed Products made using any chemical substance used or useful for the manufacture of OLEDs, the composition of matter of which is covered by a Valid Claim of a patent owned or controlled by Universal Display (a “ Universal Display Proprietary OLED Chemical ”), unless such Universal Display Proprietary OLED Chemical was purchased directly from Universal Display.  Pioneer and its Affiliates shall not make, or assist or encourage any third party to make or supply to them, any chemical substance that they know, or have reason to know, is a Universal Display Proprietary OLED Chemical.
 
2.4.1   Pioneer shall obtain written warranties from its third-party suppliers of OLED chemicals used to manufacture Licensed Products (each, a “ Third-Party Supplied Chemical ”), which warranties shall indicate that the third parties are authorized to make and supply the Third-Party Supplied Chemical to Pioneer for Pioneer’s intended usage thereof.  If Pioneer begins using a Third-Party Supplied Chemical for the manufacture of Licensed Products after having obtained the foregoing warranties and without knowing or having reason to know that the material is a Universal Display Proprietary OLED Chemical, and then Pioneer subsequently learns that the Third-Party Supplied Chemical is or might reasonably be a Universal Display Proprietary OLED Chemical, Pioneer shall promptly notify Universal Display thereof in writing, and the parties shall promptly discuss the matter.  If need be, Pioneer and Universal Display shall cooperate to determine whether the Third-Party Supplied Chemical is in fact a Universal Display Proprietary OLED Chemical.
 
2.4.2   If the Third-Party Supplied Chemical is a Universal Display Proprietary OLED Chemical, the parties shall use good faith efforts to promptly transition to Universal Display supplying Pioneer with the Universal Display Proprietary OLED Chemical, or with an alternative material offered by Universal Display that has comparable performance characteristics, for Pioneer’s continued manufacture of Licensed Products.  If Universal Display is unable to supply Pioneer with such a material, the parties shall [***].
 
2.4.3   Nothing herein shall limit any rights or remedies that Universal Display may have against any person or entity that is the manufacturer or supplier to Pioneer of any Universal Display Proprietary OLED Chemical.  Moreover, subject to its compliance with the procedure outlined above, Universal Display reserves the right to seek monetary compensation or other relief on account of Pioneer’s unauthorized importation or usage of any Universal Display Proprietary OLED Chemical.
 
2.5   No Rights Respecting Certain OLED Manufacturing Equipment .  Notwithstanding the foregoing, Pioneer and its Affiliates are not authorized under this Agreement to sell or offer for sale any Licensed Products made using any manufacturing equipment or machinery used or useful for the manufacture of OLEDs by organic vapor phase deposition (OVPD) or organic vapor jet printing (OVJP) processes, the design or construction of which is covered by a Valid Claim of a patent owned or controlled by Universal Display (“ Universal Display Proprietary OLED Equipment ”), unless such Universal Display Proprietary OLED Equipment was purchased from an authorized Universal Display equipment vendor.  Pioneer and its Affiliates shall not make, or assist or encourage any unauthorized third party to
 

 
Page 5 of 21

 

  make or supply to them, any equipment or machinery that they know, or have reason to know, is Universal Display Proprietary OLED Equipment.
 
2.6   Acknowledgement of Derivative Rights .  Pioneer acknowledges that certain of the Universal Display Technology is licensed by Universal Display from the Trustees of Princeton University (“ Princeton ”), the University of Southern California (“ USC ”), and the University of Michigan (“ Michigan ”) and, therefore, that Pioneer’s license rights under this Agreement with respect to such Universal Display Technology are subject to the reserved rights of and obligations to such third parties under their license agreement with Universal Display.  Pioneer further acknowledges that the U.S. Government has certain reserved rights with respect to those Universal Display Patents claiming inventions that were first conceived or reduced to practice under contracts between the U.S. Government and Universal Display or its licensors.  Universal Display hereby covenants to Pioneer that: (a) Universal Display shall comply in all material respects with the terms of its license agreements with such third-party licensors and its contracts with or awards from the U.S. Government as in either case are relevant to Pioneer’s exercise of the license rights granted by Universal Display hereunder; and (b) no additional consideration shall be owed by Pioneer to such third-party licensors or the U.S. Government on account of Pioneer’s exercise of such license rights.  Nothing herein shall be construed as limiting or restricting the reserved rights of or obligations to Universal Display’s third-party licensors or the U.S. Government with respect to the Universal Display Technology.  Upon Pioneer’s request, Universal Display will provide Pioneer with copies (which may be reasonably redacted by Universal Display to avoid disclosing confidential information not relevant to this Agreement) of such of Universal Display’s agreements with these third-party licensors and of the applicable portions its relevant contracts with or awards from the U.S. Government.  Even if Universal Display’s license agreement with Princeton, USC and Michigan is terminated, that license agreement enables Pioneer, as a sublicensee of Universal Display, to become a direct licensee of Princeton, USC and Michigan under the conditions specified therein.  Universal Display warrants to Pioneer that for the license rights granted hereunder, the total payments by Pioneer and its Affiliates as such a direct licensee, as a sublicensee of one of the licensors of Universal Display (if any), and/or as a licensee of Universal Display, shall not exceed the amounts due to Universal Display hereunder.
 
2.7   Business Consolidations .  Should Pioneer or its Affiliates acquire the existing OLED business of any third party, the license rights granted to Pioneer under this Agreement shall not extend to any then-current products of such third party’s OLED business unless expressly agreed to by Universal Display in writing.  In addition, if the OLED business of the third party is not fully integrated into Pioneer’s or its Affiliates’ OLED business, the license rights granted to Pioneer under this Agreement shall not extend to any future products of the third party’s OLED business unless expressly agreed to by Universal Display in writing.  Should Universal Display have already entered into a similar license agreement with the third party at the time of such acquisition, there shall be no reduction in the payment or other obligations of Pioneer under this Agreement as they pertain to products of Pioneer’s or its Affiliates’ OLED business, or of such third party under its similar license agreement as they pertain to products of the third party’s OLED business, unless expressly agreed to by Universal Display in writing.
 
2.8   Reservation of Rights .  Except for the license rights expressly granted to Pioneer under this Article 2, all rights to practice under the Universal Display Patents and to use the
 

 
Page 6 of 21

 

  Universal Display Know-How are reserved unto Universal Display and its licensors.  No implied rights or licenses to practice under any patents or to utilize any unpatented inventions, Know-How or technical information of Universal Display are granted to Pioneer or its Affiliates hereunder.
 
Article 3   Patent Matters, Attribution and Samples
 
3.1   Patent Validity .  During the Term, Pioneer shall not, and shall ensure that its Affiliates do not, challenge or oppose, or assist others in challenging or opposing, in whole or in part, the issuance, validity, scope or enforceability of any of the Universal Display Patents, nor shall Pioneer initiate or continue, or assist others in initiating or continuing, proceedings to have any of the Universal Display Patents cancelled or invalidated, in whole or in part, except that the foregoing shall not apply to the extent such prohibitions are contrary to law or regulation in the relevant patent jurisdiction.  If Pioneer or any of its Affiliates challenges, opposes or seeks to invalidate or cancel, in whole or in part, any of the Universal Display Patents, or assists others in challenging, opposing or seeking to invalidate or cancel, in whole or in part, any of the Universal Display Patents, and if the action or proceeding is fully or substantially unsuccessful, then Pioneer shall reimburse Universal Display, promptly on demand, for all attorneys’ fees, costs and out-of-pocket expenses reasonably incurred by Universal Display or its licensors of the Universal Display Patents in resisting or responding to such action or proceeding.  The foregoing shall be in addition to, and not in lieu of, any other rights or remedies that may be available to Universal Display, at law or equity, including, without limitation, actions for injunctive relief and the recovery of damages.
 
3.2   Patent Marking .  Upon Universal Display’s request, Pioneer shall apply or cause to be applied to all Licensed Products, or to their packaging, such reasonable markings or notices of the Universal Display Patents as may be requested in writing by Universal Display in order to reasonably protect Universal Display’s rights and interests therein under the laws of the countries in which such Licensed Products are or are likely to be marketed, sold or used; provided however, that Pioneer shall be required to apply such markings or notices to the products or their packaging only to the extent that Pioneer applies or would be likely to apply similar markings or notices of Pioneer’s own patents to the products or their packaging in order to protect Pioneer’s rights and interests therein under laws of the relevant countries.
 
3.3   Non-Use of Certain Names .  Pioneer shall not, and shall ensure that its Affiliates do not, use the names of Princeton, USC or Michigan in connection with any products, promotion or advertising without the prior consent of Princeton, USC or Michigan, as applicable, except to the extent reasonably required by law.  Notwithstanding the foregoing sentence, Pioneer may state that its license rights hereunder are derivative of rights granted by Princeton, USC and Michigan to Universal Display under the license agreement among them.
 
3.4   Samples .  Except for extraordinarily expensive Licensed Products, upon Universal Display’s written request and at no additional cost to Universal Display, Pioneer shall supply Universal Display with [***] samples of each type of Licensed Product that Pioneer or its Affiliates offer for sale to third parties, provided however, that such sample of Licensed Product shall not include those which are custom products subject to confidentiality obligations under agreement between Pioneer or its Affiliates and any third parties.  Universal Display shall limit
 

 
Page 7 of 21

 

  its requests for such samples to a reasonable number of different Licensed Products and Pioneer shall supply such samples promptly following Pioneer’s or its Affiliates’ first sale of the Licensed Product to a third party.  Universal Display agrees to use such samples only (a) to verify compliance with the terms of this Agreement, and (b) for promotional purposes such as in displays at shareholder meetings, industry conferences or other similar venues (with appropriate attribution being given to Pioneer or its Affiliates).
 
3.5   Amendments to the Universal Display Patents .  To the extent applicable law requires Universal Display to obtain Pioneer’s approval for amendments to the specifications of any Universal Display Patent licensed hereunder, Pioneer shall promptly approve all such reasonable amendments proposed by Universal Display.
 
Article 4   Consideration
 
4.1   License Fees .  In partial consideration of the license rights granted by Universal Display hereunder, Pioneer shall pay to Universal Display the license fees specified in Exhibit B hereto.  Said license fees are due and payable by the date(s) specified in Exhibit B hereto.  All such fees are non-refundable and shall be in addition to, and not applied to reduce, any royalties payable hereunder.
 
4.2   Royalties .  In further consideration of the license rights granted by Universal Display hereunder, Pioneer shall pay to Universal Display running royalties at the rates specified in Exhibit B hereto on account of Net Sales Revenue from Pioneer’s or its Affliates’ worldwide sales or other disposition of Licensed Products.  No multiple royalties shall be due because any Licensed Product, or its manufacture, sale, other disposition or usage, is or may be covered by more than one Universal Display Patent licensed to Pioneer hereunder.  Both Parties acknowledge and agree that the royalty rates and the methods by which they are to be calculated and paid hereunder have been determined through arms length negotiations between the Parties, and that such rates and methods have been agreed upon because they are mutually convenient, reasonable and appropriate notwithstanding whether and to what extent any of the Universal Display Patents have been issued, granted, allowed or registered, or have expired, in any particular country in which Licensed Products are made, sold or used, or whether the Universal Display Patents encompass each and every feature of any particular Licensed Product.  It is acknowledged and agreed between the parties that the rates and the methods specified in Exhibit B hereto are determined by considering the prices of OLED chemicals separately supplied by Universal Display for the manufacture of Licensed Products,   as discussed and agreed in parallel with this Agreement.
 
4.3   Royalty Reports .  Within forty-five (45) days following the end of each calendar quarter during the Term (and if the Term ends in the middle of a calendar quarter, within forty-five (45) days following the end of the Term), Pioneer shall submit to Universal Display a written report, in English, that includes the following information (each, a “ Royalty Report ”): (a) a description of all Licensed Products sold, leased or otherwise disposed of by Pioneer or its Affiliates during such calendar quarter, including the number and type of each Licensed Product sold and the countries of destination or sale; (b) gross amounts invoiced or received on account of such sales or other disposition of Licensed Products; and (c) Pioneer’s reasonably detailed
 

 
Page 8 of 21

 

  calculation of the royalties due and owing to Universal Display on account of such sales or other disposition of Licensed Products.
 
4.4   Payment of Royalties.   Within forty-five (45) days following the end of each calendar quarter during the Term (and if the Term ends in the middle of a calendar quarter, within forty-five (45) days following the end of the Term), Pioneer shall pay directly to Universal Display the royalties due and payable with respect to Licensed Products sold, leased or otherwise disposed of during such calendar quarter.
 
Article 5   Payment Terms; Audit Rights
 
5.1   Payments .  All amounts due to Universal Display hereunder shall be paid in U.S. Dollars by wire transfer to a bank designated by Universal Display in writing, or by such other means as the Parties may agree in writing.  Universal Display’s current wire instructions are as follows:
 
[***]

Each payment shall be fully earned when due and nonrefundable once made.  All payments due hereunder shall be made without set-off, deduction or credit for any amount owed (or alleged to be owed) by Universal Display to Pioneer or any of its Affiliates.  Without limiting its other rights or remedies on account of any late payment, Universal Display may require Pioneer to pay interest on any late payments at a per annum rate equal to the Prime Rate as published by the Authorized Bank at the close of business on the date that payment was due (or, if such date is not a business day, at the close of business on the immediately preceding business day), plus [***] percent [***] .
 
5.2   Payment Authorization and Associated Charges .  Pioneer shall secure all authorizations required for payment of all amounts due to Universal Display hereunder, and shall bear any transfer fees, taxes and any other charges associated therewith.  If Pioneer believes that any income taxes imposed by any national, provincial or local government of relevant countries on amount payable to Universal Display hereunder need to be withheld, Pioneer shall provide Universal Display with prompt written notice thereof.  Thereupon, the Parties shall cooperate in good faith and use their best efforts to promptly file for and obtain appropriate governmental exemptions that would eliminate the requirement for Pioneer to withhold such taxes.  If, notwithstanding these efforts, tax withholding is nonetheless required, Pioneer may make the appropriate withholding from amounts payable to Universal Display hereunder, and Pioneer shall then promptly pay the withheld amounts to the appropriate tax authorities.  Promptly upon making each such tax payment, Pioneer shall obtain and forward to Universal Display the official tax receipt(s) issued by the relevant government to support Universal Display’s claim to applicable tax credits or refunds.
 
5.3   Currency Conversion and Restriction .  All royalties due hereunder based on Licensed Products sold or otherwise disposed of by Pioneer or its Affiliates outside of the United States shall be payable in U.S. Dollars at the rate of exchange for the currency of the country in which such sales or usage occurs, which rate shall be the wire transfer selling rate of the designated currency as officially quoted for payment of currency transactions by the Authorized
 

 
Page 9 of 21

 

  Bank at the close of business on the last business day of the period for which royalties are due.  All royalties shall be paid to Universal Display without deduction of currency exchange fees or other similar amounts.  If at any time the legal restrictions of countries outside of the United States prevent Pioneer from paying Universal Display any amounts due hereunder, or otherwise upon Universal Display’s written instruction, Universal Display may direct Pioneer to make all or any portion of these payments to Universal Display’s accounts established at banks or depositories in one or more countries other than the United States.
 
5.4   Records; Audit .  Pioneer shall keep, and shall require its Affiliates to keep, accurate and complete records relating to all Licensed Products until the three (3) year anniversary of the date of payment of royalties with respect to such Licensed Products.  An independent certified public accountant selected by Universal Display and approved by Pioneer (such approval not to be unreasonably withheld) shall have the right to audit such records as are reasonably necessary in order to verify Pioneer’s and its Affiliates’ compliance with their license obligations under Article 2 and their payment under Articles 4 and 5 above.  Universal Display shall give reasonable advance notice of any such audit to Pioneer, and such audit shall be conducted during Pioneer’s or the Affiliates’ normal business hours and in a manner that does not cause unreasonable disruption to the conduct of their business.  The results of any such audit shall be deemed a Confidential Item of Pioneer and shall not be disclosed by Universal Display except as may be necessary for Universal Display to enforce its rights and interests hereunder.  If the audit reveals that Pioneer has underpaid any royalties due to Universal Display, Pioneer shall immediately pay to Universal Display all unpaid royalties, plus interest on the unpaid amounts from the date payment was initially due at the rate specified in Section 5.1 above.  Universal Display shall be responsible for paying the fees and expenses charged by the accountant for conducting any audit hereunder; provided, however, that if the unpaid royalties exceed [***] percent [***] of the total royalties that should have been paid by Pioneer during the audited period, Pioneer shall promptly reimburse Universal Display for the reasonable fees and expenses charged by such accountant.  Nothing herein shall limit any other rights or remedies available to Universal Display on account of Pioneer’s underpayment of royalties or other breach of its obligations under this Agreement.
 
Article 6   Confidentiality and Publicity
 
6.1   Obligations of Confidentiality and Non-Use .  Each Party (“ Recipient ”) shall handle and maintain all Confidential Items of the other party (“ Discloser ”) in accordance with the following terms and conditions:
 
6.1.1   Recipient shall not publish, disclose or otherwise disseminate any Confidential Items of Discloser, except to such of Recipient’s employees who have a “need to know” them to accomplish the purposes of this Agreement.  Recipient may disclose Confidential Items of Discloser to Recipient’s Affiliates who are directly involved in implementing this Agreement, provided such Affiliates are bound by the terms and conditions of the Agreement, or terms and conditions substantially similar thereto.
 
6.1.2   Recipient shall use reasonable safeguards to prevent any unauthorized access to or disclosure of Confidential Items of Discloser.  As used herein, “reasonable safeguards” means all safeguards that a reasonable person would take to protect the Confidential
 

 
Page 10 of 21

 
 
Item in question, which safeguards shall be no less than the safeguards Recipient takes to protect its own confidential or proprietary items of a similar nature.
 
6.1.3   Recipient may copy Confidential Items of Discloser only as is reasonably necessary for Recipient to accomplish the purposes of this Agreement.
 
6.1.4   Recipient shall not utilize or exploit any Confidential Items of Discloser, or permit or assist others to utilize or exploit such Confidential Items, except as is reasonably necessary to accomplish the purposes of this Agreement.
 
6.1.5   Recipient shall not publish or otherwise disclose to third parties, or reference or include in any patent application or other similar filing, any test results or other information or data derived from Recipient’s evaluation of any Confidential Items of Discloser without Discloser’s prior written consent.
 
6.1.6   Promptly upon learning of any unauthorized use or disclosure of any Confidential Item of Discloser, Recipient shall provide Discloser with written notice thereof and take such other steps as are reasonably requested by Discloser in order to limit the effects of such use or disclosure and/or prevent any further unauthorized use or disclosure of any Confidential Items of Discloser.
 
6.1.7   Promptly upon Discloser’s written request, Recipient shall return to Discloser, destroy and/or delete from Recipient’s records and computer systems all Confidential Items of Discloser, including any copies or portions thereof, in Recipient’s possession or control; provided, however, that Recipient may retain one copy of documents incorporating such Confidential Items for archival purposes only.  Within thirty (30) days following Discloser’s written request, Recipient shall provide Discloser with a certificate of Recipient’s compliance with the foregoing requirements.
 
6.2   Definition of Confidential Items .  As used herein, "Confidential Items" of Discloser include all information and materials, in written, oral, visual or other tangible form, relating to Discloser’s technologies, compounds, devices, research programs, operations, business relationships and/or financial or business condition (including, without limitation, know-how, data, drawings, designs, specifications, formulations, processes, methods, equipment, software and pricing information) that are (a) disclosed in writing or other tangible form and marked as “Confidential”, “Proprietary” or with similar words at the time of disclosure, or (b) orally or visually disclosed and identified as confidential or proprietary at the time of disclosure and confirmed as such in writing within thirty (30) days thereafter.  Notwithstanding the foregoing, “Confidential Items” of Discloser shall not include any information that:
 
6.2.1   is approved by Discloser in writing for release by Recipient without restriction;
 
6.2.2   Recipient can demonstrate by written records was previously known to Recipient other than through a prior disclosure by Discloser or any third party with an obligation of confidentiality to Discloser;
 
 
Page 11 of 21

 
6.2.3   is publicly known as of the date of this Agreement, or becomes public knowledge subsequent thereto, through no act or omission of Recipient or any third party receiving such information from or through Recipient;
 
6.2.4   is obtained by Recipient in good faith from a third party without the violation of any obligation of confidentiality to Discloser by either Recipient or the third party; or
 
6.2.5   is independently developed by or on behalf of Recipient without the benefit of Discloser’s Confidential Items, as shown by competent written records.
 
6.3   Disclosure Required by Law .  This Agreement shall not restrict Recipient from disclosing any Confidential Items of Discloser to the extent required by applicable law, or by the order of any court or government agency; provided, however, that Recipient shall afford Discloser prompt notice of such law or order, so that Discloser may interpose an objection to such disclosure or take whatever other actions Discloser deems appropriate to protect such Confidential Items, and provided further that Recipient shall use all reasonable efforts to limit such disclosure to only those Confidential Items that are required to be disclosed and to ensure that the person or entity to whom such Confidential Items are disclosed agrees to keep them confidential.
 
6.4   Responsibility for Personnel .  Recipient shall be responsible for the acts or omissions of its employees and Affiliates receiving Confidential Items of Discloser from or through Recipient to the extent such acts or omissions, if performed or not performed by Recipient, would constitute violations of this Agreement by Recipient.
 
6.5   Confidentiality of this Agreement .  The terms of this Agreement shall be deemed Confidential Items of each Party and treated as such by both Parties.  Notwithstanding the foregoing sentence, either Party may disclose in its public filings such of the terms of this Agreement as are reasonably required for such Party to comply with applicable securities laws and regulations, including, without limitation, by filing appropriate reports with applicable securities agencies or commissions and/or by filing an appropriately redacted copy of this Agreement in connection therewith.  In addition, either Party may issue a press release or other public announcement describing the general nature of this Agreement, or the Parties may agree to issue such a release or announcement jointly; provided, however, that no such release or announcement shall disclose any information about Pioneer’s or its Affiliates’ product launch strategy without Pioneer’s prior written consent.  Subject to the foregoing provisions of this paragraph, any such public disclosure of the specific financial terms or other provisions of this Agreement, or any other information regarding the relationship between the Parties hereunder, shall require the other Party’s prior written consent.
 
6.6   Trading in Securities .  If information disclosed under this Agreement is material non-public information about a Party or its Affiliates, then the other Party agrees not to, and to cause its Affiliates not to, trade in the securities of the first Party or its Affiliates, or in the securities of any appropriate or relevant third party, until such time as no violation of the applicable securities laws would result from such securities trading.
 
 
Page 12 of 21

 
6.7   Universal Display’s Licensors .  Notwithstanding the foregoing, Universal Display shall have the right to provide an unredacted copy of this Agreement, along with copies of all Royalty Reports, to each of Princeton, USC and Michigan; provided that in such case Universal Display shall first have caused such third-party licensors to agree in writing to handle and maintain such items in accordance with the provisions of this Article 6, or provisions substantially similar thereto.
 
6.8   Other Collaborative Efforts .  Upon request and subject to the obligations of confidentiality set forth herein, each Party shall use good faith efforts to reasonably feature the name and logo, technologies and products of the other in its public promotions respecting the Licensed Products, such as at industry conferences or in other similar venues.
 
Article 7   Representations and Warranties; Disclaimers and Limitations of Liability
 
7.1   Warranties by Both Parties .  Each Party represents and warrants to the other that such Party has the right, power and authority to enter into this Agreement and to perform its obligations hereunder, and that such performance will not violate any other agreement or understanding by which such Party is bound.
 
7.2   Further Warranty by Universal Display .  Universal Display additionally represents and warrants to Pioneer that Universal Display owns or has sufficient rights in the Universal Display Technology to grant the license rights granted to Pioneer hereunder.  If Universal Display assigns one or more of the Universal Display Patents to a third party(ies), Universal Display shall ensure that the assignment of such Universal Display Patents is subject to the license rights granted to Pioneer hereunder without additional cost to Pioneer (other than the obligation to pay amounts due and owing hereunder) for the rest of the Term of this Agreement.  If a patent or patent application is jointly owned by Universal Display and a third party(ies) in relation to OLED Light Source but not included in the Universal Display Patents because Universal Display does not have a right to grant a license for such patent or patent application, Universal Display warrants that it shall not assert its right in and to such patent or patent application against Pioneer or its Affiliates on account of their authorized practice of the license rights granted hereunder during the Term of this Agreement, or against their customers on account of their purchase of Licensed Products manufactured and sold by Pioneer or its Affiliates as authorized hereunder.
 
7.3   Disclaimer of Additional Warranties .  ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF NON-INFRINGEMENT, VALIDITY, QUALITY, PERFORMANCE, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ARE HEREBY DISCLAIMED BY UNIVERSAL DISPLAY.  In particular, Universal Display makes no representation or warranty that Pioneer or its Affiliates will be able to manufacture, sell or use any Licensed Products without obtaining additional license rights from third parties.
 
7.4   Required Disclaimer of Princeton, USC and Michigan .  PRINCETON, USC AND MICHIGAN MAKE NO REPRESENTATIONS AND WARRANTIES AS TO THE PATENTABILITY AND/OR DISCOVERIES INVOLVED IN ANY OF THE UNIVERSAL DISPLAY PATENTS LICENSED HEREUNDER.  PRINCETON, USC AND MICHIGAN
 
 
Page 13 of 21

 
MAKE NO REPRESENTATION AS TO PATENTS NOW HELD OR WHICH WILL BE HELD BY OTHERS IN ANY FIELD AND/OR FOR ANY PARTICULAR PURPOSE.  PRINCETON, USC AND MICHIGAN MAKE NO EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.
 
7.5   Limitation on Certain Damages .  IN NO EVENT SHALL UNIVERSAL DISPLAY BE LIABLE TO PIONEER, OR TO ANY THIRD PARTY CLAIMING THROUGH PIONEER OR ITS AFFILIATES, WHETHER AS A RESULT OF BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, FOR ANY INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE OR CONSEQUENTIAL DAMAGES ARISING UNDER OR IN CONNECTION WITH A BREACH OR ALLEGED BREACH OF THIS AGREEMENT.  The foregoing shall not limit Universal Display’s liability for any breach of the provisions of Article 6 respecting Confidential Items of Pioneer and its Affiliates.
 
7.6   Essential Part of the Bargain .  The Parties acknowledge that the disclaimers and limitations of liability set forth in this Article 7 reflect a deliberate and bargained for allocation of risks between them and are intended to be independent of any exclusive remedies available under this Agreement, including any failure of such a remedy to achieve its essential purpose.
 
Article 8   Term and Termination
 
8.1   Term .  The term of this Agreement shall commence on the Effective Date ( i.e. , May 1, 2011) and shall continue, unless terminated sooner as permitted hereunder, until the cumulative Net Sales Revenue for Licensed Product sold, leased or otherwise disposed of reaches [***] Japanese Yen.  If Pioneer wishes to extend the term of this Agreement thereafter, both Parties shall discuss in good faith the terms and conditions of any such extension; provided, however, that neither Party shall have any right or obligation to enter into such an extension unless expressly agreed in writing.  In addition, [***] ; provided, however, that neither party shall have any right or obligation to enter into such a license unless expressly agreed in writing.
 
8.2   Termination for Breach .  Either Party may terminate this Agreement on written notice to the other Party if the other Party materially breaches any of its obligations under this Agreement and fails to cure such breach within sixty (60) days following written notice thereof by the terminating Party.
 
8.3   Termination for Challenge of Patents .  Universal Display may terminate this Agreement on written notice to Pioneer if Pioneer or any of its Affiliates asserts or assists another in asserting (including through the use of a “dummy” person or entity), before any court, patent office or other governmental agency, that any of the Universal Display Patents are invalid or unenforceable, should be cancelled or invalidated in whole or in part, or should otherwise not be granted, allowed or issued in whole or in part.
 
8.4   Termination for Change in Control.   Universal Display may terminate this Agreement on written notice to Pioneer if Pioneer undergoes a Change in Control.  A “Change in Control” of Pioneer shall be deemed to have occurred if there is a change in ownership of securities representing more than [***] percent [***] of the voting capital stock of Pioneer, or of other interests having majority voting rights with respect to the election of the board of directors
 
 
Page 14 of 21

 
or similar governing authority of Pioneer, or of any other power by contract or in any other form which entitles the holder thereof to majority voting rights with respect to management decisions of Pioneer.
 
8.5   Other Termination .  Either Party may terminate this Agreement on written notice to the other Party if the other Party permanently ceases conducting business in the normal course, becomes insolvent or is adjudicated bankrupt, makes a general assignment for the benefit of its creditors, admits in writing its inability to pay its debts as they become due, permits the appointment of a receiver for its business or assets, or initiates or becomes the subject of any bankruptcy or insolvency proceedings which proceedings, if initiated involuntarily, are not dismissed with sixty (60) days thereafter.
 
8.6   Survival .  The following provisions of this Agreement shall survive the expiration or termination of this Agreement:  (a) any payment or reporting obligations of Pioneer respecting the sale or other disposition of Licensed Products occurring prior to the date of such expiration or termination; (b) for three (3) years, any audit rights of Universal Display with respect to such Licensed Products; (c) for five (5) years, the provisions of Articles 6; and (d) the provisions of Article 7.  Any termination of this Agreement shall be in addition to, and not in lieu of, any other rights or remedies that may be available to a Party under this Agreement, at law or in equity.
 
8.7   Service Parts Supplied After the Term .  Notwithstanding Section 8.1 above, Universal Display agrees that Pioneer may manufacture and supply Service Parts upon the request by its customers after the termination of this Agreement, provided that Pioneer shall pay the running royalties as stated in Section 4.2 and submit Royalty Reports as stated in Section 4.3 for such Service Parts, and Universal Display’s audit rights under Section 5.4 shall apply with respect to such Service Parts.
 
Article 9   Miscellaneous
 
9.1   Independence .  This Agreement is not intended by the Parties to constitute, create, give effect to, or otherwise recognize a joint venture, partnership, or formal business organization of any kind.  Each Party hereto shall act as an independent entity, and neither shall act as an agent of the other for any purpose.  Neither Party has the authority to assume or create any obligation, express or implied, on behalf of the other.
 
9.2   Notices .  Any notices pertaining to the administration of this Agreement or any breach, alleged breach or termination thereof shall be in writing and shall be deemed effectively given upon receipt of such notices by the recipient.  Such notices shall be given by personal delivery, certified mail with postage prepaid and return receipt requested, or prepaid delivery using an international private courier, to each Party at its address set forth below; provided, however, that the Parties may agree to exchange information by confirmed email or facsimile correspondence in lieu of the methods described above.  Either Party may change its address for such notices at any time by means of a notice given in the manner provided in this paragraph.
 
 
Page 15 of 21

 
All Royalty Reports and any other financial notices, to:

Universal Display Corporation
 
Pioneer Corporation
375 Phillips Boulevard
 
1-1, Shin-ogura, Saiwa-ku, Kawasaki-shi
Ewing, New Jersey  08618
 
Kanagawa 212-0031, Japan
Attn: [***]
 
Attn: [***]
Fax No.: [***]
 
Fax No.: [***]
Tel No.: [***]
 
Tel No.: [***]
E-mail: [***]
 
E-mail: [***]

All other notices and communications:

[same as above]
 
[same as above]
Attn: [***]
 
Attn: [***]
Fax No.: [***]
 
Fax No.: [***]
Tel No.: [***]
 
Tel No.: [***]
E-mail: [***]
 
E-mail: [***]

9.3   Non-Assignment .  Pioneer may not assign or transfer any of its rights or delegate any of its obligations hereunder, by application of law or otherwise, without the prior written consent of Universal Display.  Universal Display may assign or transfer this Agreement, in its entirety and on written notice to Pioneer, to a successor in interest to all or substantially all of Universal Display’s business or assets to which this Agreement relates.  Any attempted assignment, transfer or delegation in violation of this paragraph shall be null and void and without force and effect.  Nothing herein shall confer any rights upon any person other than the Parties hereto and their respective permitted successors and assigns.
 
9.4   Equitable Relief .  In the event of Pioneer’s actual or reasonably anticipated infringement of the Universal Display Patents, or unauthorized use of the Universal Display Know-How, Universal Display may seek to obtain such injunctions, order and decrees as may be necessary to restrain the infringement or unauthorized use, without the necessity of proving actual damages and without posting any bond or other security.  Such relief shall be in addition to, and not in lieu of, any other rights or remedies available to Universal Display under this Agreement, at law or in equity.
 
9.5   Choice of Law .  This Agreement shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York, U.S.A., without respect to its rules on the conflict of laws.  Any law or regulation providing that the language of a contract shall be construed against the drafter shall also not apply.
 
9.6   Severability .  In the event that any clause in this Agreement is found invalid according to laws or governmental regulations, such a clause shall not affect the validity of the remainder of this Agreement.  The invalid clause shall then be replaced, upon mutual written consent between the parties hereto, by such a valid provision as, in its effect, corresponds or comes closest to the effect of the invalid provision.
 
9.7   No Waivers .  The failure of either Party to enforce, or any delay in enforcing, any right, power or remedy that such Party may have under this Agreement shall not constitute a waiver of any such right, power or remedy, or release the other Party from any of its obligations under this Agreement, except by a written document signed by the Party against whom such waiver or release is sought to be enforced.
 
9.8   Entire Agreement; Amendments .  This Agreement constitutes the entire understanding and agreement of the Parties respecting the subject matter hereof and, except for the NDA, supersedes any and all prior agreements, arrangements or understandings between the Parties, whether written or oral, relating thereto.  This Agreement may not be amended or supplemented in any way except by a written document signed by both of the Parties.
 
9.9   Counterparts .  This Agreement may be executed by the Parties hereto in separate counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
 

 
Page 16 of 21

 


IN WITNESS WHEREOF, the Parties have executed this Agreement by their duly authorized representatives.


Pioneer Corporation
 
Universal Display Corporation
         
         
By:
 /s/ Susumu Kotani
 
By:
 /s/ Steven V. Abramson
         
Name:
 Susumu Kotani
 
Name:
 Steven Abramson
         
Title:
 President
 
Title:
 President and CEO
         
Date:
 Sep. 27, 2011
 
Date:
 Sept 5, 2011


 
Page 17 of 21

 

Exhibit A

OLED Light Source


Two Potential Configurations (by example only)


[***]


 
Page 18 of 21

 


Exhibit B

License Fees and Royalty Rates

License Fees :

US$[***], payable within thirty (30) days after contract execution by the parties hereto and Universal Display delivers to Pioneer the appropriate withholding tax documents required by Section 5.2; and

US$[***], payable within thirty (30) days after May 1, 2012.

Royalty Rates :

[***] for all Licensed Products; provided, however, that

(1)  
if the Licensed Product does not include every element of an OLED Light Source, this royalty rate shall be adjusted so that the overall royalty payment to Universal Display is the same as it would have been if the Licensed Product sold or otherwise disposed of had consisted of a complete OLED Light Source; and

(2)  
if the Licensed Product includes components in addition to those of an OLED Light Source, the Net Sales Revenue on which royalties are payable shall exclude the portion of such revenue attributable to the additional components.

Notwithstanding (1) and (2) above, the parties have agreed that for a Licensed Product which is an OLED Light Source minus [***], the adjusted royalty rate during the term of this Agreement shall be [***].  It is also agreed between the parties that for a Licensed Product which is an OLED Light Source minus [***], the royalty rate during the term of this Agreement shall be [***].


 
Page 19 of 21

 

Exhibit C

Universal Display Patents


To be provided separately.





Exhibit 31.1

CERTIFICATIONS REQUIRED BY
RULE 13a-14(a)/15d-14(a)

I, Steven V. Abramson, certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Universal Display Corporation (the “registrant”) for the quarter ended September 30, 2011;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 8, 2011
By:    /s/ Steven V. Abramson
 
Steven V. Abramson
 
President and Chief Executive Officer





Exhibit 31.2

CERTIFICATIONS REQUIRED BY
RULE 13a-14(a)/15d-14(a)

I, Sidney D. Rosenblatt, certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Universal Display Corporation (the “registrant”) for the quarter ended September 30, 2011;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: November 8, 2011
By:    /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer





Exhibit 32.1

CERTIFICATIONS REQUIRED BY
RULE 13a-14(b)/15d-14(b) AND 18 U.S.C. SECTION 1350

In connection with the quarterly report of Universal Display Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven V. Abramson, President and Chief Executive Officer of the Company, hereby certify, based on my knowledge, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 8, 2011
By:    /s/ Steven V. Abramson
 
Steven V. Abramson
 
President and Chief Executive Officer





Exhibit 32.2

CERTIFICATIONS REQUIRED BY
RULE 13a-14(b)/15d-14(b) AND 18 U.S.C. SECTION 1350

In connection with the quarterly report of Universal Display Corporation (the “Company”) on Form 10-Q for the quarter ended September 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Sidney D. Rosenblatt, Executive Vice President and Chief Financial Officer of the Company, hereby certify, based on my knowledge, that:

(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
   
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: November 8, 2011
By:    /s/ Sidney D. Rosenblatt
 
Sidney D. Rosenblatt
 
Executive Vice President and Chief Financial Officer